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ABSTRACT 
Coeliac disease (CD) coexists with type 1 diabetes (T1D) substantially more than in the 
general population. This body of work examines the broad and pervasive relationship 
between CD on T1D, including the epidemiology, screening practices, microvascular 
complications, quality of life (QoL), nutrition, glycaemic variability, and bone health. In 
particular, the contribution of gluten free diet (GFD) adherence is explored.  
Study 1: The 20-year incidence of CD in 4,379 people with T1D aged <18 years was 7.7 per 
1000 person years. Incidence was significantly higher in those with T1D onset < age 5 years, 
but this subgroup developed CD after significantly longer T1D duration than those with T1D 
onset >5 years.    
Study 2: We systematically reviewed the epidemiology of CD in 11,157 youth with T1D 
alone and 587 with coexisting CD; 55% of CD cases were diagnosed within 2 years of T1D 
and 79% within 5 years. We concluded that CD screening should be performed at T1D 
diagnosis and repeated within 5 years of T1D.  
Study 3: Comparing 129 youth with T1D and CD vs 2,510 with T1D alone, retinopathy, 
albumin excretion rate (AER) and neuropathy did not differ. HbA1c was lower in those with 
CD (8.3% vs 8.6%, p=0.04), however elevated AER was more prevalent in those who did not 
adhere to the GFD (40% vs 23%, p=0.04). 
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Study 4: In a case control study of 35 youth with T1D and 35 with coexisting CD, and their 
carers, generic and diabetes-specific QoL did not differ. Youth using insulin pumps had 
similar generic and diabetes specific QoL to those using multiple daily injections. However, 
those who did not adhere to the GFD had lower diabetes specific QoL and lower general 
wellbeing, as did their carers.   
Study 5: In a case control study using continuous glucose monitoring, youth with T1D and 
CD had greater glycaemic variability, with a shorter time to peak blood glucose levels (BGL), 
higher peak, and higher postprandial BGLs than T1D alone, despite similar pre-meal BGLs. 
Both groups had inadequate calcium, folate and fibre, with excessive saturated fat and 
sodium intake.  
Study 6: In a case control study utilising dual energy x-ray absorptiometry and peripheral 
quantitative computational tomography, youth with coexisting T1D and CD had lower bone 
mineral content, abnormal trabecular and cortical bone development, and a lower bone 
turnover state with reduced muscle pull vs T1D alone.  
These studies further our understanding of the impact of coexisting CD in T1D. The findings 
inform screening and management of CD, and provide evidence in support of GFD 
adherence to optimise clinical, dietary, and psychosocial management.  
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CHAPTER 1: THESIS OVERVIEW AND AIMS  
 
THESIS OVERVIEW  
The overarching theme of this body of work is to examine the broad impact of coexisting 
coeliac disease in young people with type 1 diabetes. Research questions explored the 
epidemiology, screening practices, microvascular complications, quality of life (QoL), 
nutrition, glycaemic variability, and bone health. In particular, the contribution of gluten 
free diet (GFD) adherence to clinical outcomes in young people with both conditions is 
explored.  
 
RESEARCH HYPOTHESES AND AIMS 
Primary Hypotheses:  
i. Children with co-existing type 1 diabetes and coeliac disease are younger at 
diabetes onset compared with those with type 1 diabetes alone 
ii. Published studies on the recommendations for frequency of screening for coeliac 
disease in type 1 diabetes are varied and not evidence based  
iii. Young people with type 1 diabetes and coeliac disease, who do not adhere to the 
gluten free diet, have higher complications rates, independent of glycaemic 
control, compared with those who adhere 
iv. Quality of life scores are lower (a) in youth with type 1 diabetes and coeliac 
disease compared with type 1 diabetes only, and (b) in those who do not adhere 
to the gluten-free diet compared with those who adhere 
24 
 
v. Youth with type 1 diabetes and coeliac disease demonstrate greater glycaemic 
excursions and lower nutrient intake compared with those with type 1 diabetes 
alone 
vi. Youth with type 1 diabetes and coeliac disease exhibit abnormal measures of 
bone health compared with those with type 1 diabetes alone 
Aims 
i. To determine the incidence and prevalence of coeliac disease in young people 
with type 1 diabetes and to examine the association with age at diabetes onset  
ii. To systematically review the epidemiology of coeliac disease in people with type 
1 diabetes to inform screening guidelines  
iii. To compare microvascular complications rates in youth with and without coeliac 
disease and examine the association between gluten-free diet adherence and 
complications 
iv. To evaluate quality of life and glycaemic control in youth with type 1 diabetes 
and coeliac disease versus type 1 diabetes only 
v. To compare glucose variability using continuous glucose monitoring in youth 
with type 1 diabetes and coeliac disease compared to those with type 1 diabetes 
alone 
vi. To compare macronutrient, micronutrient and fibre intake in youth with type 1 
diabetes and coeliac disease compared to those with type 1 diabetes alone 
vii. To compare bone mineral density in youth with type 1 diabetes and coeliac 
disease versus type 1 diabetes alone 
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CHAPTER 2: LITERATURE 
REVIEW 
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2.1 PATHOPHYSIOLOGY OF COELIAC DISEASE 
Coeliac disease (CD) is a chronic autoimmune condition characterised by an immune 
mediated reaction to dietary gluten in genetically susceptible individuals. More than 95% of 
people with CD have the major histocompatibility complex II class human leukocyte antigen 
(HLA) DQ2 or DQ8 haplotype, although only 1 in 30 people who have HLA DQ2 or HLA DQ8 
will develop coeliac disease. Treatment requires a strict, life-long gluten free diet (GFD), 
which excludes the ingestion of the grains; wheat, rye, oats and barley. Symptoms at 
presentation may include diarrhoea, recurrent abdominal pain, bloating, failure to thrive, 
iron-deficiency anaemia or reduced bone density. However, it is also recognised that 
patients may have minimal, or no overt symptoms. Undiagnosed, and untreated, CD is one 
of the most common causes of chronic malabsorption (Rubio-Tapia et al. 2013). 
 
CD is diagnosed by detection of CD-specific serology, and confirmed by an intestinal biopsy 
(Bai et al. 2013, Mahmud et al. 2018). Screening for CD is based on detection of IgA 
antibodies (tissue transglutaminase [tTG-A] and/or endomysial [EmA]), and in those with IgA 
deficiency, IgG-specific antibodies (tTG or EmA IgG). The Marsh classification is widely used 
in clinical practice to classify histologic damage, with villous atrophy (Marsh type 3, Figure 1) 
diagnostic of CD (Marsh et al. 1995, Bai et al. 2013).  
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Figure 2.1 Histological stages of villous atrophy according to Marsh Criteria (Marsh et al. 
1995). 
 
2.2 EPIDEMIOLOGY OF TYPE 1 DIABETES AND COELIAC DISEASE 
Coeliac disease (CD) frequently coexists with type 1 diabetes (T1D), with rates ranging from 
1.6% to 16.4% in T1D (Westman et al. 1999, Poulain et al. 2007, Kordonouri et al. 2014). This 
is substantially higher than the general population prevalence of CD, ranging from 0.3 to 
1.0% (Bai et al. 2013). Over a million children and adolescents are estimated to be living 
with T1D globally (International Diabetes Federation 2017), and therefore thousands are 
living with both chronic conditions. The global mean annual incidence rates of T1D are 
presented in Figure 2.2. 
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The management of T1D requires a life-long regimen of daily insulin injections or continuous 
subcutaneous insulin infusion (CSII) and blood glucose testing by finger-prick or continuous 
glucose monitoring (CGM), which must be balanced with carbohydrate intake. However, the 
treatment is imperfect and creates a burden for the individual, their family/carers and the 
health care system. Overlayed by the requirement of a gluten-free diet (GFD) for the 
management of CD, the impact of living with both conditions has possible adverse effects on 
psychosocial well-being, and health related outcomes such as microvascular complications, 
adverse bone health, and dietary related inadequacies. To date, most studies examining the 
coexistence of both conditions have focused on glycaemic control and growth (Mohn et al. 
2001, Sud et al. 2010). 
 
CD often presents asymptomatically in children with T1D (Mahmud et al. 2018) and is not 
necessarily associated with poor growth or deterioration in glycaemic control (Rami et al. 
2005, Simmons et al. 2007, Sun et al. 2009). There is some evidence that dietary treatment 
improves quality of life (QoL) in silent CD, but studies in people with coexisting T1D and CD 
are limited.  Adherence to the GFD for those with T1D and CD improves growth (Sponzilli et 
al. 2010), weight z-scores, haemoglobin and serum ferritin (Hansen et al. 2006).  
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Figure 2.2. Global mean annual incidence rates of type 1 diabetes in children and 
adolescents aged 0-14 yr (Craig et al. 2014) 
 
2.2.1 PREVALENCE OF COELIAC DISEASE IN TYPE 1 DIABETES 
The prevalence of CD is higher in T1D compared to the general population, with rates 
reported between 1.6% - 16.4%, vs 1% (Poulain et al. 2007, Kordonouri et al. 2014) and 2 to 
8% in Australia (Doolan et al. 2005). The higher prevalence of CD in T1D reflects the shared 
genetic predisposition of both conditions, as well as regular screening at and after diagnosis 
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of T1D (Mahmud et al. 2018). Those that develop both CD and T1D appear to be younger  at 
T1D diagnosis compared with the typical age distribution of T1D onset (Cerutti et al. 2004, 
Frohlich-Reiterer et al. 2011) and are generally diagnosed after relatively short diabetes 
duration (Larsson et al. 2008). However, a clear relationship between age at T1D diagnosis, 
and time development to CD diagnosis has yet to be established. This may provide guidance 
for the frequency of CD screening, which could be stratified by age at T1D diagnosis.   
Chapter 3 of this thesis presents the results of a clinic-based, 20-year cohort study of 4,379 
youth with T1D; to determine the incidence and prevalence of CD and examine the 
relationship between age at T1D onset and disease duration. Our novel finding of a 
relationship between younger age at diabetes diagnosis and longer time to CD 
seroconversion had not been recognized previously, highlighting the importance of regular 
screening. We reported an incidence rate of 7.7 per 1,000 person years, and a prevalence 
rate of 7.1%. Since Chapter 3 was published, clinical characteristics associated with the T1D 
and CD presentation included iron deficiency (Al-Hussaini et al. 2012), female gender (Al-
Hussaini et al. 2012, Bianchi et al. 2016) and a higher prevalence in the first 2 years after 
diabetes diagnosis (Bybrant et al. 2014). Notably, a large multi-national cross-sectional study 
of 52,571 youth from Germany/Austria, the United States, the United Kingdom and 
Australia found CD in 3.5% of patients; their findings similarly found a higher prevalence in 
those younger at diabetes diagnosis compared to T1D alone, with the prevalence rate from 
the Australasian Diabetes Data Network (ADDN) database of 7.7%. The majority of T1D 
patients who then develop biopsy-proven CD are asymptomatic of CD, reinforcing the 
importance of routine screening, which is systematically reviewed in Chapter 5. 
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2.2.2 SCREENING FOR COELIAC DISEASE IN TYPE 1 DIABETES 
Screening for CD in T1D is widely recommended, however recommendations for frequency 
of screening are variable and not evidence based. The International Society of Pediatric and 
Adolescent Diabetes (ISPAD) recommends screening at the time of diagnosis and every 1 to 
2 years thereafter, with more frequent assessment if clinically indicated or if there is a first-
degree relative with CD (Kordonouri et al. 2014) . In the United Kingdom, the National 
Institute for Health and Care Excellence (NICE) guidelines recommend screening for CD at 
the time of T1D diagnosis, and when symptomatic (National Institute for Health and Care 
Excellence 2015). Up until, and including 2017, the American Diabetes Association’s (ADA) 
annual Standards of Medical Care in Diabetes recommendations for CD screening were to 
consider CD screening soon after diabetes diagnosis in those with symptoms suggestive of 
CD (American Diabetes Association 2017).   
 
Prospective studies have reported seroconversion after T1D diagnosis, with patients testing 
negative for CD antibody tests at diabetes onset becoming positive during the follow-up 
period and CD confirmed on small bowel biopsy (Barera et al. 2002, Glastras et al. 2005, 
Larsson et al. 2008). Seroconversion from negative to positive CD autoantibodies can occur 
beyond 10 years of diabetes duration, highlighting the necessity for repeated CD screening 
(Glastras et al. 2005). These studies provide evidence to justify the practice of screening for 
CD in children with T1D. In T1D, undiagnosed CD may be associated with unstable blood 
glucose levels, a greater risk of hypoglycaemia (Mohn et al. 2001), and increased risk of 
retinopathy (Hill et al. 2005). In view of the variable recommendations, risks associated with 
undiagnosed CD, and to build upon the findings of Chapter 3 that those at greatest risk of 
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developing diabetes, were likely to develop CD over a longer median period of diabetes 
duration, the epidemiology of CD in people with T1D was systematically reviewed to inform 
screening guidelines (Chapter 5). 
 
2.3 ADHERENCE TO THE GLUTEN-FREE DIET  
The European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
guidelines state following the diagnosis of CD, dietary counselling for a GFD is paramount, 
followed by serological normalisation of CD-specific antibody titres (Husby et al. 2012). 
Dietary assessment of GFD compliance by a dietitian via a thorough interview is considered 
the best available method (Leffler et al. 2007). 
  
GFD adherence in youth with CD has been reported to vary from 25% to 81% of participants 
in those with or without coexisting T1D (Saadah et al. 2004, Wagner et al. 2008, van Koppen 
et al. 2009, Husby et al. 2012). GFD adherence is often assessed by a thorough dietary 
assessment (Saadah et al. 2004), self-reported (Wagner et al. 2008) or with the 
normalisation of CD specific serology  (van Koppen et al. 2009, Husby et al. 2012). Factors 
found to increase compliance with the GFD include being female, younger of age, having 
better school academic performance  and higher self-esteem (Greco et al. 1997).  Those 
diagnosed with CD at a younger age are more likely to maintain a GFD, with dietary 
transgressions most likely to occur in adolescents or those diagnosed via mass screening 
(Hogberg et al. 2003). A Swedish study (Hogberg et al. 2003) measuring compliance utilising 
a questionnaire and serological markers found at least 80% of patients who were diagnosed 
with CD before the age of 4 complied to the GFD, compared to 36% of patients aged  more 
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than 4 at CD diagnosis. This study also highlights the importance of early diagnosis to 
minimise the risk of CD-related complications and reduced well-being.   
 
Adherence to the GFD is also variable in patients with CD alone. In a follow-up evaluation of 
adolescents with CD diagnosed following mass screening, adherence to the GFD was 52.2% 
with dietary transgressions reported as occasional and commonly happening on weekends  
(Fabiani et al. 1996).  This same Italian study group later compared adherence to the GFD in 
those with screen-detected CD, vs those symptomatic of CD prior to diagnosis, and report a 
higher proportion of dietary transgressions in those screen-detected (Fabiani et al. 2000). In 
contrast, a Finnish study found no difference in GFD adherence between screen-detected, 
or symptom-detected children and adolescents (71% vs 84% strict adherence, P=0.11) 
(Kinos et al. 2012).  
 
In comparison, patients with coexisting CD and T1D have lower compliance to the GFD than 
those with CD alone, and this has been demonstrated to be less than 30% of participants 
(Westman et al. 1999, Saadah et al. 2004), as assessed by a dietitian.A case controlled study 
from Australia (Westman et al. 1999) assessed the growth, diabetes control, dietary intake 
and compliance with a GFD in children with T1D and CD. Dietary intake and compliance 
were assessed by a 3 day food record and a 7 day food frequency questionnaire, diabetes 
control was measured by HbA1c and was found to be similar in for those with or without 
CD. Strict compliance to the GFD was observed in only 30% of patients, with no differences 
in energy or nutrient intake, growth, or diabetes control. Of note, the availability of gluten 
free foods is greater today than 20 years ago.  
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Glycaemic control in those with coexisting T1D and CD was shown to be no different 
compared to those with T1D alone (Rami et al. 2005, Simmons et al. 2007, Sun et al. 2009). 
A trend towards a lower BMI SDS score, but not height SDS scores denoting negative weight 
gain has also been observed in patients with T1D and CD who were non-compliant with the 
GFD (Rami et al. 2005), which may be attributed to CD affecting the absorption of some 
nutrients. 
 
2.3.1 BARRIERS TO THE ADHERENCE OF THE GFD   
Adolescence is often described as a very difficult and tumultuous time during which the 
young person attempts to find their individuality, fit in amongst friends, and rebel towards 
adults; these challenges may be further complicated by living with a chronic condition, and 
more so by two.  Hence it can be expected that GFD compliance during adolescence is lower 
compared to other age groups (Cinquetti et al. 1997, Wagner et al. 2008). In a qualitative 
Swedish study using focus group sessions in 47 adolescents aged 15-18 years with 
confirmed CD, who had been on the GFD for at least a year, compliance with the GFD was 
easiest at home, where family members were well acquainted with the GFD and foods were 
readily available. This is likely due to home providing an easy environment where 
adolescents did not have to ask questions or explain the need for a GFD (Olsson et al. 2008). 
By contrast, situations outside the home were more troublesome for adolescents – 
contributory factors included limited social support and lack of CD-related knowledge in 
significant others (such as teachers, school-kitchen staff, friends, extended family 
members), the unavailability of GF foods, problems with sensory acceptance, the absence of 
symptoms following the ingestion of gluten, and lack of knowledge of the health-related 
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harms of gluten ingestion (Olsson et al. 2008). This study highlights the multi-factorial and 
overlapping nature of factors affecting GFD compliance in adolescents with CD alone. 
However, there is no research on factors affecting GFD adherence in youth with coexisting 
T1D and CD. 
 
2.3.2 CLINICAL BENEFIT OF THE GFD IN PATIENTS WITH T1D AND CD 
Following introduction of the GFD in those with coexisting T1D and CD, a range of clinical 
parameters can improve. A Swedish study of patients followed over 2 years while 
consuming a GFD showed improvements with weight-SDS scores, haemoglobin, and serum 
ferritin, with no difference in glycaemic control (Hansen et al. 2006). However, as HbA1c 
measures average blood glucose levels, fluctuations between hypoglycaemia and 
hyperglycaemia are not detected. Indeed, patients experienced fewer hypoglycaemic 
episodes after the start of the GFD, which was also demonstrated by another study of youth 
(Mohn et al. 2001). 
 
Maintaining a GFD in those with screen detected CD shows improved clinical parameters. In 
a comparative study from Colorado of children with T1D and CD identified by screening, and 
matched controls, those with positive CD screen at baseline had altered body composition 
with lower weight Z scores, body mass index, mid-arm circumference, and increased bone 
turnover (Simmons et al. 2007). In contrast, both groups had similar BMD and glycaemic 
control.  The follow up study of this group is currently the largest prospective study in 
children with T1D and CD autoimmunity, with 80% retention during the follow-up (Simmons 
et al. 2011).  All children who screened positive for CD received dietary education on the 
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GFD, but self-selected whether to consume a GFD or a gluten-containing diet: 43/79 (54%) 
chose a GFD and 36 (46%) chose a regular diet.  Those who had persistently high CD 
antibodies throughout the study period had lower weight and BMI z scores, increased bone 
turnover, and lower vitamin D 25-OH levels, conferring an increased fracture risk, and lower 
ferritin levels, indicating generalised malnutrition.  Consistent with other studies (Hogberg 
et al. 2003), a relationship between age and CD compliance was also observed, with school-
age children less compliant than younger children and adults. 
 
2.4.1 COMPLICATIONS OF TYPE 1 DIABETES   
The landmark Diabetes Control and Complications Trial (DCCT 1993) was a multi-centre, 
randomised controlled clinical trial involving 1441 patients with T1D, which showed that 
intensive therapy reduced the risk of diabetes related complications.  Participants were 
assigned to either conventional diabetes therapy of one or two daily injections of insulin or 
intensive diabetes management, consisting of three or more daily injections of insulin or 
CSII, with target blood glucose ranges pre and post-prandially.  Intensive therapy delayed 
the onset and slowed the progression of clinically important retinopathy, including vision-
threatening lesions, nephropathy, and neuropathy. Risk reductions ranged from 39% for 
microalbuminuria to more than 76% for retinopathy (DCCT 1993). This widely cited study 
provided unequivocal evidence that intensive diabetes treatment and improved glycaemic 
control, often measured by glycated haemoglobin (HbA1c) conferred a significant risk 
reduction for vascular complications. Glycated haemoglobin (HbA1c) has its metric 
limitations as it does not consider the degree of fluctuations between high and low blood 
glucose levels – this is best defined by glycaemic variability. Glycaemic variability is a 
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potential complication of T1D, as even in those without diabetes, is an independent risk 
factor for cardiovascular disease (Hirsch 2015). 
 
2.4.2 COMPLICATIONS OF COELIAC DISEASE  
There is strong evidence that individuals with untreated CD are at risk of complications such 
as iron deficiency, anaemia, growth retardation, fertility problems and gastrointestinal 
malignancy (Gasbarrini et al. 2000, Bai et al. 2013), as well as low BMD and osteoporosis 
(Matysiak-Budnik et al. 2007, Zanchetta et al. 2016). Even asymptomatic individuals in 
whom CD is detected by screening are at risk of these co-morbidities (Bjorck et al. 2017), 
including children with coexisting T1D (Hansen et al. 2006).   
 
BMD is reduced in children and adults with CD (Bianchi et al. 2008, Mora 2008) and low 
BMD in children improves after the introduction of a GFD (Tuna Kirsaclioglu et al. 2016).  
There is also an increased risk of osteoporotic fracture (Kamycheva et al. 2017) and severe 
osteopenia (Zanchetta et al. 2016), which can be corrected by adherence to the GFD 
(Newnham et al. 2016, Zanchetta et al. 2017). In a Swedish prospective population-based 
cohort study, screening detected CD 10-year old children had reduced BMD and lower levels 
of vitamin D compared to controls (Bjorck et al. 2017). In comparison, the same study 
reported similarly aged children diagnosed with CD via screening at the age of three, and 
commenced on a GFD were found to have no difference in BMD compared to controls, 
indicating children with screening-detected CD benefit from early diagnosis and treatment.  
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2.4.3 VASCULAR COMPLICATIONS IN PEOPLE WITH T1D AND CD 
There is strong evidence that individuals with either T1D or CD are at risk of complications, 
which have a multifactorial aetiology including poor compliance with treatment. Therefore, 
it can be speculated that the co-existence of both conditions may confer a greater risk of 
complications, particularly in the setting of suboptimal adherence to therapy.  In a case-
control study from the UK of adults with T1D, those with undetected CD demonstrated 
worse glycaemic control (8.2 vs 7.5%, P=0.05), and a higher prevalence of both retinopathy 
(58.3% vs 25%, p=0.02) and nephropathy (41.6% vs 4.2%, p=0.009) (Leeds et al. 2011). 
Similarly, a population-based Swedish cohort study of 41,566 patients, of whom 980 (2.3%) 
had coexisting CD, demonstrated that CD duration >10 years was an independent risk factor 
for the development of diabetic retinopathy (Mollazadegan et al. 2013). CD was an 
independent risk factor for retinopathy and nephropathy in patients with T1D (Rohrer et al. 
2015), with CD duration > 15 years associated with a 2.8 fold increased risk of death 
(Mollazadegan et al. 2013). These studies highlight not only the importance of screening and 
treating CD in T1D, but also monitoring for the development of microvascular complications.  
 
Established risk factors for vascular complications of diabetes include worse glycaemic 
control and higher blood pressure, but there are limited data on the role of GFD adherence 
on microvascular complications. In the UK study of adults with coexisting T1D and CD (Leeds 
et al. 2011), nine individuals who were GFD adherent for one year had clinically significant 
favourable increases in HDL cholesterol, total cholesterol: HDL ratios, and a lower 
prevalence of advanced nephropathy; however the authors acknowledged their limitations 
of small numbers.  
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In view of the limited data on microvascular complications in those living with coexisting CD 
and T1D, the PhD candidate sought to compare complications rates in youth with or without 
CD and examined the association between GFD adherence and complications. Chapter 4 
presents the results of a comparative study of 2,510 adolescents with T1D alone and 129 
with CD, of whom 60 (47%) did not adhere to the GFD.  
 
2.5 QUALITY OF LIFE (QOL) OF PATIENTS WITH T1D OR CD  
The intensive management of T1D, which includes multiple daily insulin injections or CSII, 
regular blood glucose monitoring and carbohydrate counting, has the potential to negatively 
affect QoL. There is some evidence that QoL is lower in children and adolescents with 
diabetes compared with healthy children (Varni et al. 2003, Delamater et al. 2018), 
particularly when parents rate their children’s QoL (Varni et al. 2003, Hesketh et al. 2004, Yi-
Frazier et al. 2016).  QoL is lower in girls and youths with shorter diabetes duration, those 
with disease-related family conflict (Delamater 2009), or the fear of hypoglycaemia 
(Johnson et al. 2013). However in general, when youth with diabetes rate their own QoL, it 
does not differ from their healthy peers (Laffel et al. 2003, Varni et al. 2003, Hesketh et al. 
2004).  
 
The only treatment for CD is strict adherence to a GFD, which is safe and efficient, but is 
very restrictive. The GFD poses both lifestyle restrictions, with some families avoiding 
travelling or eating out (Cinquetti et al. 1997, Roma et al. 2010) as well as financial strain 
due to increased costs of gluten-free foods compared to gluten-containing foods (Lee et al. 
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2007, Stevens et al. 2008). Gluten-free foods are less readily available and more costly; a 
study from Canada demonstrated that gluten-free products were 252% more expensive 
than regular products (Stevens et al. 2008).  The restrictive nature, limited availability, and 
increased costs of the GFD may result in social burden and poor compliance (Matysiak-
Budnik et al. 2007, Olsson et al. 2008). 
 
The role of a supportive family for children and adolescents living with either T1D or CD 
plays a pivotal role in the child’s management adherence (Olsson et al. 2008, Delamater et 
al. 2018). Supportive behaviours such as family cohesion, agreement about management 
responsibilities, and collaborative problem-solving are associated with better regimen 
adherence and glycaemic control in T1D (Delamater et al. 2018) and those with a familial 
better perception of their own health have higher QoL (van Doorn et al. 2008). In contrast, 
conflict, diffusion of responsibilities and regimen-related conflict have been associated with 
worse regimen adherence and glycaemic control in T1D (Wysocki et al. 2008, Hilliard et al. 
2013, Tsiouli et al. 2013, Delamater et al. 2018), and the perception that GFD adherence is 
difficult (Barratt et al. 2011).  
 
Nutritional management is a cornerstone of care for both T1D and CD. In T1D, mealtime 
behaviour problems are commonly reported and range from parents feeling anxious or 
frustrated when feeding their child,  does not readily come to mealtimes, or has a poor 
appetite in young children (Powers et al. 2002), and are often compounded by the demands 
of carbohydrate counting, eating to manage blood glucose levels independent of hunger 
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(Mehta et al. 2009), and normal child developmental behaviours such as fussy eating.   QoL 
is higher in people with T1D treated with CSII (Misso et al. 2010, Craig 2011), which allows 
flexibility with meal times and food choices (Overby et al. 2008, Mehta et al. 2009). As a GFD 
requires substitution of commonly available carbohydrate foods such as wheat-based 
breads, cereal, and pasta (Stevens et al. 2008), CSII could alleviate the restrictive nature of 
the GFD. However, the impact of CSII on QoL in people with coexisting T1D and CD, and the 
impact of carbohydrate free meals on total insulin doses has not been studied 
 
To date, there is only one paediatric study examining the impact of coexisting CD and T1D 
on QoL, which found no difference in generic, or diabetes-specific QoL compared to children 
with T1D alone (Sud et al. 2012). However, CD specific QoL was not examined, nor was the 
effect of symptoms on QoL. Surprisingly, QoL did not differ between those GFD adherent, vs 
GFD non-adherent, although the number GFD non-adherent in this study was small (n=6), 
which may suggest this subgroup analysis was underpowered. Chapter 6 of this thesis 
reports a larger comparative study of youth with T1D (n=35) vs T1D and CD (n=35), and their 
parents (n=70), and further stratified results by GFD adherence, symptoms of CD, and mode 
of diabetes management - MDI vs CSII.  
 
2.6 DIETARY QUALITY AND GLYCAEMIC VARIABILITY OF THE GLUTEN 
FREE DIET  
CD  is managed by a strict GFD, requiring the complete avoidance of the grains wheat, oats, 
barley and rye, which is often replaced by white rice or corn (Lee et al. 2009). These grains 
may contribute to a higher glycaemic index (GI) (Atkinson et al. 2008), higher glycaemic load 
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(Farnetti et al. 2014) and lower fibre diet (Hopman et al. 2006, Shepherd et al. 2013) 
compared to the gluten containing equivalents. Higher fibre diets in the general population 
have well-known benefits such as improved cardiovascular and bowel health (Anderson et 
al. 2009), and in T1D, these benefits extend to improved glycaemic control (Katz et al. 2014). 
 
Restrictive diets such as the GFD may cause nutritional deficiencies, requiring increased 
vigilance in growing children and adolescents (Collin et al. 1989). The mandatory 
fortification of wheat flour with micronutrients such as thiamine and folic acid (FSANZ 
2016), but not gluten-free grains further places those consuming a GFD at risk of inadequate 
nutrient intake. Studies investigating the nutritional composition of the GFD in adults have 
shown inadequacies of specific micronutrients including thiamine, folate, vitamin A and 
calcium (Thompson et al. 2005, Shepherd et al. 2013). However, there are limited dietary 
studies in youth with CD (Mariani et al. 1998, Hopman et al. 2006, Ohlund et al. 2010)  and 
only one  in children with coexisting T1D (Liu et al. 2018). 
 
Adults and children with CD have lower carbohydrate intake, compared to the general 
population (Mariani et al. 1998, Shepherd et al. 2013), which has been attributed to poor 
palatability, and increased costs of the GFD (Stevens et al. 2008). Carbohydrate intake in 
children with T1D is often at the lower level of dietary guidelines (Delahanty et al. 2009), 
which may be due to a conscious effort to reduce the risk of postprandial hyperglycaemia 
(Mehta et al. 2009). In studies of children with CD, fibre and iron intakes are also 
significantly lower than recommendations (Mariani et al. 1998, Hopman et al. 2006), due to 
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the naturally low fibre and iron content of GF grains (Thompson et al. 2005).  However, 
whether the coexistence of T1D and CD is associated with a greater reduction in 
carbohydrate and fibre intake has not been previously examined. It is unknown whether the 
traditional GFD, with a higher GI and lower fibre content, impacts on glycaemic variability in 
this population.  
 
Technological advancements in diabetes management include continuous glucose 
monitoring systems (CGMS) measuring 5-minutely readings of interstitial glucose levels 
(Bailey et al. 2014), enabling a 24 hour glucose profile, as well as studying the effect of 
individual meals and snacks on blood glucose levels. Utilising this technology, Chapter 7 of 
this thesis reports a comparative case-control, observational study of youth with T1D vs T1D 
and CD. We hypothesised that youth with coexisting T1D and CD would demonstrate 
greater glycaemic excursions and lower nutrient intake. Participants wore a blinded CGMS 
for 6 days, maintained weighed 3 day food diaries, and consumed a test GF meal to 
compare post-prandial excursions (PPE), and macronutrient, micronutrient and fibre 
intakes.   
 
2.7 BONE HEALTH IN TYPE 1 DIABETES AND COELIAC DISEASE 
There is substantial evidence that adults with T1D have abnormal bone mineral density 
(BMD) and are at increased risk of fractures (Thong et al. 2018). There is also limited 
evidence that children and adolescents with T1D have lower BMD (Thrailkill et al. 2005) and 
smaller bone mass (Lettgen et al. 1995, Roggen et al. 2013). Whilst the mechanisms for 
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adverse bone health are multifactorial; in T1D they include inadequate accrual of peak bone 
mass due to impaired bone formation and osteoblast function (Hamann et al. 2012), 
elevated HbA1c (Campos Pastor et al. 2000), and increased production of advanced 
glycation end products (AGEs) (Botushanov et al. 2009) .  
 
Adults with CD also have an increased fracture risk (Heikkila et al. 2015), while both children 
and adults with CD have lower BMD compared with the general population. Proposed 
mechanisms include dietary malabsorption of calcium and vitamin D, which are important 
for bone growth and development (Forestier-Zhang et al. 2016),  or chronic intestinal 
inflammation, which interferes with bone formation and increases bone resorption (Larussa 
et al. 2012).  
 
Collectively these data suggest that individuals with coexisting T1D and CD have an additive 
risk for adverse measures of bone health, but the evidence for this is limited. Low BMD at 
the lumbar spine, defined as a z-score < -2SD, was more prevalent in a cross-sectional study 
of children and adolescents with T1D and coeliac autoimmunity (but not biopsy confirmed 
CD) vs T1D only (12% vs 3%), however actual BMD z-scores were not reported (Simmons et 
al. 2016). In contrast, coexisting T1D and CD was not associated with an increased fracture 
risk in a population based Swedish cohort study of individuals aged <30 years, however BMD 
was not examined (Reilly et al. 2016).     
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Traditional measures of bone, utilizing dual energy x-ray absorptiometry (DXA) in children 
and adolescents, include BMD for age, height and weight, bone mineral content (BMC) and 
BMC for lean tissue mass (LTM). In comparison to DXA, peripheral quantitative computed 
tomography (pQCT) provides characterization of bone, including measures of volumetric 
BMD (vBMD), bone geometry (dimension, area, and cortical thickness), and quantifies 
mineral distribution within the cross-section (Stagi et al. 2016). These parameters allow for 
calculation of bone strength. pQCT also enables the separate measurement of trabecular 
and cortical bone compartments, which may allow for earlier detection of changes in bone 
in response to disease (Stagi et al. 2016).  Trabecular bone is metabolically active, and thus 
any changes in bone structure would usually first be observed here (Lettgen et al. 1995, 
Roggen et al. 2013). Whilst pQCT has demonstrated that children with T1D have smaller 
bones compared with non-diabetic controls (Lettgen et al. 1995, Roggen et al. 2013), this 
tool has not been used to examine bone in youth with coexisting T1D and CD.  
 
Chapter 8 of this thesis presents a case-control study using both DXA and pQCT, of young 
people with coexisting T1D and CD vs T1D alone to address our hypothesis that coexisting 
CD confers a greater risk of abnormal BMD, BMC and bone structure.  
 
2.8 SUMMARY  
Chapter 2 provided the background upon which this doctoral body of work is based. The 
increased prevalence of T1D and CD compared to the general population is due to the 
shared genetic predisposition of both conditions, as well as regular screening (Mahmud 
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2018). However, a clear relationship between the age at T1D diagnosis, and time 
development to CD diagnosis has yet to be established. This relationship is explored and 
reported in Chapter 3, and may provide guidance on the frequency of CD screening, which 
could be stratified by age at T1D diagnosis.  
 
Screening for CD in T1D is widely recommended, however recommendations for frequency 
of screening are variable. Seroconversion from negative to positive CD autoantibodies can 
occur beyond 10 years of diabetes duration (Glastras 2005), highlighting the necessity for 
repeated CD screening. Chapter 4 presents a systematic review of the epidemiology of CD in 
people with T1D to inform screening guidelines.  
 
There is strong evidence that individuals with either T1D or CD are at risk of complications, 
which have a multifactorial aetiology including poor compliance with treatment. Therefore, 
it can be speculated that the co-existence of both conditions may confer a greater risk of 
complications, particularly in the setting of suboptimal adherence to therapy. In adults, the 
coexistence of T1D and CD was associated with worse glycaemic control, higher prevalence 
of retinopathy and nephropathy (Leeds et al 2011). CD duration > 10 years is an 
independent risk factor for rentionpathy (Mollazadegan et al 2013), and >15 years 
associated with a 2.8 fold increase of risk of death. Chapter 2 presents the importance of 
not only screening and managing CD in T1D, but also monitoring for the development of 
microvascular complications. Chapter 5 presents a study comparative study of complications 
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rates in  2,510 adolescents with T1D alone and 129 with CD. The role of GFD adherence in 
particular, is also examined.  
 
T1D and CD management requires multiple daily injections, or CSII, regular blood glucose 
monitoring, carbohydrate counting, and the identification of GF foods. The pervasive nature 
of both conditions is expected to impact of QoL. However, there is only one paediatric study 
examining the impact of coexisting CD and T1D on QoL, which found no difference in 
generic, or diabetes-specific QoL compared to children with T1D alone (Sud et al 2012). 
However, CD specific QoL was not examined, nor was the effect of symptoms on QoL. 
Chapter 6 of this thesis presents a larger comparative study of youth and their parents, and 
further stratifies results by GFD adherence.  
 
CD  is managed by a strict GFD, requiring the complete avoidance of the grains wheat, oats,  
barley and rye, which is often replaced by white rice or corn (Lee et al. 2009). These grains 
may contribute to a higher glycaemic index (GI) (Atkinson et al. 2008), higher glycaemic load 
(Farnetti et al. 2014) and lower fibre diet (Hopman et al. 2006, Shepherd et al. 2013) 
compared to the gluten containing equivalents. The restrictive nature of the GFD may cause 
nutritional deficiencies, requiring increased vigilance in growing children and adolescents 
(Collin et al. 1989).  In adults, the GFD has shown to be inadequate of thiamine, folate, 
vitamin A and calcium (Thompson et al. 2005, Shepherd et al, 2013).  Carbohydrate intake in 
children with T1D (Delahanty et al. 2009), and CD alone (Mariani et al. 1998) is often at the 
lower end of dietary guidelines. However, whether the coexistence of T1D and CD is 
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associated with a greater reduction in carbohydrate and fibre intake has not been previously 
examined.  The impact of the GFD on glycaemic variability has also not been previously 
examined. Chapter 7 of this thesis reports a case-control, observational study of youth with 
T1D vs T1D and CD which examines glycaemic excursions and nutrient intake.  
 
There is substantial evidence that adults with T1D have abnormal BMD and are at increased 
risk of fractures (Thong et al. 2018). There is also limited evidence that youth with T1D have 
lower BMD (Thrailkill et al. 2005) and smaller bone mass (Lettgen et al. 1995, Roggen et al. 
2013). Adults with CD also have an increased fracture risk (Heikkila et al. 2015), while both 
children and adults with CD have lower BMD compared with the general population. 
Collectively, these data suggest those with coexisting T1D and CD have an additive risk for 
adverse measures of bone health. Chapter 8 of this thesis presents a case-control study of 
youth with coexisting T1D and CD vs T1D alone which examines bone health and bone 
quality, as measured by DXA and pQCT.  
 
Understanding the impact of the coexistence of T1D and CD in youth may be important in 
shaping clinical practice guidelines and assist in the practical management of both chronic 
conditions. Obtaining evidence to support CD diagnosis, and thus GFD adherence may 
optimise clinical, dietary and psychosocial management in youth and their families. The 
following chapters present published works relating to the epidemiology of type 1 diabetes 
and coeliac disease – the importance of screening (Chapter 3), and recommendations for 
screening frequency (Chapter 4). The clinical impact of the dual diagnosis on the risk of 
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microvascular complications (Chapter 5), quality of life (Chapter 6), glycaemic variability and 
nutrient intake (Chapter 7), and bone health (Chapter 8) follows.  
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CHAPTER 3: COELIAC DISEASE IN TYPE 1 DIABETES FROM 1990 TO 
2009: HIGHER INCIDENCE IN YOUNG CHILDREN AFTER LONGER 
DIABETES DURATION 
Pham-Short A, Donaghue KC, Ambler G, Chan AK, Craig ME, Diabetic Medicine 2012 Sept; 
29(9): e286-e289. Epub 2012 Aug 12 
 
SYNOPSIS 
This chapter presents a manuscript that reports the incidence and prevalence of CD in 
young people with T1D. The primary hypothesis for this study (Hypothesis 1) was that 
children with co-existing type 1 diabetes and coeliac disease are younger at diabetes onset 
compared with those with type 1 diabetes alone. Key findings include the observation that 
children with coexisting T1D and CD were younger at diabetes onset and those in the 
youngest age group (< 5 years) developed CD after longer diabetes duration compared with 
older children who developed CD. 
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Abstract
Aims To determine the incidence of coeliac disease in young people with Type 1 diabetes and to examine the effect of age at
diabetes onset and disease duration.
Methods This was a clinic-based observational cohort study of 4379 people aged £ 18 years (49% male) between 1990
and 2009 from Sydney, Australia. Screening for coeliac disease was performed at diagnosis and 1–2 yearly using anti-
endomysial and ⁄or anti-tissue transglutaminase immunoglobulin A (IgA) antibodies. Coeliac disease was diagnosed by small
bowel biopsy based on Marsh score ‡ III.
Results Coeliac disease was confirmed by biopsy in 185; of these, 61 (33%) were endomysial or tissue transglutaminase IgA
antibody-positive at diabetes diagnosis. Mean age at diabetes onset was 6.6  4.0 vs. 8.4  4.1 years in those without
coeliac disease (P < 0.001). Mean incidence was 7.7 per 1000 person years (95% CI 6.6–8.9) over 20 years. Incidence was
higher in children aged < 5 years at diabetes diagnosis (10.4 per 1000 person years) vs. ‡ 5 years (6.4 per 1000), incidence
rate ratio 1.6 (95% CI 1.2–2.2, P = 0.002). Coeliac disease was diagnosed after 2, 5 and 10 years of diabetes in 45, 78 and
94% of cases, respectively. Median time to coeliac disease diagnosis was longer in children aged < 5 years at diabetes onset
(3.3 years) compared with older children (0.7 years, P < 0.001).
Conclusions Coeliac disease is common in young people with Type 1 diabetes; the risk is greatest with diabetes onset
< 5 years, but after longer diabetes duration. Screening for coeliac disease should be performed at diabetes diagnosis and for
at least 10 years in young children.
Diabet. Med. 29, e286–e289 (2012)
Keywords age of onset, diet, paediatrics, screening, Type 1 diabetes
Introduction
The association between Type 1 diabetes and coeliac disease is
well documented, but there are few longitudinal studies
reporting incidence [1]. Prevalence rates vary from 1 to 10%
worldwide [2–6] and from 2 to 8% in Australia [7–9]. There is
some evidence for an association with younger age at Type 1
diabetes diagnosis [3] and shorter diabetes duration [4]; how-
ever, none of the published studies have been sufficiently large
enough to determine the influence of both age and duration on
incidence of coeliac disease in the population with diabetes.
Incidence provides a more robust measure of disease risk and
has implications for screening.
Left untreated, long-term effects of coeliac disease include
iron deficiency, anaemia, growth retardation [10] and osteo-
porosis [11]. In Type 1 diabetes, untreated coeliac disease may
be associated with unstable blood glucose levels and a greater
risk of hypoglycaemia [12]. The rationale for coeliac disease
screening includes prevention of these complications and
maximizing growth [13].
The present study was designed to determine the incidence
and prevalence of biopsy-confirmed coeliac disease in a diabe-
tes clinic cohort over 20 years and to examine the association
between age at diabetes diagnosis and diabetes duration on risk
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of coeliac disease. We also sought to examine whether
screening guidelines should vary with age at diagnosis of
Type 1 diabetes.
Patients and methods
This was an observational cohort study of 4379 young people
(2147 male, 49%) with Type 1 diabetes, aged < 18 years,
attending the Children’s Hospital at Westmead, a tertiary
paediatric diabetes centre in New South Wales, Australia,
between January 1990 and December 2009. Type 1 diabetes
was diagnosed by clinical criteria and the presence of islet
antibodies (IAA, GAD and IA-2), as previously described [14].
Serological screening for coeliac disease was performed by
endomysial immunoglobulin A (IgA) autoantibodies, measured
by indirect immunofluorescence until June 2004 and subse-
quently by anti-tissue transglutaminase IgA antibodies
measured by enzyme-linked immunosorbent assay. Screening
was performed at diagnosis and 1–2 yearly thereafter [1].
Coeliac disease was diagnosed by small bowel biopsy findings
of villous atrophy, crypt hyperplasia and increased intraepi-
thelial lymphocyte count (Marsh score ‡ III) [15].
Children were classified into three groups by age at diabetes
diagnosis (< 5, ‡ 5 and ‡ 10 years). Continuous variables were
compared between groups using analysis of variance and cat-
egorical variables using v2-tests. Incidence of coeliac disease
was estimated for the entire population, and by age group, as
the number of new coeliac disease cases during the study period
divided by total person years of follow-up [16]. Incidence was
also estimated by age at diabetes diagnosis (< or ‡ 5 years).
Poisson regression was used to examine the effect of age group,
gender and time period on incidence; estimates are reported as
incidence rate ratio and 95% confidence interval. The preva-
lence of coeliac disease in 2009 was estimated as the number of
young people with coeliac disease divided by the total Type 1
diabetes clinic population at that time [16]. Statistical analyses
were performed using Stata version 11.0 (Stata Corp., College
Station, TX, USA).
Results
Of the 4379 young people, 185 were diagnosed with coeliac
disease; of these 61 (33%) were endomysial or tissue trans-
glutaminase IgA antibody-positive at diabetes diagnosis. Mean
age at diabetes diagnosis was 6.6  4.0 vs. 8.4  4.1 years in
those without coeliac disease (P < 0.001). Characteristics of
children stratified by age group at diabetes diagnosis are shown
in Table 1. Children aged < 5 years at diagnosis had a signifi-
cantly longer median time to coeliac disease diagnosis
(3.3 years) compared with older children (0.7 years,
P < 0.001). One female aged 13 years was diagnosed with
coeliac disease prior to Type 1 diabetes. After excluding this
case, 45, 78 and 94% of children were diagnosed with coeliac
disease within 2, 5 and 10 years of diabetes diagnosis, respec-
tively. A greater proportion of children aged < 5 years at
diabetes diagnosis were diagnosed after longer diabetes dura-
tion compared with older children (P < 0.001) (Fig. 1). An
additional 12 children who were endomysial or tissue trans-
glutaminase IgA antibody-positive subsequently became anti-
body negative and ⁄or had a negative small bowel biopsy,
yielding an assay sensitivity of 94%. Frequency of screening did
not vary significantly over time (P = 0.25) or by age (P = 0.1).
More children were of Caucasian ethnicity among those with
coeliac disease (93%) vs. without coeliac disease (83%,
P = 0.004).
The incidence of coeliac disease over the 20-year period was
7.7 per 1000 person years (95% CI 6.6–8.9). Comparing the
two decades, incidence was 7.5 per 1000 (95% CI 5.8–9.5) in
1990–1999 vs 7.7 (95% CI 6.4–9.3) per 1000 in 2000–2009
(P = 0.85). Incidence of coeliac disease was higher in children
aged < 5 years at diabetes diagnosis (10.4 per 1000 person
years) vs. ‡ 5 years (6.4 per 1000), incidence rate ratio 1.6
(95% CI 1.2–2.2, P = 0.002). Incidence did not differ by gen-
der (P = 0.25) or across the two different antibody assays
(P = 0.26). Prevalence of coeliac disease was 7.1% (95% CI
5.6–8.8) in 2009 (75 biopsy-proven coeliac disease ⁄1051 clinic
population).
Discussion
In this 20-year study of 4379 young people with Type 1
diabetes, coeliac disease incidence was 7.7 per 1000 person
years. Incidence was 60% higher in children aged < 5 years at
diabetes onset, but they were more likely to be diagnosed after
longer diabetes duration. Our data support the importance of
screening for coeliac disease throughout childhood [4], partic-
ularly in children diagnosed with diabetes in early childhood.
The consistent screening frequency over time across all age
groups and steady incidence despite changes in assay method-
ology suggest these findings are not attributable to methodo-
logical bias. In contrast to a higher rate of coeliac disease in
females in the general population, we found no gender bias,
reflecting a population at high risk of coeliac disease [3,17].
There are few longitudinal studies reporting coeliac disease
incidence in children with Type 1 diabetes [1] and none of
these have examined the effect of age at diabetes diagnosis,
although two studies demonstrated an association between
younger age at diabetes diagnosis and coeliac disease preva-
lence [3,18]. Incidence is a robust measure of assessing disease
risk within a population that has varying times of follow-up
[16] and is particularly useful for determining appropriate
screening frequency. In contrast, prevalence represents the
number of diagnosed cases at a single time point and is there-
fore not the best measure to examine the effect of age or
diabetes duration on disease risk.
The relationship between younger age at diagnosis of Type 1
diabetes and longer time to coeliac disease seroconversion has
not been recognized previously. The median time between
diagnosis of diabetes and coeliac disease was 3 years in children
aged < 5 years at diabetes onset, vs. 0.7 years in those aged
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‡ 10 years (Table 1). In a Finnish birth cohort study of children
at genetic risk of Type 1 diabetes, 3 ⁄51 (6%) of young children
who developed Type 1 diabetes also developed coeliac disease
[19]. While the sample size is small, the contemporaneous
diagnosis of both conditions may reflect the high background
risk of the population studied, although it is likely that addi-
tional cases of coeliac disease will be diagnosed over time. In
contrast, the temporal association between onset of Type 1
diabetes and coeliac disease in children aged ‡ 10 years in our
population may reflect the more gradual preclinical onset of
both diseases in older children.
The 7.1% prevalence of coeliac disease indicates a sub-
stantial burden of disease in our diabetes population. In a
multi-centre study from Germany and Austria, there was an
increasing prevalence of coeliac disease over time, which
coincided with a marked increase in screening. However, the
prevalence was relatively low (1.2%), suggesting under-ascer-
tainment of cases. In contrast, we found no difference in coeliac
disease incidence over the two decades, in parallel with an
unchanged rate of coeliac disease screening.
The rationale for early detection and treatment of coeliac
disease in asymptomatic children with Type 1 diabetes is
improved health outcomes following introduction of a gluten-
free diet, as demonstrated in two recent longitudinal studies
[20,21]. Clinical improvements in weight z-scores, haemoglo-
bin and serum ferritin were observed in those compliant with a
gluten-free diet [21]. In contrast, non-compliance was associ-
ated with lower total bone mineral density, lower volumetric
lumbar spine z-score, higher bone turnover, lower vitamin D
and lower ferritin [20]. These findings support routine coeliac
disease screening in young people with Type 1 diabetes and
highlight the importance of adherence to a gluten-free diet to
prevent complications of untreated coeliac disease. The higher
risk of coeliac disease at the time of diagnosis of Type 1
diabetes in the older children in our cohort emphasizes the
importance of timely diagnosis, education and initiation of the
gluten-free diet to maximize the adolescent’s growth and bone
mineral density, particularly as preclinical coeliac disease may
have been present prior to diabetes diagnosis.
Potential limitations of our study include its observational
design; however, data were collected prospectively in our hos-
pital database. While cases are from one centre, the sample is
population-based for Western Sydney. Furthermore, because
the majority of children with diabetes are managed through
tertiary referral diabetes centres, the study population repre-
sents more than half of young people with diabetes in New
South Wales. The change in screening assay from endomysial
to tissue transglutaminase IgA antibodies may have influenced
case ascertainment; however, the consistent frequency of
screening and unchanged incidence both over time and across
screening assays argue against increased detection in recent
years. Finally, those diagnosed with diabetes in recent years
have shorter duration of follow-up, but the majority were
followed for longer than 2 years.
Coeliac disease was diagnosed within the first 5 years of
diabetes for most children (78%); but the proportion was lower
among those aged < 5 years at diabetes diagnosis (64%). The
International Society for Pediatric and Adolescent Diabetes
(ISPAD) guidelines [5] advocate screening at diagnosis in all
children with Type 1 diabetes; our findings support this
recommendation. The guidelines further recommend repeat
annual screening for the first 5 years after diagnosis and second
yearly thereafter; our data demonstrate ongoing screening of
Table 1 Characteristics of young people at diagnosis of coeliac disease, stratified by age group (n = 185)
Age at diabetes diagnosis
P-value< 5 years (n = 80) 5–10 years (n = 61) ‡ 10 years (n = 44)
Mean age at coeliac disease diagnosis (sd) 7.1 (3.4) 10.5 (2.6) 13.3 (1.6)
Male gender (%) 50 46 51 NS
Median time in years to diagnosis of coeliac
disease after diabetes diagnosis (range)
3.0 (0.1–14.3) 2.1 (0.1–10) 0.7 (0.2–3.8) < 0.001
Diagnosed with coeliac disease within 2 years of diabetes (%) 33 48 75 < 0.01
Incidence of coeliac disease per 1000 person years (95% CI) 10.4 (8.2–13.0) 6.5 (4.7–8.8) 6.4 (4.9–8.2) < 0.01*
*< 5 years vs. ‡ 5 years.
NS, not significant.
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FIGURE 1 Proportion of young people diagnosed with coeliac disease
within each year following diabetes diagnosis, stratified by age at diabetes
diagnosis; v2 = 41.4 (d.f. 9), P < 0.001.
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younger children is required for at least 10 years, as they are
more likely to seroconvert. Our findings also indicate that the
yield from annual screening is low beyond 5 years of diabetes
duration in older children. However, children with symptoms
suggestive of coeliac disease should be screened irrespective of
diabetes duration [5].
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CHAPTER 4: SCREENING FOR CELIAC DISEASE IN TYPE 1 DIABETES: A 
SYSTEMATIC REVIEW 
Pham-Short A, Donaghue KC, Ambler G, Phelan H, Twigg S, Craig ME, Pediatrics, 136:1, e170-
176 (2015) 
 
SYNOPSIS 
This chapter presents a manuscript that builds on the findings of Chapter 3, which 
highlighted the importance of regular screening.  Chapter 4 answers the research question 
associated with hypothesis 2 that published guidelines on the frequency of screening for 
coeliac disease in type 1 diabetes are varied and not evidence based. Key findings of this 
study were that the highest yield of CD cases was within 1, 2 and 5 years of diabetes 
duration, at 40%, 55% and 79% respectively, and thus screening should be considered at 
diagnosis, and within 2 and 5 years thereafter.  Another key finding of this paper was that 
85% of CD cases were asymptomatic at the time of CD diagnosis. Although the merits of 
early diagnosis may be argued, we demonstrate in Chapter 5 the benefits of GFD adherence 
on reducing the risk of complications, and further examine the impact of the coexistence of 
both conditions on QoL in chapter 6, glycaemic variability in chapter 7 and bone health in 
chapter 8.   
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Screening for Celiac Disease in Type 1
Diabetes: A Systematic Review
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Helen Phelan, RN, BA, MPHc, Stephen Twigg, MBBS Hons-I, PhD, FRACPb,d, Maria E. Craig, MBBS, PhD, FRACP, MMed(ClinEpi)a,b,e
abstract BACKGROUND AND OBJECTIVES: Prevalence rates of type 1 diabetes (T1D) and celiac disease (CD) vary
from 1.6% to 16.4% worldwide. Screening guidelines are variable and not evidence based. Our
aim was to conduct a systematic review of CD in T1D.
METHODS: Medline, Embase, and the Cochrane Library were searched. Studies were limited to
those in English and in humans. We selected longitudinal cohort studies screening for CD in
T1D with at least 5 years of follow-up. Screening rates, characteristics, and prevalence of
biopsy-proven CD in people with T1D were extracted.
RESULTS: We identiﬁed 457 nonduplicate citations; 48 were selected for full-text review. Nine
longitudinal cohort studies in 11 157 children and adolescents with 587 cases of biopsy-
proven CD met the inclusion criteria. Median follow-up was 10 years (range: 5–18 years). The
weighted pooled prevalence of CD was 5.1% (95% conﬁdence interval: 3.1–7.4%). After
excluding 41 cases with CD onset before T1D, CD was diagnosed in 218 of 546 (40%) subjects
within 1 year, in 55% within 2 years, and in 79% within 5 years of diabetes duration. Two
studies (478 cases) reported higher rates of CD in children aged ,5 years at T1D diagnosis.
The duration of follow-up varied across the included studies. CD screening frequency
progressively decreased with increased T1D duration.
CONCLUSIONS: Because most cases of CD are diagnosed within 5 years of T1D diagnosis, screening
should be considered at T1D diagnosis and within 2 and 5 years thereafter. CD screening
should be considered at other times in patients with symptoms suggestive of CD. More
research is required to determine the screening frequency beyond 5 years of diabetes
duration.
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The association between type 1
diabetes (T1D) and celiac disease
(CD) is well documented in young
people, although reported rates vary.
Prevalence rates from both cross-
sectional and longitudinal studies
range from 1.6% to 16.4%
worldwide,1–5 with the majority of
studies only including children and
adolescents. In contrast, CD
prevalence is 0.3% to 1.0% in the
general population of all ages.6
A greater risk is conferred by female
gender,1,7 younger age, and, in type 1
diabetes, younger age at diabetes
diagnosis.7,8
Recognized adverse effects of
untreated CD include iron deﬁciency,
anemia, growth retardation, and
osteoporosis.9 In T1D, undiagnosed
CD may be associated with unstable
blood glucose levels, a greater risk of
hypoglycemia,10 and increased risk of
retinopathy.11 In those with
conﬁrmed CD and T1D, nonadherence
to a gluten-free diet (GFD) is
associated with early elevation of
albumin excretion rate,12 whereas CD
duration .10 years, irrespective of
GFD adherence, is a risk factor for the
development of diabetic
retinopathy.13 Other clinical
improvements associated with GFD
compliance, including weight z scores,
hemoglobin, and serum ferritin, have
been reported,14 as well as height z
scores and the reversal of iron-
deﬁciency anemia.15 In contrast,
noncompliance with a GFD was
associated with lower total bone
mineral density, lower volumetric
lumbar spine z score, higher bone
turnover, lower vitamin D, and lower
ferritin.16 The rationale for CD
screening is to prevent these adverse
effects and complications, and to
maximize growth. Because
seroconversion from negative to
positive CD autoantibodies can occur
beyond 10 years of diabetes
duration,17 repeated screening for CD
is necessary.
Despite the well-recognized increased
risk of CD in T1D and the potential for
increased morbidity, there are no
systematic reviews examining the
incidence of CD or optimal screening
frequency for CD in T1D.
Contemporary guidelines for T1D
recommend screening by
measurement of tissue
transglutaminase (TTG) or anti-
endomysial antibodies (EMAs).18–20
Recommendations for screening
frequency are variable and not
evidence based. The International
Society for Pediatric and Adolescent
Diabetes recommends screening at
the time of diagnosis and every 1 to
2 years thereafter, with more
frequent assessment if clinically
indicated or if there is a ﬁrst-degree
relative with CD,18 whereas the
American Diabetes Association
recommends considering CD
screening soon after diabetes
diagnosis and in those with clinical
symptoms suggestive of CD.20 In
view of these variable
recommendations, we systematically
reviewed the epidemiology of CD in
people with T1D to inform screening
guidelines.
METHODS
Study Aims
There are 2 speciﬁc aims of this
review. First, we systematically
reviewed the epidemiology of biopsy-
proven CD in people with T1D, with
subgroup analysis by age, gender, and
duration of diabetes. Our second
speciﬁc aim was to examine the risk
of CD in people with T1D, at diagnosis
and at speciﬁc time intervals after
diagnosis, to determine the optimal
frequency of screening.
Study Selection
Inclusion criteria were longitudinal
cohort studies that screened for CD
by using either EMAs and/or TTG in
children, adolescents, or adults with
T1D at least twice. Only studies in
humans and reported in the English
language were included. Exclusion
criteria were studies other than
longitudinal cohort studies, not in
individuals with T1D, and no reports
of screening frequency. The diagnosis
of T1D was based American Diabetes
Association criteria,21 and CD was
conﬁrmed by small bowel biopsy.
Data Sources and Searches
Two reviewers (A.P.-S. and H.P.)
independently searched Medline,
Embase, and the Cochrane Library
from 1946 to November 30, 2014, for
studies of celiac autoimmunity and
biopsy-proven CD in people with T1D.
Search terms were as follows:
“Diabetes Mellitus, type 1/or diabetes
mellitus, type 1.mp,” “celiac disease or
celiac disease.mp,” “celiac sprue or
celiac sprue.mp,” “celiacs or coeliacs.
mp,” “silent celiac or silent celiac.mp,”
“asymptomatic celiac or
asymptomatic celiac.mp,” “subclinical
celiac or subclinical celiac.mp,”
“gluten sensitive enteropathy.mp or
exp celiac disease,” “reticulin.mp or
exp Reticulin,” “gliadin.mp or exp
Gliadin,” “endomysial or endomysium.
mp,” “tissue transglutaminase.mp,”
“antireticulin.mp,” “antigliadin.mp,”
“antiendomysial.mp,” and
“antiendomysium.mp.” We also
performed manual searches through
article reference lists.
Data Extraction and Quality
Assessment
Two reviewers independently
extracted data from the included
studies. For each individual study,
data were collected regarding study
design, country, population and size,
duration of follow-up, age at CD
diagnosis, age at diabetes diagnosis,
gender, diagnostic test(s) performed,
frequency of screening, small bowel
biopsy results, and prevalence rates.
Reports of CD-related symptoms
around the time of CD diagnosis were
also collated. Study quality was
assessed by using the Newcastle-
Ottawa quality assessment scale for
cohort studies.22 This scale evaluates
3 areas, selection, comparability
(confounding factors), and outcome
(assessor blinding and follow-up),
giving a possible total score of 9, with
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a score of .7 indicating good
methodologic quality. Corresponding
authors of included studies were
contacted to request additional data
when applicable.
Data Synthesis and Analysis
Meta-analysis of prevalence rates for
CD was conducted by using a quality-
effects model, which takes into
account differences in study quality in
the estimation of weighted pooled
prevalence.23 Incidence density,
which provides an estimate of
incident cases of CD during
a speciﬁed time period, was
calculated as the total number of
diagnosed cases divided by the
number of patients screened during
follow up (n = 4839, 8789, and 20
299 at 1, 2, and 5 years, respectively).
Incidence is reported per 1000
patient-years, with 95% conﬁdence
intervals estimated assuming
a Poisson distribution. Statistical
analyses were performed by using
Stata, version 13 (StataCorp, College
Station, TS), and meta-analysis of
prevalence was conducted by using
MetaXL (Epigear, Brisbane
Australia).23
RESULTS
The initial search returned a total of
605 citations. After review of abstracts
and full texts, 596 studies were
excluded (Fig 1), leaving 9 cohort
studies that met the inclusion
criteria.1,7,8,17,24–28 The studies were
from Europe (n = 7) and Australia (n =
2). Study characteristics are
summarized in Table 1. They included
a total of 11 157 young people
diagnosed with T1D #21 years of age
(range: 0.6–21.0 years). The overall
methodologic quality of the studies
was fair, with 4 of 9 studies (44%)
scoring $7 on the Newcastle-Ottawa
Scale.8,24,26,27 No adult studies were
identiﬁed. There were a total of 587
cases of coexisting biopsy-proven CD
and T1D, and of these, 41 were
diagnosed before T1D. Median follow-
up after diabetes diagnosis was
10 years (range: 5–18 years).
Deﬁnition of T1D
Three studies provided a deﬁnition of
T1D8,17,28 or reported the presence of
islet autoantibodies.8,17
Prevalence of Biopsy-Proven CD
Prevalence was reported by all
studies and varied from 1.6% to 9.7%
(Fig 2). CD was reported in 587 of 11
157 children and adolescents with
T1D; a meta-analysis of prevalence
using the quality-effects model was
5.1% (95% conﬁdence interval:
3.1–7.4%). CD was diagnosed in 41
cases before diabetes diagnosis (7%
of all CD cases), and these cases were
excluded from further analysis.
Incidence and Incidence Density
Two Australian studies8,17 reported
the incidence of biopsy-proven CD
per 1000 person-years, with similar
rates: 7.2 (1990–1996)17 and 7.7
(1990–2009).8 For 6 studies,7,8,24–27
the number of patients screened per
year of diabetes duration was
available, enabling incidence density
to be calculated (Table 2). Incidence
density was 43.4 per 1000 patient-
years at 1 year, 32.8 at 2 years, and
20.1 at 5 years (Table 3). This ﬁnding
indicates that the rate of CD was
highest within the ﬁrst year after
diagnosis of T1D. The incidence
density rates decreased signiﬁcantly
between the 3 time points: year 2
compared with year 1 (P = .002) and
year 5 compared with year 2 (P ,
.001).
Seroconversion
Five studies reported seroconversion
to positive EMAs and/or TTG after
diabetes diagnosis1,17,24,25,27; time to
seroconversion ranged from 2 years1
to 10.2 years.17 The other 4 studies
reported time between CD and T1D
diagnosis, without providing
information on seroconversion.
Association Between CD, Gender, and
Age
Seven studies reported CD prevalence
by gender,1,7,8,17,25,26,28 and of these,
the prevalence was higher in girls in 2
studies (67% and 61%),1,7 higher in
boys in 3 studies (range:
64–69%),25,26,28 and not different in
FIGURE 1
Flowchart showing the number of citations retrieved by individual searches and number of studies
included in the review.
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2 studies8,17 Six studies reported CD
prevalence by age at diabetes
diagnosis,7,8,17,24,26,28 2 studies
reported an association between
younger age (,5 years) at T1D
diagnosis and development of CD,7,8
with 1 study noting a tendency
toward younger age at diabetes
diagnosis, although the relationship
was not statistically signiﬁcant.26
Three studies reported no
relationship with age at diabetes
diagnosis.17,24,28
Association Between CD and
Diabetes Duration
Of the 546 CD cases diagnosed after
diabetes, 40% were within 1 year of
diabetes, 55% within 2 years, and
79% within 5 years of diabetes
diagnosis. The proportion of patients
screened decreased from 50% at
the end of year 1, to 35% (P , .001)
at the end of year 5, and 12% at the
end of year 10.
Symptomatology
Five studies reported data on
CD-related symptoms and signs
(gastrointestinal, short stature,
anemia, or asymptomatic; n =
308),1,7,25,28,29 with 85% of cases
asymptomatic at the time of CD
diagnosis.
Recommendations for Screening
The majority of studies (7 of 9)
recommended screening for CD at
least once in people with
T1D.1,7,8,17,24–26 Four studies
recommended screening at diabetes
onset,1,8,24,26 whereas follow-up
screening recommendations were
variable in frequency and duration,
ranging from annually for at least
2 years26 up to an unspeciﬁed
duration of diabetes (described as
several years).1,17,24
TABLE 1 Characteristics of Included Studies Screening for CD in T1D
First Author,
Year
Country Study Design Number
Screened
CD
Prevalence,
%
Follow-
up, y
Age at CD
Diagnosis,a y
Age at
Diabetes
Diagnosis, y
Screening Test Screening
Frequency
Newcastle-
Ottowa
Scale
Barera,
200224
Italy Prospective 274 6.2 6 NR 8.3 6 4.6 EMA IgA; if IgA
deﬁcient, IgG
EMAs and
AGAs
At diagnosis and
annually
7
Cerutti,
20047
Italy Retrospective 4322 6.8 10 7.2 6 4.3 5.5 6 3.7 IgA/IgG AGAs
and/or EMAs
Annually 6
Crone,
200325
Austria Longitudinal 157 5.1 8 NR NR EMAs 2–3 times yearly 5
Glastras,
200517
Australia Prospective 173 4.6 13 NR NR EMAs and/or
AGAs
At diagnosis,
1–3 times
yearly
thereafter
6
Larsson,
200826
Sweden Prospective 300 9.7 5 11.1 6.5 IgA EMAs At diagnosis,
then annually
8
Pham-Short,
20128
Australia Prospective 4379 4.2 $10 9.6 6 3.7 6.6 6 4.0 IgA EMAs and/
or IgA TTG
At diagnosis 1–2
times yearly
thereafter
8
Poulain,
20071
France Retrospective 950 1.6 .10 9.4 6 4.8 6.0 6 4.2 EMA and or TTG NR 6
Salardi,
200827
Italy Prospective 331 6.6 18 NR NR EMA At diagnosis and
then every
6–12 mo
8
Uibo, 201028 Estonia Prospective 271 4.1 6 9.9 (range: 3.1–16.2) NR IgA EMA and IgA
TTG
NR 6
AGA, anti-gliadin antibody; NR. not reported.
aData are presented as means 6 SDs or medians (range)NR not reported
FIGURE 2
Prevalence of CD in T1D. The forest plot shows unadjusted prevalence estimates (boxes) and pooled
prevalence (diamond) with 95% conﬁdence intervals (bars).
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DISCUSSION
In this systematic review of 9
longitudinal cohort studies involving
11 157 children and adolescents with
T1D, of whom 587 had biopsy-proven
CD, the prevalence of CD varied from
1.6% to 9.7%, with a weighted pooled
prevalence of 5.1%. Incidence density
at 1, 2, and 5 years of diabetes
duration was 43.4, 32.8, and 20.1 per
1000 patients-years, respectively,
indicating that the risk of CD is
highest within the ﬁrst year of
diabetes duration. Because 55% of
cases were diagnosed within 2 years
and 79% within 5 years of diabetes
duration, screening should be
considered at diabetes diagnosis and
within 2 and 5 years after diagnosis.
Because of limited evidence from
long-term studies, it is not possible to
recommend the screening frequency
beyond 5 years of diabetes duration.
However, among the studies with
longer follow-up, 16% of CD cases
were diagnosed between 5 and
10 years of diabetes duration and 5%
were diagnosed after .10 years. CD
should be considered at any time in
patients with symptoms suggestive
of CD.
Prevalence of CD in T1D
There was considerable variation in
the prevalence of CD across the 9
included studies. Possible
explanations for this heterogeneity
include ethnic differences across the
study populations, which is likely to
reﬂect the greater risk of CD among
individuals with high-risk HLA
antigen genotypes,30 as well as the
varying impact of environmental
inﬂuences across different
countries.31 Our ﬁnding of the highest
prevalence rate in Sweden (9.7%) is
in keeping with the The
Environmental Determinants of
Diabetes in the Young (TEDDY) study,
which recently reported a higher risk
of CD in Swedish children compared
with those in the United States,
Finland, and Germany.31 The
variation in prevalence rates may also
be related to differences in study
design, including retrospective versus
prospective, the frequency of
screening, and duration of follow-up.
To address this issue, we chose to use
a quality-effects model in the meta-
analysis of prevalence,23 which
accounts for study quality in the
estimation of pooled prevalence.
Clinical Importance of CD Screening
in T1D
It is notable that 85% of cases
presented asymptomatically in this
review. Although the merits of early
diagnosis may be argued,32 especially
in those with a milder disease
phenotype,33 compliance to a GFD in
those with biopsy-proven CD may
improve clinical variables such as
weight and serum ferritin.14
Improvements in quality of life and
depression scores have been reported
1 year after CD diagnosis.34 In
contrast, nonadherence to a GFD has
been associated with elevated
albumin excretion rate,12 lower bone
mineral density, lower vitamin D, and
lower ferritin14 in youth with
coexisting CD and T1D. These clinical
and psychological improvements
support routine CD screening in T1D
and highlight the importance of
adherence to a GFD to prevent
complications of untreated CD.
Strengths and Weaknesses
This is the ﬁrst systematic review, to
our knowledge, to examine screening
for CD in T1D to determine the
optimal screening frequency. The
strengths of this review are the large
sample size and long observation
period, providing representative data
on the epidemiology in T1D across
different countries. Our analysis is
limited by the variable follow-up
periods across the studies, as well as
missing data on the number of
patients screened throughout each
year of diabetes duration. The
frequency of antibody screening for
CD progressively decreased with
increased duration of diabetes, which
is likely to have led to an
underestimate of incidence and
prevalence.
There are various factors associated
with the systematic review process
that may inﬂuence our ﬁndings.
Although predetermined selection
criteria were implemented to ensure
an unbiased selection, we sought to
minimize this bias by placing no
limitations on the basis of age;
however, the lack of adult studies
identiﬁed may inﬂuence the
generalizability of our results beyond
the pediatric age range. Another
potential weakness is that the
populations of the included studies
were predominantly of European
descent, whereas no studies from
other regions such as North America
and the Middle East met the eligibility
TABLE 2 Number of New CD Cases Diagnosed in Relation to T1D Duration
Number Proportion, %
Total CD cases in study 587
Before diabetes diagnosis 41 7
Within 1 year of diabetes diagnosis 220 37
Within 1–2 years of diabetes diagnosis 78 13
2 to ,5 years after diabetes diagnosis 135 24
5–10 years after diabetes diagnosis 89 15
More than 10 years after diabetes diagnosis 25 4
TABLE 3 Pooled Incidence Density of CD in Young People With T1D
Population Screened Biopsy-Proven CD Cases Incidence per 1000 Patient-Years (95% CI)
Year 1 4839 210 43.4 (37.8–49.5)
Year 2 8789 288 32.8 (29.2–36.7)
Year 5 20 299 407 20.1 (18.2–22.1)
Incidence was calculated from available data in 6 publications.7,8,24–27 Year 2 versus year 1, P = .002; year 5 versus year 2,
P , .001. CI, conﬁdence interval.
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criteria. The reduced screening
frequency between years 2 and 5
coincided with reduced prevalence
and incidence rates; however, we
estimate that this would not have
signiﬁcantly inﬂuenced case detection
rates had the screening rate been
maintained at 50% between 2 and 5
years. Furthermore, some studies did
not provide sufﬁcient information to
be able to calculate incidence
density,1,17,28 and thus our reported
values are conservative.
Screening in Adults
No longitudinal adult studies
examining the screening frequency of
CD in T1D were identiﬁed. However,
a retrospective study in 118 adults
with T1D and CD35 found that 48% of
those diagnosed with T1D after age
18 years reported CD symptoms for
.5 years before CD diagnosis, in
contrast to the group whose diabetes
was diagnosed in childhood, with
a majority (59%) reporting CD-
related symptoms for ,6 months
before CD diagnosis. Prospective
studies are required in adults to
determine the optimal frequency of
screening.
Implications for Clinical Practice
On the basis of our systematic review
of data from cohort studies, more
than half of CD cases were diagnosed
within 2 years of diabetes duration,
with most cases diagnosed within the
ﬁrst 5 years after diabetes diagnosis.
The contemporaneous diagnosis of
both conditions most likely describes
the diagnosis of preexisting CD not
previously recognized and may reﬂect
the high background risk of the
population studied.30 Although CD
can be diagnosed beyond 10 years
after diabetes diagnosis, more
research is required to establish the
optimal screening frequency beyond
5 years of diabetes duration as well as
the optimal screening frequency in
adults with T1D. The impact of
gender, age at diabetes diagnosis, and
diabetes duration on CD development
is unclear. In patients with clinical
symptoms such as growth failure,
weight loss, and frequent unexplained
hypoglycemia, or those with a ﬁrst-
degree relative with CD, screening for
CD should be considered irrespective
of diabetes duration.18,36 Although
not examined in this review, it should
be noted that screening for
immunoglobulin (Ig) A deﬁciency
(prevalence: 1:500) is recommended
in recent guidelines18 due to the risk
of a false-negative TTG result, and if
present, then IgG-speciﬁc antibody
tests (TTG or EMA IgG or both)
should be performed.18,19
Future Directions
This systematic review shows an
elevated risk of CD in people with
T1D, particularly in the early course
of disease. We were unable to
examine the effect of gender and age
at diabetes diagnosis on CD
development, highlighting the need
for prospective cohort studies
beyond 5 years of diabetes duration
as well as those that report on the
impact of annual CD screening and
with the inclusion of adults to
further quantify the frequency of CD
screening in T1D.
ABBREVIATIONS
CD: celiac disease
EMA: anti-endomysial antibody
GFD: gluten-free diet
Ig: immunoglobulin
T1D: type 1 diabetes
TTG: tissue transglutaminase
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CHAPTER 5 EARLY ELEVATION OF ALBUMIN EXCRETION RATE IS 
ASSOCIATED WITH POOR GLUTEN FREE DIET ADHERENCE IN YOUNG 
PEOPLE WITH COELIAC DISEASE AND DIABETES  
Pham-Short A, Donaghue KC, Ambler G, Chan AK, Hing S, Cusumano J, Craig ME, Diabetic 
Medicine 2014 Feb; 31(2):208-212. Epub Oct 2013  
 
SYNOPSIS 
The following chapters (5,6,7 and 8) present manuscripts which examined the clinical impact 
of coexisting T1D and CD. This chapter presents a manuscript that reports the diabetes 
related microvascular complications rates in youth with or without CD and examines the 
association between GFD and complications. The primary hypothesis for this study 
(Hypothesis 3) was young people with type 1 diabetes and coeliac disease, who do not 
adhere to the gluten free diet, have higher complications rates, independent of glycaemic 
control, compared with those who adhere.  Key findings include non-adherence to the GFD, 
as measured by serological markers and confirmed by dietary assessement and is associated 
with early elevation of albumin excretion rates, a sign of early kidney disease. The dual 
diagnosis of T1D and CD and its effects on other aspects of health such as psychological 
wellbeing, glycaemic variability, nutrient intake and bone health are further examined in 
chapters 6, 7 and 8.  
 
Short Report: Complications
Early elevation of albumin excretion rate is associated
with poor gluten-free diet adherence in young people
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Abstract
Aims There are conflicting data on microvascular complications in coexisting Type 1 diabetes and coeliac disease. We
compared complications rates in youth with or without coeliac disease and examined the association between gluten-free
diet adherence and complications.
Methods This was a comparative study of adolescents (2510 without coeliac disease, 129 with coeliac disease); 60
(47%) did not adhere to a gluten-free diet—defined as elevated anti-tissue transglutaminase or endomysial
immunoglobulin A titres. Retinopathy was detected using 7-field fundal photography and albumin excretion rate by
timed overnight urine collections, with early elevation defined as albumin excretion rate ≥ 7.5 lg/min. Logistic
regression was used to examine the association between complications and explanatory variables, including coeliac
disease vs. no coeliac disease, gluten-free diet adherence vs. non-adherence, diabetes duration and HbA1c.
Results Median age at last assessment was 16.5 years. Those with coeliac disease vs. those without were younger at
diabetes diagnosis (7.1 vs. 8.6 years, P < 0.001) and had longer diabetes duration (9.3 vs. 7.2 years, P < 0.001). HbA1c
was lower in those with coeliac disease vs. those without (67 vs. 70 mmol/mol, 8.3 vs. 8.6%, P = 0.04) and adherence to
a gluten-free diet vs. non-adherence (66 vs. 72 mmol/mol, 8.2 vs. 8.7%, P = 0.003). There were no differences in
complication rates between those with coeliac disease vs. those without (retinopathy 22 vs. 23%, elevated albumin
excretion rate 31 vs. 28%). Non-adherence to a gluten-free diet was associated with elevated albumin excretion rate (40
vs. 23%, P = 0.04). In multivariable logistic regression, elevated albumin excretion rate was associated with
non-adherence to a gluten-free diet (odds ratio 2.37, 95% CI 1.04–5.40, P = 0.04) and diabetes duration (odds
ratio 1.13, 95% CI 1.02–1.25, P = 0.03), but not HbA1c.
Conclusions While glycaemic control is better in patients with coeliac disease, non-adherence to a gluten-free diet is
associated with elevated albumin excretion rate. The possible protection of a gluten-free diet on complications warrants
further investigation.
Diabet. Med. 31, 208–212 (2014)
Introduction
There are conflicting data on the risk of microvascular
complications among individuals with both Type 1 diabetes
and coeliac disease [1–3]. While coexisting coeliac disease is
associated with an increased risk of retinopathy in unde-
tected coeliac disease [3] and vascular disease [3,4], several
studies have shown a reduced risk of nephropathy and
retinopathy following diagnosis of coeliac disease and
gluten-free diet commencement [1–3]. The risk factors are
likely to be multifactorial, although glycaemic control has
not consistently been associated with complications risk in
coeliac disease. Furthermore, the effect of long-term glu-
ten-free diet adherence on complications risk has not been
examined. We hypothesized that young people with Type 1
diabetes, coeliac disease and poor adherence to a gluten-free
diet would have higher complications rates, independent of
glycaemic control.Correspondence to: Maria Craig.
E-mail: m.craig@unsw.edu.au; maria.craig@health.nsw.gov.au
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Patients and methods
This was a comparative study of 2510 young people with
Type 1 diabetes without coeliac disease and 129 with coeliac
disease aged < 20 years at their most recent visit to the
Diabetes Complications Assessment Service from 1990 to
2010. Type 1 diabetes was diagnosed by clinical criteria and
the presence of islet antibodies [insulin, glutamic acid
decarboxylase (GAD) and islet antigen 2 (IA-2)], as previ-
ously described [5]. Coeliac disease was diagnosed by
positive coeliac serology, either endomysial immunoglobu-
lin A (IgA) or anti-tissue transglutaminase IgA antibodies,
and confirmed by small bowel biopsy [6]. For those with
coeliac disease, a gluten-free diet was defined as endomysial
or tissue transglutaminase autoantibodies within the normal
range at the complications assessment and non-adherence to
a gluten-free diet defined as elevated endomysial or tissue
transglutaminase autoantibodies. The study was approved by
the Sydney Children’s Hospital Network Ethics Committee.
Complications assessment
At their most recent visit, participants were assessed using
our established complications screening methods [7–10],
including clinical examination, anthropometry, 7-field ste-
reoscopic fundal photography for retinopathy, timed over-
night urine collections for measurement of albumin excretion
rate, quantitative sensory methods (thermal threshold and
vibration perception at the foot) for peripheral neuropathy
and pupillometry for autonomic neuropathy. Early elevation
of albumin excretion rate was defined as ≥ 7.5 lg/min,
which we have shown predicts subsequent development of
persistent microalbuminuria [7]. HbA1c was assessed by
high-performance liquid chromatography (Diamat BioRad,
Hercules, CA, USA; non-diabetic range 4–6%). Endomy-
sial or tissue transglutaminase were performed at all study
visits.
Statistical analysis
Cases of coeliac disease were stratified as adherence or
non-adherence to a gluten-free diet for analysis. Continuous
variables were compared between groups using analysis of
variance and categorical variables using v2-tests (Table 1).
Binary logistic regression was used to examine the association
between complication outcomes (presence or absence of early
retinopathy, early elevation of albumin excretion rate or periph-
eral nerve abnormalities) and explanatory variables, including
adherence to a gluten-free diet vs. non-adherence, age, most
recent HbA1c measurement, gender, BMI standard deviation
score (SDS), insulin per kg per day and use of continuous
subcutaneous insulin infusion therapy. Clinically relevant inter-
action terms, such as HbA1c 9 non-adherence to a gluten-free
diet, were examined in multivariable models. Analyses were
performed using SPSS, version 20 (SPSS Inc., Chicago, IL, USA).
Results
Overall, 129/2639 (4.9%) had coeliac disease, with a median
coeliac disease duration of 5.6 years. Comparing patients
with coeliac disease and those without, there was no
difference in current age, but those with coeliac disease were
significantly younger at diabetes diagnosis and therefore had
longer diabetes duration (Table 1). HbA1c was lower in
those with coeliac disease and more patients with coeliac
disease used continuous subcutaneous insulin infusion
(Table 1). There was some evidence for a higher total daily
insulin dose per kg body weight in those with coeliac disease,
but this did not reach statistical significance. There were no
differences in anthropometry, total cholesterol or complica-
tions rates in those individuals without coeliac disease vs.
those with coeliac disease. When patients with coeliac disease
were matched for age, diabetes duration and HbA1c with
those without coeliac disease (2:1), complications rates did
not differ between the two groups (data not shown).
Adolescents adhering to a gluten-free diet had significantly
better glycaemic control vs. non-adherence at the most recent
visit and over the preceding 12 months (Table 1). Despite
this, reported total daily insulin dose was higher in those
without a gluten-free diet. There were no differences in
current age, gender, diabetes duration or coeliac disease
duration between adherence to a gluten-free diet and
non-adherence (Table 1). There was a high correlation
between gluten-free diet adherence status (adherence or
non-adherence) at the last visit and at previous complications
assessments (data not shown).
The frequency of early elevation of albumin excretion rate
was significantly higher in non-adherence vs. adherence to a
gluten-free diet. In multivariable logistic regression, elevated
What’s new?
• There are no studies investigating the effect of glu-
ten-free diet non-adherence in young people with
Type 1 diabetes and coeliac disease.
• This is the first study in young people with Type 1
diabetes with or without coeliac disease, examining the
influence of gluten-free diet adherence on complications
rates.
• We report data on 2639 young people with Type 1
diabetes, of whom 129 had coeliac disease. While
glycaemic control was better in those with coeliac
disease, non-adherence to a gluten-free diet was asso-
ciated with early elevation of albumin excretion rate, a
recognized risk factor for diabetic nephropathy.
• Our findings support the need for coeliac disease
screening and adherence to a gluten-free diet in those
with coeliac disease.
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albumin excretion rate was associated with non-adherence to
a gluten-free diet (odds ratio 2.37, 95% CI 1.04–5.40,
P = 0.039) and diabetes duration (odds ratio 1.13, 95% CI
1.02–1.25, P = 0.026). HbA1c was not significant in univar-
iate analysis (odds ratio 1.24, 95% CI 0.96–1.61, P = 0.1)
or in the multivariable model. The interaction between
HbA1c and non-adherence to a gluten-free diet was also not
significant (P = 0.13). Non-adherence to a gluten-free diet
was not associated with higher rates of other microvascular
complications. When the subgroup of gluten-free diet
adherence were compared with those without coeliac disease,
there was no difference in the rate of early elevation of
albumin excretion rate (P = 0.36).
Discussion
The burden of coexisting Type 1 diabetes and coeliac disease
may be expected to result in worse glycaemic control,
conferring a greater risk of complications. However, in our
study of 2639 young people with Type 1 diabetes, glycaemic
control was actually better in the 129 individuals with
coeliac disease, despite younger age at diabetes onset and
longer diabetes duration. Reassuringly, coeliac disease was
not associated with higher rates of any microvascular
complications, lower height SDS [11–13] or adverse lipid
profiles. There was a higher rate of continuous subcutaneous
insulin infusion use in those with coeliac disease, which may
have contributed to better glycaemic control and may assist
in management of both diseases, although this was not
explored in the present study.
This is the first study in young people with coexisting
Type 1 diabetes and coeliac disease to compare complica-
tion rates stratified by gluten-free diet adherence. We found
early evidence of renal disease associated with non-adher-
ence vs. adherence to a gluten-free diet. Conversely, a
case–control study (matched for age, sex, duration and
Table 1 Characteristics and complication rates in young people with Type 1 diabetes, stratified by (1) coexisting coeliac disease and (2) gluten-free
diet adherence
Type 1 diabetes
Type 1 diabetes +
coeliac disease P
Gluten-free diet,
adherent
Gluten-free diet,
non-adherent P
n 2510 129 69 60
Age at diabetes
diagnosis
(years)
8.6 (5.3–11.4) 7.1 (2.9–10.0) < 0.001 6.7 (2.9–9.6) 7.3 (2.8–1.0) 0.48
Current age (years) 16.5 (14.8–17.9) 16.1 (14.3–17.8) 0.13 15.8 (14.4–17.8) 16.4 (14.3–17.9) 0.43
Diabetes duration
(years)
7.2 (4.9–10.4) 9.3 (6.3–12.2) < 0.001 9.2 (6.60–12.22) 9.4 (6.3–12.3) 0.81
Coeliac disease
duration
(years)
— 6.6 (3.0–10.3) 6.2 (3.1–9.6) 6.7 (2.8–11.5) 0.54
Male gender (%) 1206/2510 (48%) 55/129 (43%) 0.24 26/69 (38%) 29/60 (48%) 0.22
HbA1c (mmol/mol) 70 (61–81) 67 (60–78) 0.04 66 (60–75) 72 (62–86) 0.003
HbA1c (%) 8.6 (7.7–9.6) 8.3 (7.6–9.3) 0.04 8.2 (7.6–9.0) 8.7 (7.8-10.0) 0.003
Mean HbA1c
over last
12 months (%)
70 (62–81) 67 (62–79) 0.08 66 (62–73) 73 (62–8.6) 0.009
Mean HbA1c
over last
12 months
(mmol/mol)
8.6 (7.8–9.6) 8.3 (7.8–9.4) 0.08 8.2 (7.8–8.8) 8.8 (7.8–10.0) 0.009
HbA1c > 75
mmol/mol
(9.0%)
927/2447 (38%) 33/127 (26%) 0.025 10/69 (14%) 23/58 (40%) 0.002
Insulin pump
therapy
322/2468 (13%) 25/126 (20%) 0.04 15/68 (22%) 10/58 (17%) 0.50
Height SDS 0.23 (–0.45 to 0.90) 0.20 (–0.58 to 0.85) 0.28 0.75 (–0.60 to 0.72) 0.29 (–0.58 to 1.00) 0.51
Weight SDS 0.78 (0.17–1.26) 0.75 (0.15–1.22) 0.86 0.59 (0.13–1.13) 0.95 (0.22–1.33) 0.39
BMI SDS 0.70 (0.15–1.20) 0.81 (0.16–1.26) 0.59 0.61 (0.06–1.10) 1.00 (0.28–1.30) 0.61
Cholesterol (mmol/l) 4.3 (3.8–5.0) 4.4 (3.8–5.0) 0.54 4.20 (3.70–5.00) 4.45 (3.93–5.1) 0.08
Insulin dose
(unit kg–1 day–1)
1.05 (0.87–1.28) 1.08 (0.91–1.34) 0.08 1.03 (0.88–1.27) 1.15 (0.99–1.46) 0.002
Albumin excretion
rate ≥ 7.5 lg/min
600/2118 (28%) 36/117 (31%) 0.60 15/65 (23%) 21/52 (40%) 0.04
Peripheral nerve
abnormality
627/2425 (26%) 36/128 (28%) 0.61 17/68 (25%) 19/60 (32%) 0.40
Retinopathy 556/2381 (23%) 27/125 (22%) 0.75 12/67 (18%) 15/58 (26%) 0.38
Pupillary
abnormality
1020/1771 (58%) 63/105 (60%) 0.69 32/55 (58%) 31/50 (62%) 0.69
Data are number (%) or median (interquartile range).
SDS, standard deviation score.
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HbA1c) found albumin:creatinine ratio was lower in those
with coeliac disease vs. those without coeliac disease [1],
those with coeliac disease had negative tissue transgluta-
minase antibodies, indicating a gluten-free diet. However,
there was no comparison group of those non-adherent to
the gluten free diet. The authors speculated that this lower
albumin:creatinine ratio was attributable to consumption
of less high-temperature processed foods in the gluten-free
diet, demonstrated by lower plasma advanced glycation
end-product fluorescence in coeliac disease vs. no coeliac
disease-. Whilst we did not assess dietary intake, we
speculate our patients not adhering to a gluten-free diet (as
demonstrated by the patients’ elevated antibodies) may
have consumed more highly processed gluten-containing
foods, along with higher salt and high-fat intake. Whilst
we did not measure inflammatory markers, non-adherence
to a gluten-free diet may be associated with chronic
low-grade inflammation, which may also play a role in
early elevation of albumin excretion rate. Collectively,
these data support further investigation of dietary factors,
including advanced glycation end-products on complica-
tions risk, particularly in coeliac disease.
In adults, only a few studies have examined the impact of
coeliac disease on microvascular complications [2–4] and
none investigated the role of gluten-free diet non-adherence
beyond 1 year of coeliac disease duration. Whilst undetected
coeliac disease was associated with higher nephropathy
prevalence [3], 1 year of gluten-free diet adherence resulted
in a reduction in estimated glomerular filtration rate (eGFR).
A large Swedish study found coeliac disease duration
> 10 years was a risk factor for retinopathy [4]; however,
neither gluten-free diet adherence nor glycaemic control were
examined. An Italian study showed the combination of
Type 1 diabetes and coeliac disease was associated with
severe subclinical atherosclerosis than either condition alone
[14], independent of glycaemic control, disease duration,
lipid and anthropometric parameters. Similarly, glycaemic
control was not associated with early elevation of albumin
excretion rate in our patients with coeliac disease, suggesting
the risk of albumin excretion rate in coeliac disease is
multifactorial, including diet, inflammation, blood pressure
and genetic predisposition [17].
Potential limitations of our study include the use of
cross-sectional analysis, which cannot determine causality,
however, we elected to analyse data at the last study visit to
enable the longest diabetes and coeliac disease duration to be
included in the analysis. The singular tissue transglutaminase
measurement as a marker of gluten free diet adherence may
not reflect the general adherence to the gluten-free diet over
time; however, gluten free diet adherence status was consistent
with previous visits in the majority of cases.
In summary, we have demonstrated that gluten free diet
non-adherence is associated with early elevation of albumin
excretion rate, which is a recognized risk factor for
future development of microalbuminuria in Type 1 diabetes
[7,15–17]. While the role of poor glycaemic control on
microvascular complications development is well estab-
lished, non-adherence to a gluten-free diet was associated
with albumin excretion rate, independent of HbA1c. Our
findings support the need for adherence to the gluten-free
diet in people with coeliac disease and regular dietetic
review to ensure adequate dietary education. They also
provide further rationale for coeliac disease screening in
Type 1 diabetes [8,18,19].
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CHAPTER 6 QUALITY OF LIFE IN TYPE 1 DIABETES AND CELIAC 
DISEASE: ROLE OF THE GLUTEN-FREE DIET 
Pham-Short A, Donaghue KC, Ambler G, Garnett S, Craig ME, The Journal of Pediatrics, 179: 
131-8 (2016) 
 
SYNOPSIS 
Chapter 5 demonstrated that GFD non-adherence was associated with early signs of renal 
disease, which suggests that those who struggle with the coexistence of two chronic 
conditions are at higher risk of complications. However, there is a paucity of data on the 
impact of living with both conditions on QoL and general well-being. This chapter presents a 
manuscript that helps fill this knowledge gap.   Chapter 6 answers the research question 
associated with hypothesis 4 that quality of life scores are lower (a) in youth with type 1 
diabetes and coeliac disease compared with type 1 diabetes only, and (b) in those who do 
not adhere to the gluten-free diet compared with those who adhere. Key findings are there 
was no difference in QoL in those with diabetes alone, vs those with T1D and CD, however 
once stratified by GFD adherence, found those non-adherent had lower QoL, and worse 
glycaemic control. This highlights the role of GFD adherence and the importance of finding 
strategies to understand and improve adherence in those with both conditions. 
 
  
Quality of Life in Type 1 Diabetes and Celiac Disease:
Role of the Gluten-Free Diet
Anna Pham-Short, BSc(Nutr)(Hons-I)1,2, Kim C. Donaghue, MBBS, PhD, FRACP1,2, Geoffrey Ambler, MBBS, MD, FRACP1,2,
Sarah Garnett, BSc, MNutrDiet, PhD1,2, and Maria E. Craig, MBBS, PhD, FRACP1,2,3
Objective To evaluate quality of life (QoL) and glycemic control in youth with type 1 diabetes (T1D) and celiac
disease vs T1D only. We hypothesized that QoL scores would be lower in youth with T1D and celiac disease and
those nonadherent to the gluten-free diet (GFD).
Study design This case control study included 35 youth with T1D and 35 with T1D and celiac disease matched
for age, sex, diabetes duration, and hemoglobin A1c level. QoL was assessed in participants and parents using
the Pediatric Quality of Life Inventory Generic Core Scale, Pediatric Quality of Life Inventory Diabetes Module. and
the General Well-Being Scale; youth with T1D and celiac disease also completed the celiac disease-specific DUX
questionnaire and parents completed the Pediatric Quality of Life Inventory Family Impact Scale. Questionnaires
were scored from 0 to 100; higher scores indicate better QoL or well-being. Scores were compared between T1D
vs T1D with celiac disease, with subgroup analysis by GFD adherence vs nonadherence and therapy (continuous
subcutaneous insulin infusion vs multiple daily injections).
Results Youth with T1D and celiac disease reported similar generic and diabetes-specific QoL to T1D only. GFD
nonadherent vs adherent youth reported lower diabetes-specific QoL (mean score 58 vs 75, P = .003) and lower
general well-being (57 vs 76, P = .02), as did their parents (50 vs 72, P = .006), and hemoglobin A1c was higher
(9.6% vs 8.0%, P = .02). Youth with T1D and celiac disease using continuous subcutaneous insulin infusion vs
multiple daily injections had similar generic and diabetes-specific QoL and A1C (8.6 vs 8.2%, P = .44), but were
less happy having to follow a lifelong diet (59 vs 29, P = .007).
Conclusions Youth with T1D and celiac disease who do not adhere to the GFD have lower QoL and worse
glycemic control. Novel strategies are required to understand and improve adherence in those with both conditions.
(J Pediatr 2016;179:131-8).
Emerging evidence indicates long-term negative outcomes for individuals living with type 1 diabetes (T1D) and celiacdisease, including an increased risk of retinopathy, nephropathy, and subclinical atherosclerosis. We recently demon-strated an association between lack of adherence to the gluten-free diet (gluten-free diet nonadherence [GFD−]) and
early evidence of renal disease, independent of glycemic control.1 This suggests that those who struggle with the coexistence of
2 chronic conditions are at higher risk of complications; however, there is a paucity of data on the impact of living with both
conditions on quality of life (QoL) and general well-being.
It is well-established that T1D negatively affects QoL, particularly among girls and prepubertal children.2 Mealtime behav-
ior problems are common,3,4 which may be compounded by the demands of carbohydrate counting, eating to manage blood
glucose levels independent of hunger,5 and normal child developmental behaviors such as fussy eating. QoL is higher in people
with T1D treated with continuous subcutaneous insulin infusion (CSII),6,7 which allows flexibility with meal times and food
choices.5,8 Because a GFD requires substitution of commonly available carbohydrate foods such as wheat-based breads, cereal,
and pasta,9 CSII could alleviate the restrictive nature of the GFD by allowing for carbohydrate-free meals. However, the impact
of CSII on QoL in people with coexisting T1D and celiac disease has not been studied.
BMI Body mass index
CDC Centers for Disease Control and Prevention
CDDUX Celiac disease–specific DUX
CSII Continuous subcutaneous insulin infusion
GFD Gluten-free diet
GFD+ Gluten-free diet adherence
GFD− Gluten-free diet nonadherence
GWBS General Well-Being Scale
HbA1c Hemoglobin A1c
MDI Multiple daily injections
T1D Type 1 diabetes
QoL Quality of life
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In the general population, celiac disease is diagnosed either
by clinical suspicion or screening of at-risk individuals, who
are frequently asymptomatic.10 In those who are symptom-
atic, the uptake of a GFD may be expected to have a greater
impact onQoL than for asymptomatic individuals. Indeed,QoL
was higher in symptomatic youth with biopsy proven celiac
disease who were GFD adherent (gluten-free diet adherence
[GFD+]).11 In a Swedish study of asymptomatic school chil-
dren screened for celiac disease, QoL did not differ between
those with biopsy-confirmed celiac disease and their peers after
1 year.12 In contrast, asymptomatic adults with celiac disease
randomized to a GFD experienced alleviation of anxiety and
improved perception of health after 1 year compared with those
randomized to a gluten-containing diet.13
The only pediatric study to examine the impact of coexist-
ing celiac disease and T1D on QoL found no difference in
generic and diabetes-specific QoL compared with children who
had T1D alone.14 However, celiac disease–specific QoL was not
examined, nor was the effect of symptoms on QoL. Surpris-
ingly, QoL did not differ between youth who were GFD+ vs
GFD−, although the number of youth who were GFD– was
small (n = 6), suggesting that this subgroup analysis may have
been underpowered.14 In contrast, the coexistence of T1D and
celiac disease in adults was associated with lower generic and
diabetes-specific QoL.15 Given these conflicting findings, we
examined the effect of the “double diagnosis” on QoL, well-
being and eating behaviors in youth and their parents.We hy-
pothesized that QoL scores would be lower in children with
celiac disease, and those GFD−, compared with their peers with
T1D only.We also examined the relationship between QoL and
presence or absence of celiac disease symptoms and therapy
(CSII vs multiple daily injections [MDI]).
Methods
This cross-sectional case control study was conducted at the
Sydney Children’s Hospital Network (Westmead), Australia,
from May 2013 to December 2014. Inclusion criteria were
age 8-18 years, T1D for ≥1 year, and biopsy-proven celiac
disease for ≥6 months. Patients with T1D and celiac disease
were recruited at routine clinic appointments. Celiac disease
was diagnosed based on our screening protocol: all patients
with diabetes undergo serologic testing for celiac disease at the
time of diabetes diagnosis and 1-2 yearly thereafter.16 Screen-
ing was performed by measurement of serum IgA and anti-
tissue transglutaminase IgA antibodies by enzyme-linked
immunosorbent assay. Deamidated IgG antibodies were also
measured to account for false-negative results in patients who
were IgA-deficient. Those with a positive screen were re-
ferred to a pediatric gastroenterologist and, where indicated,
underwent small bowel biopsy. The control population was
drawn from the same clinic population within the study time
period and were matched by age (±1 year), diabetes duration
(±1 year), most recent hemoglobin A1c (HbA1c) (±0.5%), and
mode of diabetes management (MDI or CSII). The control
population had a negative screening test for celiac disease at
least once within the previous 12 months. Exclusion criteria
were unknown celiac disease status, treatment other than MDI
or CSII, and the inability of a child/parent to speak or read
English fluently. The study was approved by the Sydney Chil-
dren’s Hospital Network research ethics committee. Written
consent was obtained from parents and verbal assent from chil-
dren aged 12-16 years before participation.
Demographic and clinical characteristics documented were
sex, age at diabetes diagnosis, T1D duration, mode of diabe-
tes management (CSII or MDI), insulin dose (U/kg/d), age at
celiac disease diagnosis, celiac disease duration, celiac disease–
related symptoms (documented at the time of celiac disease
diagnosis), anthropometric measurements (height, weight, and
bodymass index [BMI]), with z-scores computed using Centers
for Disease Control and Prevention (CDC) 2000 reference data.
The use of the US-CDC growth charts is standard practice in
Australia, both in a clinical and research setting, and aligns
with the Australian National Health and Medical Research
Council’s recommendations.17 Most recent HbA1c was docu-
mented and lifetime mean HbA1c was computed from all
available data.
Questionnaires
All participants and their parents/guardians complete age-
specific questionnaires and proxy questionnaires at the study
visit. Generic, diabetes-specific, eating behaviors–specific, and
celiac disease–specific questionnaires were used to enable mea-
surement of a wide spectrum of QoL domains. Specifically, all
patients and parents completed the PedsQL Generic Core Scale
(version 4.0), PedsQL Diabetes Module (Version 3.2), General
Well-Being Scale (GWBS, Standard Version), and an eating be-
haviors questionnaire.18 Parents/guardians also completed the
PedsQL Family Impact Scale. Patients with celiac disease com-
pleted the validated celiac disease-specific DUX (CDDUX)
questionnaire.19
The PedsQL Generic Core Scale is a 23-item questionnaire
that evaluates QoL in the subdomains of physical, emotional,
social, and school functioning, with 2 age-specific scales (8-12
and 13-18 years). It has been validated for use in the pediatric
population with T1D.20 The GWBS is a 7-item questionnaire
measuring generic well-being and health. The Diabetes Module
is a 32-item questionnaire that examines diabetes-specific QoL
in the subdomains of diabetes symptoms, treatment barriers,
treatment adherence, worry, and communication. The Family
Impact Scale, completed by parents is a 36-item questionnaire
that evaluates the impact of pediatric chronic health condi-
tions on parents and the family in the subdomains of physi-
cal, emotional, social, cognitive functioning, communication,
worry, daily activities, and family relationships.
Respondents were asked to rate how frequently each item
was problematic over the past 1 month. Each questionnaire
was assigned a total and subdomain score ranging from 0 to
100, with higher scores reflecting higher QoL/general well-
being or healthier eating behaviors.
The eating behaviors questionnaire was modified from a
locally developed questionnaire used in the Researching Ef-
fective Strategies to Improve Insulin Sensitivity in Children and
Teenagers (RESIST) study,18 which contains 23 items in the
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subdomains of individual child, family and social environ-
ment, and diabetes-related eating behaviors (Table I; avail-
able at www.jpeds.com). The questionnaire aimed to understand
how T1D, with or without celiac disease, affected the child and
their family’s meal patterns. The test items had a 5-option re-
sponse format: never, almost never, sometimes, often, and
almost always, corresponding to scores from 0 to 100.
The CDDUX questionnaire19 consisted of 16 items related
specifically to celiac disease across the subscales of commu-
nication, diet, and having celiac disease. Respondents used a
visual scale to indicate how they felt about various aspects of
celiac disease, with corresponding scores ranging from 0 to 100.
GFD Adherence
GFD adherence was assessed both clinically and serologically.
An accredited practicing dietitian documented families’ usual
dietary intake, precautions taken when eating out, and their
perceived GFD adherence. Tissue transglutaminase IgA and
deamidated IgG serology were measured to document adher-
ence. Patients with tissue transglutaminase titers in the normal
range (or declining titers if recently diagnosed) and GFD+ as
assessed by the dietitian were classified as GFD+. Patients with
elevated titers and GFD− as assessed by the dietitian were clas-
sified as GFD−. Assessment of GFD adherence by a dietitian is
recognized as the best available measure.21
Sample size calculations performed before recruitment in-
dicated that 33 patients were required with celiac disease and
T1D and 33 controls with T1D only, matched 1:1. Because no
data on QoL in T1D among children were available at the time
of study design, this was based on an estimated between group
difference in parent proxy QoL scores of young people with
T1D compared with parents of healthy peers of 11.05 (SD
12.33), using the PedsQL Pediatric Quality of Life Inventory
Generic Core Scales,20 with an alpha of 0.05 and 95% power.
Data Analyses
Youth were classified as having T1D, with or without celiac
disease. Those with celiac disease were further stratified by GFD
adherence (GFD+ vs GFD−) and mode of diabetes manage-
ment (MDI or CSII). Categorical variables were compared
between groups using c2 tests. Continuous variables, includ-
ing questionnaire subdomain and total scores for youth and
their parents, were compared between groups using the Student
t test for normally distributed data and the Mann-Whitney U
test for skewed data. Internal consistency was determined by
Cronbach a coefficient, which was calculated for each ques-
tionnaire subdomain and total score, with values of >0.70 con-
sidered satisfactory.22 Statistical analyses were performed using
SPSS version 22.0 (IBM, SPSS Inc, Chicago, Illinois) and Stata
version 13.0 (Stata Corp, College Station, Texas).
Results
Of the 42 youth with T1D and celiac disease who met the in-
clusion criteria, the first 35 to attend routine clinic appoint-
ments were approached and all agreed to participate.We also
recruited 35 controls with T1D matched for age, diabetes du-
ration, HbA1c, and mode of treatment. The total study popu-
lation had a mean ± SD age of 13.6 ± 3.0 years, age at diabetes
diagnosis of 6.1 ± 3.8 years, BMI z-score of 0.3 ± 0.8, andHbA1c
of 8.4% ± 1.5% (68 ± 10.5 mmol/mol). Characteristics of par-
ticipants stratified by presence or absence of celiac disease
are shown in Table II. Patients with coexisting celiac disease
had a significantly higher BMI z-score than their matched con-
trols, but all other characteristics were comparable.
Presentation and Symptoms of Celiac Disease
Celiac disease was diagnosed after diabetes in all cases at median
diabetes duration of 2.4 years. Classical celiac disease–related
Table II. Clinical characteristics of patient groups stratified by presence or absence of celiac disease and GFD adherence
in those with celiac disease
T1D only (n = 35) T1D and celiac disease (n = 35) P GFD+ (n = 24) GFD− (n = 11) P
Female n (%) 19 (54) 20 (57) .81 12/24 (50%) 8/11 (73%) .21
Age at study visit (y) 13.6 ± 3.0 13.7 ± 3.1 .93 13.5 ± 3.1 14.2 ± 3.1 .52
Age at diabetes diagnosis (y) 6.1 ± 3.8 6.1 ± 3.9 .9 6.3 ± 4.1 5.7 ± 3.6 .68
Diabetes duration (y) 7.5 ± 3.0 7.6 ± 3.3 .57 7.2 ± 3.4 8.5 ± 3.0 .26
HbA1c at visit (%) 8.4 ± 1.6 8.5 ± 1.6 .99 8.0 ± 1.2 9.6 ± 1.9 .02
HbA1c at visit (mmol/mol) 68 ± 6 69 ± 6 .99 64 ± 5 81 ± 9 .02
Lifetime HbA1c (%) 7.8 ± 0.8 8.0 ± 0.7 .21 7.8 ± 0.7 8.5 ± 0.6 .007
Lifetime HbA1c (mmol/mol) 62 ± 3 64 ± 3 .21 62 ± 3 69 ± 3 .007
Mean HbA1c year before visit (%) 8.1 ± 1.1 8.3 ± 1.1 .55 8.0 ± 1.1 8.8 ± 1.0 .08
Mean HbA1c year before visit (mmol/mol) 65 ± 4 67 ± 4 .55 64 ± 4 73 ± 3 .08
CSII, n (%) 26 (74) 23 (66) .43 16 (67) 7 (64) .86
Insulin, U/kg/d 0.9 ± 0.3 0.9 ± 0.2 .50 0.9 ± 0.2 0.9 ± 0.3 .9
Age at celiac disease diagnosis (y) - 9.1 ± 3.5 9.1 ± 3.6 9.1 ± 3.6 .98
Duration of celiac disease (y) 4.6 ± 2.7 4.4 ± 2.7 5.2 ± 2.7 .42
Symptomatic before celiac disease diagnosis 21/35 (60%) 18/24 (75%) 3/11 (27%) .007
GFD adopted within first year 25/35 (71%) 24/24 (100%) 1/11 (9%) <.001
Height z-score 0.4 ± 1.1 0.4 ± 1.0 .79 0.4 ± 1.0 0.2 ± 0.8 .52
Weight z-score 0.3 ± 0.8 0.6 ± 0.8 .19 0.6 ± 0.7 0.5 ± 0.9 .72
BMI z-score 0.1 ± 0.9 0.6 ± 0.7 .03 0.5 ± 0.8 0.7 ± 0.7 .54
Data are n (%) or mean ± SD.
Bold signifies results of significance, P < .05.
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symptoms such as abdominal pain, bloating, diarrhea, steat-
orrhea, poor growth, or iron deficiency were reported before
celiac disease diagnosis in 14 of the 35 cases (40%) and a further
7 of those 35 (20%) who reported improvement on the GFD
(with symptoms noted in retrospect) were classified as symp-
tomatic for data analysis. Patients and their families received
standardized GFD education from a dietitian.
GFD Adherence
On the basis of dietitian review and celiac titers, 24 of the 35
patients with celiac disease (69%)were classified as GFD+, and
11 of the 35 (31%) as GFD−. There was complete concordance
between dietetic assessment of GFD+ orGFD− and celiac titers.
Characteristics of GFD+ vs GFD− are shown in Table II; the
GFD+ group had significantly better glycemic control at the
study visit, were more likely to be symptomatic before diag-
nosis, and were more likely to adopt the GFD within the first
year of celiac disease; all other clinical variables were similar.
QoL Assessments
Four questionnaires (the PedsQL Generic Core Scale Version
4.0, the PedsQL Diabetes Module Version 3, the PedsQL GWBS
Standard version, and the Eating Behaviors questionnaire) were
completed by all 35 youth with T1D and 5 questionnaires (the
PedsQL Generic Core Scale Version 4.0, the PedsQL Diabetes
Module Version 3.2, the PedsQL GWBS Standard version, the
Eating Behaviors questionnaire, and the PedsQL Family Impact
Scale) were completed by 33 parents/guardians (2 parents did
not attend clinic). Five questionnaires (the PedsQLGeneric Core
Scale Version 4.0, the PedsQL Diabetes Module Version 3.2,
the PedsQLGWBS Standard version, the Eating Behaviors ques-
tionnaire, and the CDDUX) were completed by all 35 youth
with T1D and celiac disease and 5 questionnaires (the PedsQL
Generic Core Scale Version 4.0, the PedsQL Diabetes Module
Version 3.2, the PedsQL GWBS Standard version, the Eating
Behaviors questionnaire, and the PedsQL Family Impact Scale)
were completed by their parents/guardians. Internal consis-
tency (a coefficients) for the questionnaires’ total scores were
>0.7 (considered satisfactory), with the exception of the Eating
Behavior Questionnaire (Tables III and IV).
T1D and Celiac Disease Compared with T1D
QoL scores in children did not differ in those with andwithout
celiac disease, for generic, diabetes-specific, GWBS, family
impact, and eating behavior scales (Table III). However, for
the eating behaviors questionnaire, in the Family and Social
EatingBehaviors subdomain,youthwith coexisting celiac disease
scored lower on,“I eat the samemeals as the rest of the family”
(P = .03) and lower for “Choosing foods is easy when eating
out with family/friends” (P = .04), with parents scoring higher
for “shopping for food is expensive” (P < .001) and “it is dif-
ficult to find foods my child likes to eat” (P < .001) (Table I).
Children Compared with Their Parents
Youth with T1D and celiac disease and their parents re-
ported similar generic (P = .07) and diabetes-specific QoL
(P = .21). No differences in any subdomains were found
between youth with T1D and celiac disease and their parents.
Youth with T1D and their parents also reported similar generic
QoL (P = .06) and diabetes-specific QoL (P = .46). However,
parents of youth with T1D only reported lower scores in the
school subdomain (P = .02), indicating that parents per-
ceived more problems at school than their children did.
Youth Who Were GFD+ vs GFD−
Youth who were GFD− reported lower general well-being
(P = .02) and diabetes-specificQoL (P = .003) than youth who
were GFD+ (Table IV). Although total celiac disease-specific
QoL was similar between youth who were GFD+ and GFD−
(P = .78), those who were GFD+ were more likely to indicate
sadness for “having celiac disease” (P = .04) and in response
to“being given gluten-containing food at school”(P = .05).Al-
though there was no difference between how those GFD+ and
GFD− reported finding the uptake of the GFD, both groups
scored very low, indicated sadness at “having to follow a diet
for my celiac disease” (33 vs 28; P = .36) and “not being able
to eat anything I want” (25 vs 16; P = .19). Both youth who
were GFD− and their parents were less likely to find the diet
beneficial than their GFD+ peers (P = .04 and P = .03,
respectively).
Symptomatic vs Asymptomatic of Celiac Disease
Patients whowere symptomatic and hadT1D and celiac disease
were more likely to think what they ate was important com-
paredwith asymptomatic youth (87 vs 64;P = .048). In the family
impact scale, parents of those with symptoms reported more
problems with emotional (57 vs 77; P = .006) and social func-
tioning (69 vs 81; P = .03) as well as family relationships (64
vs 81; P = .02) than parents of asymptomatic youth, despite
there being no difference in overall scores (62 vs 72; P = .26).
CSII vs MDI Therapy in T1D and Patients with
Celiac Disease
Most youthwere treatedwithCSII (70%); the proportionswere
similar in those with or without celiac disease, and GFD+ vs
GFD− (Table II). Glycemic control was similar between those
using CSII vs MDI (8.6% vs 8.2%; P = .44). Mode of diabetes
management was not associated with differences in child or
parent generic and diabetes-specific QoL (data not shown).
However, in the CDDUX, those treated with CSII indicated
they were unhappier about “having to pay attention to what I
eat” (P = .007) and“having to follow a life-long diet” (P = .01).
Parents of youth treated with CSII reported greater diabetes
treatment barriers on the diabetes- specific PedsQL (P = .02)
and treatment adherence (P = .009), despite an overall similar
diabetes specific QoL score to their children (P = .35). In the
MDI group, youth and their parents had similar scores in all
variables.
Duration of Celiac Disease and T1D
Duration of celiac disease, either as a continuous variable or
as a categorical variable (<5 years vs ≥5 years) was not asso-
ciated with any of the QoL measures, for either youth or their
parents. Similarly, duration of T1D, as a continuous variable
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or as a categorical variable (<5 years vs ≥5 years), was not as-
sociated with any QoL measures (data not shown).
Discussion
The GFD, which is pervasive and life long, coupled with the
demands of managing T1D, may be expected to result in
lower QoL in youth living with both conditions, as shown in
adults.15 It is, therefore, reassuring that the additional diag-
nosis of celiac disease does not seem to impair QoL in youth
and their parents, although differences emerge when stratify-
ing by GFD adherence. This is the first study to demonstrate
that youth who are GFD− have lower well-being and diabetes-
specific QoL, accompanied by worse glycemic control. Youth
who were symptomatic at the time of diagnosis of celiac
Table III. QoL scores for youth with T1D vs youth with T1D and celiac disease youth
Items
T1D T1D and celiac disease
PMean ± SD a Mean ± SD a
GWBS
Child self-report n = 35 n = 35
Total score 7 64 ± 26 0.90 70 ± 24 0.90 .44
Parent proxy report n = 33 n = 33
Total score 7 72 ± 25 0.84 65 ± 22 0.84 .29
PedsQL Generic Inventory
Child self-report n = 35 n = 35
Total score 23 83 ± 12 0.87 81 ± 12 0.88 .34
Physical functioning 8 88 ± 11 0.61 86 ± 14 0.71 .7
Emotional functioning 5 77 ± 18 0.76 75 ± 18 0.72 .57
Social functioning 5 91 ± 18 0.91 91 ± 14 0.79 .41
School functioning 5 77 ± 14 0.54 81 ± 12 0.84 .34
Parent proxy report n = 33 n = 33
Total score 23 76 ± 16 0.94 76 ± 13 0.89 .98
Physical functioning 8 85 ± 23 0.86 77 ± 24 0.91 .10
Emotional functioning 5 69 ± 19 0.83 68 ± 18 0.85 .78
Social functioning 5 85 ± 21 0.91 88 ± 14 0.69 .43
School functioning 5 64 ± 24 0.87 71 ± 21 0.85 .15
PedsQL Diabetes Module 3.2
Child self-report n = 35 n = 35
Total score 33 73 ± 14 0.84 70 ± 16 0.95 .36
Diabetes symptoms 15 64 ± 11 0.73 60 ± 12 0.82 .13
Treatment barriers 5 78 ± 18 0.66 75 ± 18 0.63 .38
Treatment adherence 6 81 ± 14 0.69 84 ± 17 0.84 .21
Worry 3 63 ± 27 0.76 63 ± 28 0.89 .86
Communication 4 79 ± 20 0.70 68 ± 25 0.82 .09
Parent proxy report n = 33 n = 33
Total score 33 70 ± 17 0.94 66 ± 15 0.91 .29
Diabetes symptoms 15 62 ± 14 0.89 60 ± 12 0.84 .46
Treatment barriers 5 69 ± 22 0.83 64 ± 18 0.72 .24
Treatment adherence 6 78 ± 15 0.74 74 ± 18 0.78 .34
Worry 3 65 ± 28 0.86 67 ± 24 0.90 .72
Communication 4 68 ± 23 0.89 64 ± 25 0.88 .53
Eating behavior specific
Child report n = 35 n = 35
Total score 24 64 ± 9 0.60 62 ± 13 0.82 .34
Individual child behaviors 7 71 ± 11 0.33 73 ± 14 0.61 .16
Family and social eating behaviors 12 64 ± 10 0.43 61 ± 12 0.48 .54
Diabetes related behaviors 5 59 ± 18 0.46 49 ± 26 0.64 .34
Parent report n = 33 n = 33
Total score 24 68 ± 10 0.73 62 ± 13 0.78 .045
Individual child behaviors 7 72 ± 12 0.53 69 ± 16 0.68 .43
Family and social eating behaviors 12 69 ± 14 0.66 61 ± 12 0.65 .005
Diabetes related behaviors 5 64 ± 18 0.65 56 ± 23 0.71 .14
Family Impact Scale
Parent Report n = 33 n = 33
Total score 36 70 ± 17 0.97 68 ± 18 0.96 .93
Physical functioning 6 67 ± 21 0.88 67 ± 22 0.90 .77
Emotional functioning 5 65 ± 23 0.91 65 ± 21 0.89 .63
Social functioning 4 76 ± 22 0.89 74 ± 22 0.79 .72
Cognitive functioning 5 75 ± 20 0.95 72 ± 21 0.95 .89
Communication 3 74 ± 25 0.80 68 ± 23 0.76 .31
Worry 5 59 ± 24 0.84 58 ± 24 0.84 .99
Daily activities 3 73 ± 22 0.90 66 ± 29 0.89 .48
Family relationships 5 75 ± 17 0.91 72 ± 21 0.95 .72
Higher scores indicate higher QoL/less difficulty, with lower scores indicating more difficulty.
Bold signifies results of significance, P < .05.
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disease were more likely to adhere to the GFD and reported
better QoL. There was no difference in diabetes-specific
QoL in youth with celiac disease treated with CSII vs MDI;
however, the celiac disease–specific scale suggested a greater
burden of having to follow a lifelong diet in those treated
with CSII.
Our findings show some parallels with the Canadian study
of youth with coexisting T1D and celiac disease,14 which also
Table IV. QoL in youth who were GFD+ with T1D and celiac disease compared with youth who were GFD–
Items
GFD+ GFD–
PMean ± SD a Mean ± SD a
GWBS
Child self-report
Total score 7 76 ± 23 0.91 57 ± 20 0.86 .02
Parent proxy report
Total score 7 73 ± 22 0.83 50 ± 12 0.89 .001
PedsQL Generic Inventory
Child self-report n = 24 n = 11
Total score 23 84 ± 10 0.86 75 ± 14 0.88 .11
Physical functioning 8 88 ± 11 0.67 80 ± 17 0.73 .21
Emotional functioning 5 76 ± 16 0.69 71 ± 22 0.8 .66
Social functioning 5 92 ± 13 0.77 89 ± 16 0.84 .64
School functioning 5 78 ± 14 0.62 60 ± 22 0.81 .02
Parent proxy report n = 23 n = 10
Total score 23 77 ± 10 0.88 73 ± 17 0.9 .39
Physical functioning 8 81 ± 22 0.93 69 ± 26 0.84 .22
Emotional functioning 5 68 ± 15 0.73 69 ± 23 0.91 .88
Social functioning 5 88 ± 14 0.76 88 ± 13 0.68 .88
School functioning 5 73 ± 17 0.8 66 ± 29 0.92 .46
PedsQL Diabetes Module 3.2
Child self-report n = 24 n = 11
Total score 33 75 ± 13 0.95 58 ± 16 0.87 .003
Diabetes symptoms 15 63 ± 11 0.79 52 ± 10 0.8 .05
Treatment barriers 5 80 ± 17 0.67 63 ± 15 0.5 .007
Treatment adherence 6 89 ± 11 0.7 73 ± 23 0.86 .02
Worry 3 70 ± 24 0.86 47 ± 30 0.86 .03
Communication 4 73 ± 25 0.86 57 ± 22 0.65 .08
Parent-proxy report n = 23 n = 10
Total score 33 68 ± 13 0.9 61 ± 17 0.92 .25
Diabetes symptoms 15 62 ± 11 0.81 54 ± 12 0.83 .07
Treatment barriers 5 66 ± 16 0.7 57 ± 22 0.71 .24
Treatment adherence 6 77 ± 16 0.81 66 ± 21 0.72 .16
Worry 3 66 ± 21 0.86 69 ± 30 0.94 .78
Communication 4 68 ± 57 0.85 57 ± 29 0.91 .32
Celiac disease specific
Child self-report
Total score 12 41 ± 20 0.91 42 ± 22 0.88 .78
Communication 3 59 ± 25 0.82 43 ± 30 0.86 .11
Having celiac disease 3 32 ± 23 0.78 54 ± 27 0.58 .04
Diet 6 34 ± 23 0.92 28 ± 28 0.92 .36
Eating behavior specific
Child Report
Total score 24 64 ± 14 0.85 57 ± 9 0.66 .08
Individual child behaviors 7 74 ± 15 0.67 71 ± 11 0.33 .49
Family and social eating behaviors 12 62 ± 13 0.62 57 ± 11 0.20 .17
Diabetes related behaviors 5 55 ± 26 0.64 38 ± 25 0.65 .05
Parent report n = 23 n = 10
Total score 24 64 ± 13 0.84 57 ± 11 0.79 .11
Individual child behaviors 7 70 ± 18 0.76 71 ± 13 0.58 .79
Family and social eating behaviors 12 62 ± 12 0.72 55 ± 11 0.47 .21
Diabetes related behaviors 5 61 ± 22 0.77 42 ± 24 0.44 .07
Family Impact Scale
Parent report n = 23 n = 10
Total score 36 69 ± 17 0.96 65 ± 21 0.97 .67
Physical functioning 6 68 ± 22 0.9 67 ± 23 0.92 .96
Emotional functioning 5 69 ± 21 0.91 61 ± 23 0.91 .26
Social functioning 4 75 ± 22 0.85 74 ± 24 0.68 .93
Cognitive functioning 5 72 ± 20 0.94 74 ± 25 0.98 .85
Communication 3 70 ± 23 0.83 63 ± 26 0.7 .42
Worry 5 61 ± 22 0.81 49 ± 25 0.88 .21
Daily activities 3 68 ± 28 0.87 63 ± 32 0.97 .64
Family relationships 5 72 ± 20 0.95 72 ± 24 0.95 .99
Higher scores indicate higher QoL/less problems with the subdomain.
Bold signifies results of significance, P < .05.
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found no overall difference in QoL. Our study population had
similar age and duration of T1D and celiac disease. In contrast,
a Dutch study demonstrated significantly worse QoL in adults
with both conditions compared with T1D only.15 Notably, their
study population had longer duration of diabetes (25 years)
and celiac disease (9 years). Although we did not find a rela-
tionship between longer celiac disease duration and lower QoL,
we speculate that celiac disease is more likely to impact QoL
in the longer term. In our study, those who adopted the GFD
within the first year of celiac disease diagnosis were more likely
to maintain GFD adherence. This identifies a crucial time for
follow-up of the GFD and to discuss barriers the family may
face.
We have demonstrated a subgroup of youth with celiac
disease identified through screening who have difficulty imple-
menting the GFD. This highlights the impact of screening for
celiac disease in T1D,23 particularly given celiac disease often
presents asymptomatically.24 However, symptoms may be iden-
tified retrospectively; more than one-half of asymptomatic
children diagnosed with celiac disease indicated (on a Likert
scale) feeling “much better” or “somewhat better” after start-
ing the GFD compared with beforehand. The majority of
patients in this study were GFD+, with adherence influenced
by parental support, celiac disease awareness, and availability
of gluten-free products.25 As screening is now recognized as
a standard of care in T1D,26,27 strategies are needed to inter-
vene in those who resist the GFD.
Adherence to a GFD was higher in those displaying celiac
disease-related symptoms before being diagnosed with
celiac disease. Interestingly, however, parents of symptomatic
youth reported greater strain on their family relationships,
and emotional and social well-being . This may be owing to
parents actively supporting the GFD for their children by
educating others and preplanning for meals eaten outside
of the home. Although burdensome, this extra support has
proven beneficial for the well-being and GFD adherence of
adolescents.28 Youth who are GFD+ and their parents were
more likely to consider the diet beneficial, a finding that
mirrors studies of youth with celiac disease only.19 Youth
who were GFD+ and their family were more likely to eat
together, which is a recognized indicator of greater nutri-
tional quality in the general population,29 as well as in T1D.30
This greater level of parental involvement may also extend to
T1D management, which is reflected in the better glycemic
control in the patients who were GFD+, as we and others
have previously reported.1,31 The lower general well-being
reported by youth who were GFD− and their parents may be
owing to perceived greater difficulty with the GFD, because
youth who were GFD− expressed extreme sadness at having
to follow a diet for celiac disease, which has also been re-
ported in celiac disease alone.32,33
We found QoL, eating behavior scores, and glycemic control
were not different in youth with both conditions when strati-
fied by modality of treatment (CSII vs MDI). In contrast, other
investigators4,8 have shown CSII improves mealtime eating be-
haviors and increases food flexibility in T1D alone. We were
surprised that youth using CSII expressed more sadness about
having to pay attention to what they eat; we speculate that the
added responsibility of carbohydrate counting and limited
choices available on a GFDmay have outweighed the flexibility
CSII offers. Alternatively, patients who find the GFDmore dif-
ficult may be more likely to adopt CSII.
Young people with coexisting celiac disease had signifi-
cantly higher BMI z-scores than control subjects. Although
the mean BMI z-score for the total study population con-
firms our previous observation that young people with T1D
are more overweight than their nondiabetic peers,34 the higher
BMI in those with coexisting celiac disease is supported by
existing data in celiac disease alone.35 Weight gain after ini-
tiation of a GFD has been attributed to increased caloric
intake owing to resolution of gastrointestinal symptoms, which
can affect appetite, and increased caloric absorption after
intestinal healing.35 A Harvard study assessing BMI changes
after celiac disease diagnosis reported that 139 of 679 partici-
pants (20.5%) were classified as overweight (BMI of 25-29.9
kg/m2) at the time of celiac disease diagnosis, which in-
creased to 164 of the 679 (24.2%) after GFD adoption (mean
follow-up, 39.5 months).35
Limitations of our study include the cross-sectional nature
of the study, which prevents understanding the longitudinal
relationship between QoL and variables measured in this study,
in particular coexisting celiac disease and GFD−. Even though
the study was powered to detect differences in T1D vs
T1D and celiac disease, the ability to adjust for potential con-
founding variables or to detect differences in the subgroup
analyses are limited by the sample size. The proportion of pa-
tients who were GFD− was relatively low (31%); however, this
falls within the reported rates of 19% to 48%36 and was greater
than in the Canadian study, which did not find an effect of ad-
herence on QoL. Other potential limitations include the use
of a locally designed eating behaviors questionnaire18; however,
to our knowledge, there are no validated eating behavior ques-
tionnaires for school-aged children. Strengths include the com-
prehensive assessment of QoL in youth and their parents, more
so than the only other study in youth.
We have shown that living with T1D and celiac disease
does not seem to impact QoL negatively. However, we iden-
tified that youth who do not adhere to the GFD have lower
well-being and diabetes-specific QoL, along with worse gly-
cemic control than youth who were GFD+. This places them
at risk of vascular complications.37-39 Regular monitoring of
adherence in youth with coexisting T1D and celiac disease
will enable identification of the GFD–adherent subgroup,
who may benefit from more intensive clinical and psychoso-
cial support. ■
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Table I. Locally modified eating behaviors question-
naire for child/parent
Individual child eating behaviors
1. I like eating meals / meal times are enjoyable
2. I / my child eats the same meals as the rest of the family
3. I / my child gets to choose what to eat
4. I think my parents don't give me enough food / I give my child less food
than they want
5. I think my parents give me too much food / I give my child more food
than they want
6. I / my child likes trying new goods
7. My parents tell me when and how much to eat
8. I / my child decides how much and when to eat
Family and social environment eating behaviors
1. I help prepare meals / Preparation of family meals is difficult
2. Our family eats dinner together
3. I help shop for food / Shopping for food is difficult
4. Friends are interested in what I / my child eats
5. Friends tease me about what I eat / my friends are not supportive of my
child's eating patterns
6. Choosing foods is easy when eating out with family/friends
7. The TV is on during meals
8. I find it hard to eat at school / Meal times are difficult at school
9. My family argues about what I / my child should eat
10. I think what I eat is important / The diet is beneficial for my child
11. Outside of home, we ask how people make food
12. Parent: Shopping for food is expensive
13. Parent: It is difficult to find foods my child likes to eat
Diabetes related eating behaviors
1. My parents count carbohydrates / I count carbohydrates for my child
2. I / my child counts carbohydrates
3. Eating what the hospital has told me to is easy to follow
4. Before I / my child eats, my parents use things to figure out how much
I can eat
We use:
Measuring cups
Kitchen scales
Traffic Light Guide To Food Carbohydrate Counter
Calorie King
Other
Questions had a 5-option response formal: never, almost never, sometimes, often, and almost
always.
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CHAPTER 7 GREATER POSTPRANDIAL GLUCOSE EXCURSIONS AND 
INADEQUATE NUTRIENT INTAKE IN YOUTH WITH TYPE 1 DIABETES 
AND CELIAC DISEASE 
Pham-Short A, Donaghue KC, Ambler G, Garnett S, Craig ME, Nature Scientific Reports, DOI: 
10.1038/srep45286 (2017) 
 
SYNOPSIS 
Chapter 7 answers the research question associated with hypothesis 5, that youth with T1D 
and CD demonstrate greater glycaemic excursions and lower nutrient intake compared with 
those with type 1 diabetes alone. Utilising CGM, chapter 7 presents a manuscript that 
reports glycaemic variability in those with T1D and CD vs T1D alone. A key finding from this 
study was that youth with coexisting T1D and CD had greater postprandial glucose 
excursions than those with diabetes alone. Interestingly, there were no differences in the 
proportional macronutrient intake between the two groups, as those with T1D and CD had 
more fruit and dairy intake, which negated the expected lower carbohydrate intake often 
seen in dietary intake studies in those with CD alone. 
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Greater postprandial glucose 
excursions and inadequate nutrient 
intake in youth with type 1 diabetes 
and celiac disease
Anna Pham-Short1,2, Kim C Donaghue1,2, Geoffrey Ambler1,2, Sarah Garnett1,2 & 
Maria E. Craig1,2,3
The gluten free diet (GFD) has a high glycemic index and low-fiber content, which potentially influences 
glycemic excursions in type 1 diabetes (T1D) and celiac disease (CD). Participants in this case-control 
study of youth with T1D+CD (n = 10) and T1D only (n = 7) wore blinded continuous glucose monitoring 
systems for six days. Blood glucose levels (BGLs) were compared between groups for each meal, 
including pre-meal, peak, 2-hour postprandial and time-to-peak. Participants consumed a test-
breakfast of GF cereal and milk for three days and kept weighed food diaries; nutrient intake was 
analyzed and compared to national recommendations. Youth with T1D+CD had shorter time-to-peak 
BGL (77 vs 89 mins, P = 0.03), higher peak (9.3 vs 7.3 mmol/L, P = 0.001) and higher postprandial BGLs 
than T1D (8.4 vs 7.0 mmol/L, P = 0.01), despite similar pre-meal BGLs (9.2 vs 8.6 mmol/L, P = 0.28). 
Regarding test breakfast, greater pre and post-meal BGL difference correlated with longer CD duration 
(R = 0.53, P = 0.01). Total energy and macronutrient intake didn’t differ between groups; however 
the majority of participants collectively had inadequate intake of calcium (76%), folate (71%) and 
fiber (53%), with excessive saturated fat (12%) and sodium (>2,000 mg/day). The GFD is associated 
with greater glycemic excursions and inadequate nutritional intake in youth with T1D+CD. Clinical 
management should address both glycemic variability and dietary quality.
The gluten free diet (GFD) recommended for management of celiac disease (CD) requires the complete avoidance 
of wheat, rye and barley, which is often replaced by white rice or corn1. Such foods may contribute to a higher 
glycemic index2, higher glycemic load3 and lower fiber diet4,5 compared to gluten containing equivalents. The 
well-known benefits of a higher fiber diet in the general population include cardiovascular, and bowel health6 and 
in type 1 diabetes (T1D), these benefits extend to improved glycemic control7.
Restrictive diets such as the GFD are at risk of nutritional deficiencies, requiring increased vigilance in grow-
ing children and adolescents8. The mandatory fortification of wheat flour with micronutrients such as thiamin 
and folic acid9, but not gluten-free grains further places those consuming a GFD at risk of inadequate nutrient 
intake. Studies investigating the nutritional composition of the GFD in adults have shown inadequacies of specific 
micronutrients including thiamin, folate, vitamin A and calcium5,10. However there are limited dietary studies in 
youth with CD4,11,12 and none in children with co-existing T1D.
Adults and youth with CD have a lower carbohydrate intake compared with the general population5,12, which 
has been attributed to poor palatability and increased costs of the GFD13. Carbohydrate intake in children with 
T1D is often at the lower level of dietary guidelines14, which may be due to a conscious effort to reduce the risk of 
postprandial hyperglycemia15. In studies of children with CD, fiber and iron intakes are also significantly lower 
than recommendations12,16, due to the naturally low fiber and iron content of GF grains10. However, whether the 
coexistence of T1D+ CD is associated with a greater reduction in carbohydrate and fiber intake has not been pre-
viously examined. It is also unknown whether the traditional GFD, with a higher glycemic index and lower fiber 
content, impacts on glycemic variability in this population. Therefore the aims of this study were to compare, (i) 
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post-prandial excursions (PPE) and (ii) macronutrient, micronutrient and fiber intake in youth with T1D+ CD 
compared to those T1D alone. We hypothesized that youth with T1D+ CD would demonstrate greater glycemic 
excursions and lower nutrient intake.
Research Design and Methods
Subjects. This was a case-control, observational study of youth with T1D and biopsy-proven CD, individu-
ally matched to controls with T1D only by age, diabetes duration and HbA1c ( ± 0.5%, 3 mmol/mol). Inclusion 
criteria were T1D+ CD, age < 18 years, treatment with either multiple daily injections or insulin pump therapy, 
willingness to test at least four blood glucose levels (BGLs) per day, and the ability to read and record food dia-
ries in the English language. Participants were recruited from the Diabetes Clinic at The Children’s Hospital at 
Westmead, a tertiary pediatric hospital in Sydney, Australia. We aimed to recruit 10 youth with T1D+ CD and 10 
with T1D. The sample size was based on a minimum mean post-prandial BGL difference of 3 mmol/L (standard 
deviation 3 mmol/L) between groups over three days (30 meals per group), with α = 0.5 and power 80%, assum-
ing a drop out or missed BGL rate of 20%. The study protocol included youth wearing a blinded continuous 
glucose monitoring system (CGMS), consumption of the same test breakfast for three days, completion of a 
weighed food diary and documentation of diabetes care (injections or pumps, daily insulin doses and all BGLs 
measured using a glucometer). All participants attended their diabetes review appointment with their pediatric 
endocrinologist in the six weeks prior to the study visit for adjustment of insulin doses, or insulin pump settings. 
Participants used their pre-exiting insulin to carbohydrate ratios and insulin sensitivity factors, which had been 
set and adjusted according to standard clinical criteria17.
The study was approved by the Sydney Children’s Hospital Network Human Research Ethics Committee 
(study number: 12/SCHN/21, registration date 7th November 2012). The methods were carried out in accordance 
with the relevant guidelines and regulations. Informed consent was obtained from parents and assent from chil-
dren aged 12–16 years prior to participation.
Study visit. All participants were assessed by an Accredited Practising Dietitian (A.P-S.). Patients under-
went a structured interview, which involved documentation of their typical daily food intake, including weekend 
variations for meals both inside and outside the home. Carbohydrate counting skills were reviewed using food 
replicas (Mentone Educational, Australia), food packaging and real food (such as breakfast cereal). Measuring 
scales and cups were used as educational tools to assist with quantifying carbohydrate intake. Anthropometric 
measures were taken with the participant in light clothing and without shoes. Height was measured to the nearest 
0.1 cm (Harpenden stadiometer) and weight was measured to the nearest 0.1 kg; BMI was calculated with z-scores 
computed using Centers for Disease Control and Prevention (CDC) 2000 reference data.
Continuous Glucose Monitoring System. CGMS (Medtronic Enlite Sensor with a blinded iPro2 trans-
mitter) was inserted by the diabetes educator and worn uninterrupted for six days. Details of the sensor properties 
are described in detail elsewhere18. Patients were asked to perform at least four BGLs per day; prior to main meals 
and before bed with their own glucometers. Glycemic targets were set as 4.0–7.8 mmol/l, with hypoglycemia 
defined as a blood glucose level (BGL) ≤ 3.9 mmol/mol, euglycemia between 4.0–7.8 mmol/mol, and hypergly-
cemia as ≥ 7.9 mmol/mol.
CGMS Data Analysis. Participants were stratified by the presence or absence of CD co-existence for 
data analysis. For each main meal consumed and accompanied by a pre-prandial insulin bolus, time to reach 
peak BGL, peak BGL, and 2 hour postprandial BGL were examined. The following variability parameters were 
measured:
•	 Total variability (SDT) was calculated as the standard deviation (SD) for all of the measurements for all of the 
study days19.
•	 Within day glucose variability (SDw) was calculated as the SD of all measurements in a 24 hour period, aver-
aged over the sensor reading days19.
•	 Between day variability was measured by Mean of daily differences (MODD), and calculated as the average 
of the absolute difference in glucose values at the exact time of day (midnight), and averaged over five days19.
•	 Meal effect was measured by Area Under the Curve (AUC) and calculated as the sum of the absolute value 
of excursions from sensor value at the start of the meal and was calculated for 2 hours20 following the start of 
the meal.
Dietary intake. Participants maintained a standardized weighed food diary for three days in which they were 
asked to document meal and snack times, weigh and/or measure the quantity of all foods and drinks, the brand 
name and serving size consumed, and all BGL measurements. Participants were provided with electronic kitchen 
scales and measuring cups. Food diaries were analyzed using Foodworks 7 (Xyris, Australia), which uses the Food 
Standards Australia New Zealand (FSANZ) published AusNut and NUTTAB 2010 databases21.
Dietary intake was compared to the Australian National Health and Medical Research Council (NHMRC) 
age and gender specific nutrient reference values22. Dietary intake was compared to the Estimated Average 
Requirement (EAR), which is a daily nutrient level estimated to meet the requirements of half the healthy individ-
uals in a particular life stage. Inadequate intake in our study is defined as those not meeting EAR recommenda-
tions22. Energy requirements were calculated by Schofields’ Equation using current weight for the basal metabolic 
rate multiplied by a physical activity level of 1.223. Sodium and fiber recommendations were adopted from the 
International Society of Pediatric and Adolescent Diabetes (ISPAD), with adequate fiber calculated as age in years 
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+ 5 for grams/day24. Due to age and gender specific recommendations, proportions meeting the guidelines are 
reported as opposed to raw values of nutrient intake. Carbohydrate intake documented in the food diary was 
cross-checked with CGMS reports and insulin pump downloads. Carbohydrates used to treat mild hypoglycemic 
events (BGL < 4.0 mmol/l) were not included.
Test meal. All participants were given the same low glycemic index breakfast (Ancient Grains Gluten Free 
Cereal, Freedom Foods, Australia) for consumption on the first three study days together with portion-controlled 
ultra-high temperature (UHT) milk (Devondale, Our Lightest One). At the study visit, participants indicated 
their usual portion of cereal; using this information the dietitian weighed out the same quantity and labeled the 
carbohydrate amount for each individual breakfast. Participants were asked to refrain from consuming other 
foods for breakfast.
CD Status and Gluten Free Diet Adherence. Tissue Transglutaminase (TTG) IgA and deamidated IgG 
were measured in all participants at least once within the previous 12 months and negative CD serology was 
confirmed for the T1D only controls. For T1D+ CD patients, GFD adherence was assessed both clinically and 
serologically as previously described25. This included documentation of families’ usual dietary intake, including 
brands of products, family cooking and meal preparation practices, and precautions taken when eating out. GFD 
adherence was classified by TTG titers in the normal range (or declining titers if recently diagnosed) and assessed 
as GFD adherent (GFD+ ) by the dietitian.
Statistical analysis. Descriptive statistics are reported as mean + standard deviation (SD) for normally dis-
tributed data or median (range) for skewed data. Continuous variables, including clinical characteristics and 
glucose variability parameters, were compared between groups using student’s t-test for normally distributed data 
and Mann-Whitney U tests for skewed data. Categorical data were compared using chi-squared tests. Statistical 
analyses were performed using SPSS (IBM, SPSS Inc., Chicago, IL, USA) and Stata 14 (Stata Corp., College 
Station, TX, USA). P-values < 0.05 were considered significant.
Results
Twenty youth (10 with T1D, 10 with T1D+ CD) were recruited into the study. Three patients had CGMS equip-
ment failure (two had no data recorded and one had the sensor fall out on the first day of the study). Comparing 
patients with CD (n = 10) and those without (n = 7), there were no statistically significant differences in demo-
graphic or clinical features other than TTG titers (Table 1). Insulin to carbohydrate ratios and insulin sensitivity 
factors were not different between the two groups, nor percentage of basal insulin. All but one of the T1D+ CD 
patients was GFD adherent, and as results were not significantly different when this patient was excluded, their 
data were included in the analyses.
Dietary Intake. Dietary intake per participant was calculated as the average of the three recorded days. 
Total energy and proportional macronutrient intake were not statistically different between those on the 
gluten-containing or GFD diet (Table 2). For the micronutrients, more T1D+ CD participants met the average 
daily recommended vitamin C intake from fruit (100 vs 43%, p = 0.006). All together, the majority had inadequate 
T1D+CD T1D P-value
Number 10 7
Age at visit (years) 14.3 ± 3.6 14.7 ± 2.8 0.76
Diabetes duration (years) 6.7 ± 4.0 5.9 ± 2.2 0.63
Celiac Disease duration (years) 3.6 ± 2.7 —
Anti-deamidated gliadin IgG (ref 0–30) 14 ± 6 7 ± 7 0.25
Anti-tissue transglutaminase IgA (ref 0–30) 22 ± 14 6 ± 3 0.005
HbA1c at visit (%) 7.5 ± 0.7 8.0 ± 1.2 0.34
HbA1c at visit (mmol/mol) 58 ± 3 64 ± 8 0.34
Insulin pump therapy 7 (70%) 7 (100%) 0.11
Total daily dose 44.5 ± 20.0 50.3 ± 17.1 0.57
Insulin units/kg/day 0.81 ± 0.17 0.77 ± 0.12 0.60
% basal insulin 54 ± 4.3 54 ± 9.0 0.88
Insulin to carbohydrate ratio (ICR) 
(breakfast) 11.1 ± 6.3 10.4 ± 7.0 0.84
Insulin sensitivity factor (ISF) (breakfast) 3.3 ± 2.2 2.7 ± 1.7 0.54
Height SDS − 0.01 ± 1.6 0.8 ± 1.5 0.33
Weight SDS 0.6 ± 0.8 0.9 ± 1.0 0.52
BMI SDS 0.7 ± 0.7 0.9 ± 1.1 0.68
Serum 25 (OH) D (nmol/L) (ref: 51–250) 86 ± 30 72 ± 19 0.24
Table 1.  Clinical characteristics of patients with T1D+CD compared with T1D.
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dietary calcium (76%), folate (71%), and fiber (53%) with excessive saturated fat (12% total energy intake) and 
sodium (> 2,000 mg/day) intakes.
CGMS Data analysis. A total of 2,245 hours of data were recorded by CGMS, with a mean of 132 ± 26 hours 
and 1,585 ± 314 sensor readings per patient. Blood glucose profiles did not significantly differ between youth 
with T1D vs T1D+ CD (Table 3), including daily mean BGL and times within the hyperglycemic, euglycemic and 
hypoglycemic ranges. Overall, total, within day and between day variability was not different between groups.
Meal analysis with CGMS. A total of 222 main meals were identified from CGMS traces and pre-meal 
BGL records throughout the study period (median 16, range 8–18 meals per patient) and of these 179 (81%) 
were accompanied by an insulin bolus, with no difference in the proportion of delivered boluses in those with or 
without coexisting CD (81% vs 80%, p = 0.70). Glycemic profiles for meals where an insulin bolus was delivered 
are reported in Table 3. Youth with T1D+ CD experienced faster time to peak BGL (77 ± 32 mins vs 89 ± 34 mins, 
P = 0.03), higher peak BGL values post prandial (9.3 ± 3.6 vs 7.3 ± 3.4, P = 0.001), and 2 hour post prandial 
BGLs (8.4 ± 3.4 vs 7.0 ± 2.6, P = 0.02) (Fig. 1). For the test breakfast, youth with T1D+ CD had higher peak 
(11.3 ± 2.5 vs 6.8 ± 4.2, P = 0.02) and 2 hour post prandial BGLS (9.2 ± 2.7 vs 5.9 ± 3.1, P = 0.02). The difference 
between post-meal BGL and peak BGL post-meal was significantly correlated with longer CD duration (R = 0.53, 
P = 0.01). In the diabetes alone group, diabetes duration was not associated with change in pre- to peak BGL 
values (P = 0.50).
Conclusions
This is the first study to examine the impact of the GFD in youth with coexisting CD and T1D on glycemic 
variability and nutrient intake. The GFD was associated with greater glycemic excursions, characterized by a 
faster time to peak BGL, higher peak and higher two-hour post prandial BGLs, despite similar exogenous insulin 
requirements. The GFD and the gluten-containing diet had similar macronutrient distributions that met national 
nutritional guidelines, however the intake of saturated fat and sodium were above national and international 
recommendations, while the intake of dietary fiber and calcium was inadequate.
The test meal of GF cereal consumed by all study participants was associated with greater glycemic excursions 
in youth with T1D+ CD compared with their T1D only peers. The observation of faster glucose absorption in those 
with CD expands on a physiological study in which solutions of increasing glucose concentrations were infused 
into the small intestine and glucose absorption measured by the production of electrical activity (Apparent Km)26. 
Interestingly, higher apparent Km was correlated with longer duration of GFD consumption in patients with CD 
and was higher than in controls. Similarly, we found a positive relationship between longer CD duration and higher 
2 hour postprandial BGL. This suggests that chronic exposure to the GFD, which has a higher glycemic index, mod-
ifies glucose transport and results in more rapid glucose absorption. In support of this hypothesis, three molecules 
that transport glucose (SGLT1, PEPT1 and NHE3) were higher in patients with treated vs untreated CD27, implying 
that carbohydrates specific to the GFD may alter intra-intestinal gene transcription.
T1D+CD T1D P-value
Energy (kJ) 8065 ± 2738 7977 ± 2756 0.92
Estimated Energy requirements 7806 ± 1412 8540 ± 1563 0.10
Carbohydrate (g) 229 ± 80 234 ± 66 0.81
Carbohydrate (% total kJ intake) 49 ± 10 51 ± 9 0.35
Protein (g) 84 ± 38 85 ± 39 0.91
Protein (% kJ total intake) 18 ± 6 18 ± 6 0.77
Total fat (g) 72 ± 37 67 ± 40 0.64
Total fat (% kJ total intake) 32 ± 8 29 ± 9 0.24
Saturated fat (g) 26 ± 14 27 ± 20 0.87
Saturated fat (% kJ total intake) 12 ± 4 13 ± 7 0.64
Sodium (mg) 2287 ± 1229 2287 ± 722 0.99
Patients meeting daily age/gender specific estimated average nutrient requirements (%)
Dietary fiber 60% 27% 0.20
Thiamin 50% 86% 0.13
Riboflavin 70% 57% 0.59
Niacin equivalents 100% 100% 0.99
Vitamin C 100% 43% 0.006
Total folate 20% 43% 0.31
Sodium 20% 14% 0.76
Iron 30% 57% 0.26
Zinc 60% 57% 0.91
Calcium 30% 14% 0.45
Table 2.  Daily dietary analysis for patients with T1D+CD compared with T1D.
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The dietary intake of youth with T1D or T1D+ CD was at the lower end of both national and international 
guideline recommendations for carbohydrates, inadequate for fiber and calcium and high for saturated fats22,24. 
The latter finding is consistent with dietary data in youth with T1D from the US and Europe28–31, while the inad-
equate fiber intake is consistent with data in T1D or CD populations4,10, but not coexisting T1D and CD. Whilst 
fiber intake was inadequate for those on the GFD, they consumed more fruit, which is a naturally GF carbohy-
drate food, and may have offset the expected reduction in carbohydrate grain-based products that is often seen in 
CD alone studies10, but not observed in our study group. The detailed dietary history obtained from all patients in 
this study, irrespective of coexisting CD, indicate there is scope for improvement in dietary quality and reinforces 
the importance of dietary education in their management.
The micronutrient intake in our two study groups was comparable, however more than half of youth reported 
below average daily recommended intakes for calcium, iron and folate. The low intake of folate is surprising, since 
fortification of wheat flour with thiamin and folic acid is mandatory in many countries across the world includ-
ing Australia32. Further voluntary fortification is strictly regulated, but nonetheless allows limited quantities of 
other vitamins and minerals such as niacin, riboflavin, calcium and iron to be added to wheat-based breads and 
cereals33,34. However there is no mandated fortification of GF foods, which may explain the inadequate intake of 
folic acid, and iron observed in the GFD in other studies5,33. Similarly, there was a trend towards more patients 
T1D+CD T1D P-value
All meals
 Number of meals 110 69
 Average pre-meal BGL 9.2 ± 4.1 8.6 ± 4.1 0.28
 Peak BG value 9.3 ± 3.6 7.3 ± 3.4 0.001
 2 hour post prandial BGL 8.4 ± 3.4 7.0 ± 2.6 0.02
 Area Under Curve 47.4 ± 30.1 47.9 ± 38.3 0.92
 Time to peak (mins) 77 ± 32 89 ± 34 0.03
 Average daily BGL 9.2 ± 1.8 8.9 ± 2.4 0.83
 % time BGL > 7.8 mmol/l 55 ± 19 56 ± 27 0.78
 % time BGL < 7.8 and > 3.8 mmol/l 40 ± 16 37 ± 21 0.77
 % time BGL < 3.8 mmol/l 5 ± 5 7 ± 8 0.47
 SDw Within day variability 4.5 ± 0.6 3.7 ± 0.9 0.09
 MODD 5 days Interday variability 3.2 ± 1.2 3.8 ± 0.9 0.38
Test meal
 Test meal starting BGL 7.4 ± 3.0 6.6 ± 2.3 0.49
 2 hour post prandial BGL 9.2 ± 2.7 5.9 ± 3.1 0.02
 Peak BG value 11.3 ± 2.5 6.8 ± 4.2 0.02
 Difference between start and peak BGL 3.9 ± 1.4 0.2 ± 4.8 0.05
Table 3.  Results of meal time CGMS in youth with T1D+CD compared with T1D accompanied with an 
insulin bolus.
Figure 1. Average pre-meal, peak and post prandial blood glucose levels for meals accompanied with an 
insulin bolus for youth with T1D+CD compared to T1D alone. 
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with T1D+ CD vs T1D not meeting adequate intake of folate (20% vs 43%) and iron (30% vs 57%), but this did 
not reach statistical significance, which may be due to the small sample size.
Limitations of our study include the small patient numbers, however most CGMS studies have included simi-
lar patient numbers and are adequately powered to investigate glucose variability data20,35. Previous studies of the 
impact of mixed meals on glucose variability were performed under controlled conditions with supervised meals 
and boluses, only administering insulin for the carbohydrate content of the meals with no additional correction 
doses for elevated BGLs administered. In contrast, our free-living study enables a more accurate depiction of 
life with type 1 diabetes, with correction doses of insulin administered pre-meal, thereby providing an unbiased 
assessment of post-meal glucose excursions. Whilst 3-day food records are commonly used in practice for assess-
ing nutrient intake36, their duration may not be of sufficient length to measure adequate intake for some vitamins 
and minerals37. All but one of our patients adhered to the GFD and therefore our results may not be applicable to 
those not adherent; this is a population that warrants further study given we and others have demonstrated they 
have worse glycemic control and are at greater risk of microvascular complications25,38.
In conclusion, we have demonstrated that youth with T1D+ CD have greater post-prandial glucose excursions, 
suggesting that either the GFD or intestinal characteristics influence glucose absorption. Youth with co-existing 
T1D and CD have similar macronutrient intake to their peers with T1D alone. Dietary advice for youth with T1D 
should emphasize increasing fiber, folate and calcium intake, and reducing saturated fat and sodium intake, with 
further attention to increase thiamin intake for those on the GFD.
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CHAPTER 8 ABNORMAL CORTICAL AND TRABECULAR BONE IN YOUTH 
WITH TYPE 1 DIABETES AND CELIAC DISEASE 
Pham-Short A, Donaghue KC, Ambler G, Briody J, Garnett S, Munns CF, Craig ME, Diabetes 
Care, 2019; 42:1-7 
 
SYNOPSIS 
This chapter presents the final published study of this thesis, which examines bone health in 
youth with T1D and CD compared to T1D alone. Chapter 8 answers the research question 
associated with hypothesis 6, that youth with type 1 diabetes and coeliac disease exhibit 
abnormal measures of bone health compared with those with type 1 diabetes alone. 
Utilising both DXA and pQCT, we examined bone structure in those with coexisting T1D and 
CD, vs those with T1D alone. Chapter 8 demonstrated those with coexisting T1D and CD 
have abnormal cortical and trabecular bone compared to those with T1D alone. The 
coexistence of T1D and CD confers a lower bone turnover response to muscle pull. This 
continues the theme that the duality of disease appears to have an additive effect as shown 
in Chapter 7.   
 
 
 
 
 
 
 
 
Abnormal Cortical and Trabecular
Bone in Youth With Type 1
Diabetes and Celiac Disease
https://doi.org/10.2337/dc18-2376
OBJECTIVE
This study compared bone health in youth with type 1 diabetes and celiac disease
(CD) versus type 1 diabetes alone.
RESEARCH DESIGN AND METHODS
Thiswasa case-control studyof42youthwith coexisting type1diabetesandCD,and
40 with type 1 diabetes matched for age, sex, diabetes duration, and HbA1c. Bone
mineral density (BMD), bone mineral content (BMC), and BMC-to-lean tissue mass
(LTM) ratio were measured using DXA and reported as z-scores for height. Total,
trabecular, and cortical bone and muscle parameters were measured using
peripheral quantitative computed tomography (pQCT) and reported as z-scores
for age.
RESULTS
Mean age at assessment was 14.36 3.1 years, diabetes duration, 8.06 3.5 years;
HbA1c, 8.26 1.5% (666 5 mmol/mol); and 25-hydroxy vitamin D, 716 21 nmol/L.
Comparing youth with coexisting CD versus type 1 diabetes, DXA showed lower
BMC-to-LTM ratio (0.376 1.12 vs. 0.736 2.23, P = 0.007) but no difference in total
BMD. Youthwith coexisting CD also had lower BMC-to-LTM ratio versus the general
population (P = 0.04). Radial pQCT showed lower total BMC (20.92 6 1.40
vs. 20.26 6 1.23, P = 0.03) despite similar bone and muscle cross-sectional area.
In multivariable linear regression, lower BMC was associated with higher insulin
dose (P = 0.03) but not HbA1c.
CONCLUSIONS
Youth with both type 1 diabetes and CD have lower BMC relative to LTM and lower
BMC, indicating abnormal trabecular andcortical bonedevelopmentdespite similar
bone andmuscle size. These ﬁndings suggest that the two conditions confer a lower
bone turnover state. We recommend further examination of bone health in this
population; future research should examine early interventions to improve bone
health.
There is substantial evidence that adults with type 1 diabetes have abnormal bone
mineral density (BMD) and are at increased risk of fractures (1). There is also limited
evidence that children and adolescents with type 1 diabetes have lower bone density
(2) and smallerbonemass (3,4).Although themechanisms for adversebonehealth are
multifactorial, in type 1 diabetes they include inadequate accrual of peak bone mass
due to impaired bone formation and osteoblast function (5), elevated HbA1c (6), and
increased production of advanced glycation end products (7).
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Adults with celiac disease (CD) also
have an increased fracture risk (8),
whereas children and adults with CD
both have lower BMD compared with
the general population. Proposed mech-
anisms include dietary malabsorption of
calcium and vitamin D, which are impor-
tant for bone growth and development
(9), or chronic intestinal inﬂammation,
which interferes with bone formation
and increases bone resorption (10).
Collectively, these data suggest that
individuals with coexisting type 1 diabe-
tes and CD have an additive risk for
adverse measures of bone health, but
the evidence for this is limited. Low BMD
at the lumbar spine, deﬁned as a z-score
of ,22 SD, was more prevalent in
a cross-sectional study of children and
adolescents with type 1 diabetes and
celiac autoimmunity (but not biopsy
specimen-conﬁrmed CD) versus type 1
diabetes alone (12% vs. 3%); however,
actual BMD z-scores were not reported
(11). In contrast, coexisting type 1 di-
abetesandCDwasnot associatedwith an
increased fracture risk in a population-
based Swedish cohort study of individ-
uals aged,30 years; however, BMDwas
not examined (12).
Observed rates of hip fractures in
adults with type 1 diabetes exceed cal-
culated theoretical increases, suggesting
factors beyond BMD, such as bone qual-
ity, contribute to increase fracture risk
(6). Traditional measures of bone, using
DXA in children and adolescents, include
BMD for age, height, and weight, bone
mineral content (BMC), and the ratio of
BMC to lean tissue mass (LTM), which
takes into account the inﬂuence of mus-
cle on BMC (13). In contrast, peripheral
quantitative computed tomography (pQCT)
characterizes bonearchitecture, including
volumetric BMD (vBMD), bone geometry
(dimension, area, and cortical thickness),
and mineral distribution within the bone
cross-section (14). Theseparameters allow
for calculation of bone strength. pQCT also
enables the separate measurement of tra-
becular and cortical bone compartments,
which may allow for earlier detection of
changes inbone inresponsetodisease (14).
Trabecular bone is metabolically active;
thus, any changes in bone structure would
usually be ﬁrst observed here (3,4). Al-
though pQCT has demonstrated that chil-
dren with type 1 diabetes have smaller
bones compared with control subjects
without diabetes (3,4), this tool has not
been used to examine bone in youth with
coexisting type 1 diabetes and CD.
Using both DXA and pQCT, we per-
formed a case-control study of young
people with coexisting type 1 diabetes
and CD versus type 1 diabetes alone to
address our hypothesis that coexisting
CD confers a greater risk of abnormal
BMD, BMC, and bone structure.
RESEARCH DESIGN AND METHODS
Study Design and Population
This was a matched cross-sectional case-
control study conducted at The Child-
ren’s Hospital at Westmead, Australia.
Inclusion criteria were age 8–18 years,
type 1 diabetes duration $1 year, and
biopsy specimen-proven CD for at least
6 months. Patients with type 1 diabetes
and CD were recruited at routine clinic
appointments, and the ﬁrst 42 who con-
sented to participate were included in
the study. For each individual case pa-
tient, a control patient with type 1 di-
abetes alone,matched for age (61 year),
sex, diabetes duration (61 year), and
HbA1c (60.5%) was invited to participate
(15).
CD screening was performed based
on international guidelines (16). All pa-
tients with diabetes had serological
testing for CD at the time of diabetes
diagnosis and at 1–2 yearly assessments
thereafter (17). Screening was perfor-
med by measurement of serum IgA and
anti-tissue transglutaminase IgA anti-
bodies by ELISA. Deamidated IgG anti-
bodies were also measured to account
for false-negative results in IgA-deﬁcient
patients. Those with a positive screen
were referred to a pediatric gastroen-
terologist and underwent small bowel
biopsy. Only patients with specimen-
proven CD were included in this study.
The control population was drawn
from patients with type 1 diabetes
who were matched by age, diabe-
tes duration (61 year), most recent
HbA1c (60.5%), and mode of diabetes
management–either multiple daily injec-
tions (MDI) or insulin pump therapy
(continuous subcutaneous insulin infu-
sion [CSII]). The control population had a
negative screening test result for CD
at least once within the previous
12 months. The ﬁrst 40 to consent to
participate were included in the study.
Exclusion criteria were unknown CD sta-
tus or treatment regimens other than
MDI or CSII.
The Sydney Children’s Hospital Network
Research Ethics Committee approved the
study. Consent was obtained from all
patients and parents before participation.
Study Visits and Data Collection/
Clinical Assessment
Demographic and clinical characteristics
documented were age at diabetes di-
agnosis, type 1 diabetes duration, mode
of diabetes management (MDI or CSII),
insulin dose (units/kg/day), age at CD
diagnosis, CD duration, CD-related symp-
toms (documented at the time of CD
diagnosis), and anthropometric mea-
surements (height, weight, and BMI),
with z-scores computed using Centers
for Disease Control and Prevention 2000
reference data. The most recent HbA1c
was documented, and lifetime mean
HbA1c was computed from all available
data. Blood tests were performed at the
study visit for 25-hydroxy vitamin D (25-
OHD), albumin, thyroid function, and
liver function. Deﬁciency of 25-OHD
was deﬁned as ,50 nmol/L. Pubertal
development was assessed and docu-
mented by the clinician and quantiﬁed
byhormone levels (luteinizinghormone,
follicle stimulating hormone, and tes-
tosterone or estradiol).
Gluten-Free Diet Adherence
Gluten-free diet (GFD) adherence was
assessed clinically and serologically, as
previously described (18). An accredited
practicingdietitian documented families’
usual dietary intake, precautions taken
wheneatingout, and theirperceivedGFD
adherence. Tissues transglutaminase IgA
and deamidated IgG serology was mea-
sured to document adherence. Patients
with tissue transglutaminase titers in the
normal range (or declining titres if re-
cently diagnosed) and GFD adherent
(GFD+), as assessed by the dietitian,
were classiﬁed as GFD+. Patients with
elevated titers and GFD nonadherent
(GFD2), as assessed by the dietitian,
were classiﬁed as GFD2. There was com-
plete concordance between dietetic as-
sessment of GFD+ or GFD2 and celiac
titers. Assessment ofGFDadherence by a
dietitian is recognized as the best avail-
able measure (19).
Bone Densitometry
Total body, posteroanterior lumbar spine
(LS), and femoral neck BMD and body
composition were determined by DXA
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using a GE-Lunar Prodigy (enCORE 8.6
software; GE Lunar Radiation Corp,
Madison,WI),withpositioning, scanning,
and standard analysis according to the
manufacturer’s recommendations. These
provided total body, LS, and femoral
neck BMD and BMC adjusted for age
and height, as previously described (20).
Total BMC-to-LTM ratio and BMC ad-
justed for bone area (BA) (BMC-to-BA
ratio) were also calculated. Volumetric LS
BMD was calculated as per Carter et al.
(21) to reduce the inﬂuence of height.
Reduced bone mass and density for age
and height was deﬁned as z-score values
of,22.0, according to the International
Society for Clinical Densitometry guide-
lines (22). Height z-scores for DXA mea-
sureswere used to adjust for any variance
in stature within and between groups,
whereas age z-scores were used for pQCT
because it is a true volumetric density
measure.
Cross-sectional measurements of the
nondominant lower leg and forearm
were performed by pQCT using a Stratec
XCT-2000 (Stratec Medizintechnik
GmBH, Pforzheim, Germany). Measure-
ments were made and analyzed using
software version 6.0B. Epiphyseal scans
were performed at the 4% site of the
nondominant tibia and radius. Diaphy-
seal scans were undertaken at the 65%
site of the radius and 66% of the tibia.
Both the tibia and radius were acquired
with a voxel size of 0.4 mm. A scan speed
of 15 and 20 mm/s was used for the
radius and tibia, respectively. The slice
thickness of the machine was 2.4 mm, as
previously described (23). Bone mea-
surements included volumetric BMD
(vBMD, mg/cm3), vBMD trabecular
bone, total and cortical cross-sectional
area (CSA,mm2),muscleCSA(mm2), total
and cortical BMC (mg/mm) and polar
strength-strain indices (pSSI, mm3). pSSI
provides a good estimate of mechanical
strength (24). Conversion frompQCT raw
data to sex- and age-matched z-scores
were based on published pediatric ref-
erence data (25).
Assessment of Glycemic Variability
Glycemic controlwasmeasured byHbA1c
using high-performance liquid chroma-
tography (nondiabetic range 4–6%) (Di-
amat BioRad, Hercules, CA). Fluctuations
in HbA1c over the duration of diabetes
was calculated as previously described
(26). For each patient, the intrapersonal
mean and SD of all recorded glycemic
control measurements was calculated,
and the SD-HbA1c was considered amea-
sure of glycemic variability (26). Because
the number of individual visits (n) could
inﬂuence the SD-HbA1c (with fewer visits
likely to artiﬁcially inﬂate SD), values for
SD-HbA1c were divided by n to adjust for
this possibility. We also calculated co-
efﬁcient of variation (CV), a normalized
measure of glycemic variability. CV was
computed as the division of SD-HbA1c
by a factor ofmean HbA1c (i.e., CV = SD2
HbA1c/[mean HbA1c/10]).
Sample Size
In our previous study of BMD in patients
with cystic ﬁbrosis–related diabetes (27),
we found a difference in the total BMD
(TBMD) z-score of 0.996 1.11 compared
with cystic ﬁbrosis alone and a difference
in the LS vBMD z-score of 0.626 0.76. We
anticipated smaller but clinically signiﬁ-
cant differences may be observed for
bone parameters measured in this study
population and therefore aimed to re-
cruit 40 patients per group (z-score dif-
ference, 0.56 0.8,a = 5%, power = 90%).
Data Analysis
Descriptive statistics are reported as
mean 6 SD for continuous variables,
which were normally distributed. Cate-
gorical variables were compared between
groups using x2 tests. Continuous varia-
bles were compared between groups
using Student t tests, because all data
were normally distributed. Multivariable
linear regression analysis was used to
examine the association between bone
health indices and explanatory variables,
including presence of CD, diabetes dura-
tion, lifetime HbA1c, and insulin dose/kg/
day. Statistical analyses were performed
using SPSS 25.0 (IBM, Armonk, NY) and
Stata 13.0 (StataCorp, College Station, TX)
software.
RESULTS
Study Population and Characteristics
We recruited 82 youth with type 1 di-
abetes (42 with coexisting CD, 40 with
type 1 diabetes alone). The total study
population had a mean age of 14.3 6
3.1 years, age at diabetes diagnosis of
6.7 6 3.6 years, HbA1c of 8.2 6 1.5%
(666 5 mmol/mol), 25-OH of 686 10.5
mmol/mol, and mean height z-score of
0.26 1.2. Characteristics of participants
stratiﬁed by presence or absence of CD
are reported in Table 1. Youth with
coexisting CD had a signiﬁcantly higher
prescribed insulin doses (0.95 6 0.30
vs. 0.786 0.21 units/kg/day, P = 0.005),
but all other characteristics such as gly-
cemic control and anthropometric mea-
sures were comparable. 25-OHD levels
were signiﬁcantly different between
youth with type 1 diabetes and youth
with coexisting CD; however, both values
were clinically in the normal range, and
the proportion of patients with 25-OHD
deﬁciency did not differ. None of the
participants had abnormal results on
thyroid or liver function tests or evidence
of active inﬂammation (based on full
blood count, erythrocyte sedimentation
rate, and C-reactive protein levels), and
all patients with 25-OHD deﬁciency had
normal alkaline phosphatase levels.
None of the participants demonstrated
delayed puberty.
DXA Scan Results
Youth with coexisting CD versus type 1
diabetes alone had a signiﬁcantly lower
BMC-to-LTM ratio (P = 0.007), suggesting
an abnormal muscle and bone relation-
ship. Both groups had similar-sized BA,
height (Table 2), and TBMD.When youth
with coexisting CDwere stratiﬁed byGFD
adherence (27 GFD+ vs. 15 GFD2), there
were no statistically or clinically signiﬁ-
cant differences in any of the DXA mea-
sures (e.g., BMC-to-LTM ratio z-score
20.34 6 0.85 vs. 20.42 6 1.54, P =
0.86). Youth with coexisting type 1 di-
abetes and CD had lower TBMD for
height (z-score 20.42, P = 0.02), BMC-
to-LTM ratio (z-score, 20.37, P = 0.04),
and BMC-to-BA ratio (z-score20.69, P =
0.001) compared with the general pop-
ulation (results not shown). In multivari-
able linear regression, these associations
remained signiﬁcant after adjustment for
total daily insulin dose and HbA1c.
pQCT Results
Radial pQCT showed that youth with
coexisting CD had lower cortical total
BMC and lower trabecular bone vBMD
(P=0.03) than youthwith type1diabetes
(Table 3), despite similar muscle CSA (P =
0.45) and cortical CSA z-scores, P = 0.12).
Lower pSSI z-scores in those with type
1 diabetes and CD (P = 0.01) indicate
reduced bone strength. Youth with co-
existing type 1 diabetes and CD had
higher vBMD compared with the general
population (z-score 0.42, P , 0.001),
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whereas trabecular bone vBMD mea-
sureswere lower in thosewith coexisting
type 1 diabetes and CD versus the general
population (z-score, 21.00; P , 0001)
and total BMC (z-score, 21.02; P ,
0.001). When youth with coexisting CD
were stratiﬁed by GFD adherence, there
were no statistically signiﬁcant differen-
ces in any of the pQCT measures, al-
though there was a trend to a lower 66%
BMC cortical z-score in those GFD2 ver-
sus GFD+ (20.066 0.78 vs. 0.646 0.98,
P = 0.08). In multivariable linear regres-
sion, lower total BMC remained signiﬁ-
cantly associated with coexisting CD and
type 1 diabetes and was also associated
with higher insulin dose (b = 0.28; 95%
CI 0.12, 2.49; P = 0.03). Neither diabetes
duration nor lifetime HbA1c were sig-
niﬁcant in the model. Lower pSSI was
associated with higher insulin dose (b =
0.32; 95% CI 0.37, 2.80; P = 0.01) and
diabetes duration (b = 20.25; 95% CI
20.19,20.007; P = 0.04) but not lifetime
HbA1c. Duration of CDwas not associated
with any bone health parameter.
CONCLUSIONS
This is theﬁrst study toexamine the impact
of biopsy specimen-proven CD on bone in
youth with coexisting type 1 diabetes. We
found abnormal bone structure in those
with type 1 diabetes and CD, characterized
by lower radial BMC, lower trabecular bone,
and lower cortical BMC, despite similar-sized
bone compared with youth with type 1
diabetes alone. Those with coexisting
CD also had a lower BMC-to-LTM ratio
with higher material density (vBMD),
suggesting an impairment of bone devel-
opment comparedwith those with type 1
diabetes alone. Compared with the general
population, youth with coexisting type 1
diabetes and CD had abnormal bone struc-
ture, as demonstrated by lower TBMD,
lower BMC-to-BA ratio, and lower BMC-
to-LTM ratio. Moreover, a lower BMC-to-
LTM ratio coupled with higher total vBMD
indicates a state of lower bone turnover,
resulting in older and stiffer bones (28).
The BMC-to-LTM ratio was signiﬁcantly
lower in those with coexisting type 1 di-
abetes and CD, even though neither LTM
adjusted for height nor muscle size were
signiﬁcantly different between the two
groups. Muscle is essential for bone de-
velopment and maintenance, modeling,
and remodeling: changes in bone follow
changes in muscle mass (29) as bones
adapt to muscle force (30). The low BMC-
to-LTM in the setting of normal LTM for
height suggests the skeleton is unable to
adequately respond to the force applied
to it through muscle pull and implies a
primary bone abnormality (31). Alterna-
tively, it may be that muscle force and
Table 1—Clinical characteristics of patients stratiﬁed by presence or absence of CD
Type 1 diabetes + CD
(n = 42)
Type 1 diabetes
(n = 40) P value
Females 26 (62) 23 (58) 0.17
Age (years) 14.0 6 3.3 14.7 6 2.8 0.33
Age at diabetes diagnosis (years) 6.3 6 3.9 6.5 6 3.5 0.83
Diabetes duration (years) 7.8 6 3.8 8.1 + 3.0 0.73
CD duration (years) 5.0 6 3.6 d
GFD adherent 27 (64) d
Median HbA1c year before visit (%, mmol/mol) 8.5 6 1.5 (69 6 17) 8.0 6 1.0 (64 6 11) 0.10
HbA1c at visit (%, mmol/mol) 8.4 6 1.4 (68 6 16) 8.1 6 1.5 (65 6 17) 0.26
Lifetime HbA1c to visit (%, mmol/mol) 8.1 6 0.9 (65 6 10) 7.8 6 0.8 (62 6 9) 0.07
HbA1c variability (SD-HbA1c) 0.86 6 0.31 0.94 6 0.30 0.21
Insulin (units/kg/day) 0.95 6 0.30 0.78 6 0.21 0.005
Height SDS 0.07 6 1.26 0.34 6 1.15 0.31
Weight SDS 0.60 6 0.81 0.62 6 0.97 0.93
BMI SDS 0.67 6 0.71 0.51 6 0.96 0.40
Overweight/obese 13 (31) 11 (28) 0.73
25-OHD at visit (nmol/L) 76 6 22 65 6 18 0.02
25-OHD deﬁcient† 6 (14) 6 (15) 0.93
Alkaline phosphatase (ref: 50–350 units/L) 201 6 119 195 6 104 0.79
Data are mean 6 SD or n (%). Values in boldface type are statistically signiﬁcant. †25-OHD deﬁciency deﬁned as ,50 nmol/L.
Table 2—DXA results comparing type 1 diabetes and CD versus type 1 diabetes
alone youth
Type 1 diabetes + CD
(n = 42)
Type 1 diabetes
(n = 40) P value
Age (years) 14.0 6 3.3 14.7 6 2.7 0.52
Height SDS 0.07 6 1.26 0.34 6 1.15 0.36
Weight SDS 0.60 6 0.81 0.62 6 0.97 0.97
BMI SDS 0.67 6 0.71 0.51 6 0.96 0.57
TBMD height z-score 20.42 6 1.15 20.19 6 1.20 0.37
TBMC height z-score 20.13 6 1.29 0.24 6 1.77 0.29
BMC-to-LTM ratio z-score 20.37 6 1.12 0.73 6 2.23 0.007
BMC-to-BA ratio z-score 20.69 6 1.22 20.99 6 1.65 0.36
BA Height z-score 0.13 6 1.30 0.69 6 2.19 0.16
LTM height z-score 0.04 6 1.22 20.29 6 1.19 0.21
LS 1–4 vBMD z-score 20.59 6 1.20 20.30 6 0.88 0.21
Data are presented as the mean 6 SD. Values in boldface type are statistically signiﬁcant.
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power are additionally reduced in those
with coexisting type 1 diabetes and CD,
because adolescents with type 1 diabe-
tes alone have decreased muscle power
and force as evaluated by jumping mech-
anography (32). Exercise, particularly
resistance training, increases muscle
strength (33) and BMD (34) in children.
However, we did not document activ-
ity levels in this population or undertake
measures of muscle force, so it is un-
known whether there are differences in
these factors between the two groups.
Total body BMC as assessed by DXA
reﬂects cortical BMC. The lower total
BMC in youth with coexisting CD there-
fore indicates lower cortical bone con-
tent, despite similar muscle and cortical
bone size. The similar total and cortical
bonesize inour study supports theﬁnding
of bone size normalization in youth with
type 1 diabetes of similar age (35). Two
studies of youthwith type 1 diabetes, from
Finland (36) and France (37), demon-
strated lower BMC comparedwith healthy
control subjects despite similar anthropo-
metrical measurements, suggesting that
diabetes impairs bone mass accrual during
skeletal growth. Youth with coexisting CD
had higher insulin requirements, and sim-
ilarly, those with lower BMC had higher
insulin requirements in the French study
(37). In type 1 diabetes, adolescence is
associated with an exaggerated dysregu-
lation of the growth hormone IGF-I/
IGF-binding protein axis, contributing to
a puberty-associated deterioration in gly-
cemic control and worsening of insulin
resistance (2) and resulting in higher insulin
requirements. Although HbA1c was not
different between groups in our study
and was not correlated with BMC in
the French study (37), we speculate that
functional insulopenia at the bone level
(2) may impair bone formation.
Glycemic control and overall glycemic
variabilitywere similar between thosewith
type 1 diabetes alone and coexisting CD in
our study, despite higher total daily insulin
doses. The limited existing data on youth
with diabetes and celiac autoimmunity are
conﬂicting: one study found no association
between glycemic control and BMD (38),
while two studies demonstrated a relation-
ship betweenhigherHbA1c and lower BMD
(11,39). However, in contrast to our pop-
ulation, none of the patients in these
studies had biopsy specimen-conﬁrmed
CD, which limits the generalizability of
the data. We previously showed that gly-
cemic control was also not associated with
early evidence of renal disease in adoles-
cents with coexisting type 1 diabetes and
CD (40). Together, this suggests the mech-
anism for low BMD in CD is multifactorial
and not dependent on glycemic control
alone. Although the higher insulin require-
ments in those with CDmay also reﬂect di-
etary differences, in our previous study of
the same population, we did not ﬁnd differ-
ences in total daily carbohydrate intake in
those with coexisting type 1 diabetes and
CD versus type 1 diabetes alone (41).
The risk of fractures ishigher inpatients
with type 1 diabetes and microvascular
complications (42). Adults with type 1
diabetes and microvascular complications
have deﬁcits in cortical and trabecular
bone vBMD as examined by pQCT, which
may partly explain the excess skeletal frag-
ility (43). In contrast, the bone microarchi-
tecture in adults with type 1 diabetes
without microvascular complications was
not different from control subjects. The
increased risk of microvascular complica-
tions in those with coexisting CD (44,45)
identiﬁes a subgroupof patientswith type 1
diabetes who require ongoing monitoring,
particularly as life expectancy increases (46).
We have shown for the ﬁrst time, using
pQCT, that youth with CD and diabetes
had lower radial trabecular bone and lower
pSSI, indicating both abnormal bone struc-
ture and reduced bone strength. Diabetes-
induced changes in BMD are expected to
be ﬁrst noted in the metabolically active
trabecular bone (2), which is best visual-
ized by pQCT. However, only two studies
have used pQCT in patients with type 1
diabetes (3,4), and none have used this
tool in those with coexisting CD. In the
only study using pQCT in children and
adolescents with type 1 diabetes alone,
trabecular bone density was lower than
in age- and sex-matched control subjects
(3). Hence, our data suggest that the co-
existence of CD confers an additional
burden on trabecular bone.
Nutritional, metabolic, and demographic
factors may inﬂuence BMD, size, and con-
tent. There were no clinically signiﬁcant
differences in 25-OHD levels between those
with coexisting CD and type 1 diabetes
alone, and in our analysis of micro- and
macronutrients in this study population, we
found no differences in intake of calcium,
carbohydrate, protein, or dietary fat (18).
The standardized BMI score (SDS) was also
not different between groups. Although
none of the patients had evidence of in-
ﬂammation at the time of assessment
(based on full blood court, erythrocyte
sedimentation rate. and C-reactive protein),
we cannot exclude the possibility that pa-
tients with coexisting CDmay have a height-
ened inﬂammatory state that inﬂuences
bonemetabolism (10). Notably, however,
BMD and other bone measures did not
differ between GFD+ and GFD2 youth.
The strengths of our study include the
use of pQCT, which enables assessment
of bone structure, in addition toDXA, and
the conﬁrmation of CD based on a biopsy
specimen.
Limitations include lack of data on
exercise, which inﬂuences muscle and
bone formation. A lower BMC-to-LTM
ratio coupled with higher total vBMD
Table 3—Radial pQCT results stratiﬁed by absence or presence of CD
Type 1 diabetes + CD
(n = 39)
Type 1 diabetes
(n = 39) P value
CSA cortical 20.25 6 1.21 0.13 6 0.91 0.12
CSA muscle 20.89 6 1.56 20.64 6 1.23 0.45
4% BMC total 20.92 6 1.40 20.26 6 1.23 0.03
4% CSA total bone 20.63 6 1.40 20.39 6 1.40 0.45
4% vBMD trabecular 21.00 6 1.49 20.36 6 1.09 0.03
66% BMC cortical 20.26 6 0.88 0.21 6 0.92 0.02
66% BMC total 21.02 6 1.20 20.44 6 1.12 0.03
66% cortical thickness 20.03 6 0.73 0.02 6 0.81 0.78
66% CSA cortical 20.26 6 1.21 0.12 6 0.91 0.13
66% CSA relative cortical 0.20 6 0.81 0.00 6 0.92 0.34
66% CSA total bone 20.40 6 1.48 0.13 6 1.20 0.08
66% pSSI 20.39 6 1.31 0.32 6 1.18 0.01
66% vBMD cortical 0.42 6 2.03 1.04 6 1.00 0.09
66% vBMD total 0.47 6 1.24 0.49 6 1.29 0.93
Data are presented as the z-score 6 SD. Values in boldface type are statistically signiﬁcant.
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indicates a state of lower bone turnover,
but this is best evaluated by bone his-
tomorphometry. Although most were in
late puberty, follow-up of the study
population later in adolescence will be
important to examine whether differ-
ences are sustained. Owing to the small
sample size of GFD2 individuals (n = 15),
the study was underpowered. Given the
observed association between GFD+ and
diabetes complications, the association
between GFD+ and bone outcomes
should be explored in future studies.
We cannot exclude the possibility that
genetics plays a role in bone develop-
ment; however, this has yet to be exam-
ined in youth with type 1 diabetes. In
a community cohort study of adults,
osteoporosis was associated with posi-
tive tissue transglutaminase antibodies
but not HLA DQ2 or DQ8 (47).
Longitudinal analysis from before pu-
berty would enable examination of the
impact of puberty on differences in bone
structure development throughout child-
hood and adolescence. We did not have
fracture data in this cohort of patients;
however, this is currently being investi-
gated in a larger study from our center.
Recruitment of a larger sample size may
have enabled adjustment for potential
confounding variables; however, the
study groups were matched for age, di-
abetes duration, HbA1c, and sex (48).
In conclusion, we have shown youth
with type 1 diabetes and CD appear to
have abnormal bone structure, with def-
icits in cortical and trabecular bone, and a
lowbone turnover state, resulting in high
BMD comparedwith thosewith diabetes
alone. Youth with coexisting type 1 di-
abetes and CD also demonstrated lower
radial trabecular bone and BMC com-
pared with those with diabetes alone.
These structural differences are inde-
pendent of LTM, glycemic control, and
dietary calcium intake, but insulin doses
were higher in those with CD. We rec-
ommend regular monitoring of bone
health to monitor changes and imple-
menting early interventions, such as reg-
ular weight-bearing exercise, to optimize
bone health, particularly as longer di-
abetes duration is associated with in-
creased fracture risk (49).
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CHAPTER 9 DISCUSSION 
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This body of work presents six original studies that were conducted with the aim of 
examining the broad impact of coexisting CD among young people with T1D. Within this 
research theme, the studies demonstrated that CD in T1D is common, especially in children 
with T1D onset before age 5 years (Chapter 3); requires regular screening (Chapter 4), 
influences risk of microvascular complications (Chapter 5), affects QoL and wellbeing 
(Chapter 6), increases glycaemic variability, and is associated with inadequate micronutrient 
intake (Chapter 7), and is associated with adverse bone health (Chapter 8). The importance 
of adherence to the GFD was highlighted in Chapters 5 and 6; whereby non-adherence to 
the GFD was associated with early signs of nephropathy (Chapter 5), QoL and lower general 
well-being (Chapter 6), as well as suboptimal glycaemic control (Chapter 6). These findings 
support the importance of screening for CD (Chapters 3 and 4) to identify those at risk, and 
emphasize the need to provide dietary and psychological support to maximise health 
outcomes. The coexistence of CD and T1D, independent of glycaemic control and GFD 
adherence was associated with increased glycaemic variability (Chapter 7) and abnormal 
bone health (Chapter 8), reinforcing the need to identify CD in youth with T1D through 
screening, particularly as most are asymptomatic at the time of small bowel biopsy (Chapter 
4).  
 
9.1 SCREENING FOR CD IN T1D  
The first study (Pham-Short et al. 2012), reported in Chapter 3, reported the incidence of CD 
in a 20-year longitudinal observational study of 4,379 youth was 7.7 per 1,000 person years. 
Incidence was 60% higher in children aged < 5 years at diabetes onset; novel findings from 
this study demonstrated that this subgroup were more likely to seroconvert after T1D 
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diagnosis, and be diagnosed with CD after longer T1D duration (3.3 years vs 0.7 years in 
children aged > 5 years at T1D diagnosis, p < 0.001). The prevalence of CD in our clinic 
population was 7.1%, in keeping with subsequently published nationwide data in youth 
from ADDN (7.7%) (Craig 2017). The high prevalence of CD in T1D supports the importance 
of continued screening for CD throughout childhood, particularly in children diagnosed with 
T1D before age 5 years.  
 
The higher rate of CD at the time of diagnosis of T1D in older children in our cohort 
emphasizes the importance of screening at T1D diagnosis, as well as education and initiation 
of the GFD to maximize growth and BMD, particularly as preclinical CD may have been 
present prior to diabetes diagnosis. Recognized adverse effects of untreated CD include iron 
deficiency, anaemia, growth retardation, and osteoporosis (Matysiak-Budnik et al. 2007). 
The impact of GFD non-adherence is further examined in Chapters 5, 6, 7 and 8.   
 
The findings from Chapter 3 in youth from NSW informed the next study, a systematic 
review of the epidemiology of CD in T1D, with subgroup analysis by age, gender, and 
duration of diabetes (Pham-Short et al. 2015), reported in Chapter 4. The second specific 
aim of the systematic review was to examine the risk of CD in people at diagnosis of T1D 
and at specific time intervals after diagnosis, to determine the optimal frequency of 
screening. The systematic review of 11,157 young people with T1D diagnosed < 21 years of 
age, from nine longitudinal cohort studies with median follow up of 10 years (range 5-18 
years), demonstrated a weighted pooled CD prevalence of CD of 5.1% (range 1.6% to 9.7%). 
100 
The risk of CD was highest within the first year after T1D diagnosis: 40% were diagnosed 
within 1 year, 55% within 2 years, and 79% within 5 years of diabetes duration. Of note, 85% 
of patients were asymptomatic at the time of CD diagnosis.  The findings from this review 
suggested that screening for CD should be performed at the time of diagnosis, and within 2 
and 5 years thereafter. In addition, CD should be considered at any time in patients with 
symptoms suggestive of CD.  
The systematic review has been cited 71 times since its publication in 2015 (Google Scholar), 
including guidelines from the ADA (American Diabetes Association 2018) and ISPAD 
(Mahmud et al. 2018); both societies updated their 2018 screening recommendations to 
state that ‘screening for CD should be performed at the time of diabetes diagnosis, and at 2 
and 5 years thereafter, as it is frequently asymptomatic’, cited as level B evidence. The 
translation of these guidelines to inform clinical practice will enable improved estimates of 
CD incidence and prevalence in youth with T1D, as well as evaluation of early diagnosis and 
treatment in this at-risk population.   
9.2 THE ROLE OF GFD ADHERENCE IN T1D AND CD 
The studies reported in Chapters 5 and 6 highlight the importance of GFD adherence in 
youth with T1D and biopsy-proven CD. The burden of coexisting T1D and CD may be 
expected to result in suboptimal glycaemic control, conferring a greater risk of 
complications. However, in our study of 2639 young people with T1D (Chapter 5), glycaemic 
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control was better in the 129 individuals with CD, despite younger age at diabetes onset and 
longer diabetes duration. Reassuringly, CD was not associated with higher rates of any 
microvascular complications, lower height SDS or adverse lipid profiles. However, adherence 
to the GFD was associated with early evidence of renal disease. This was the first study in 
youth with coexisting T1D and CD to compare complication rates stratified by GFD 
adherence.  In contrast, a case–control study demonstrated that mean albumin:creatinine 
ratio was lower in youth with  T1D and CD who adhered to the  GFD  versus those without 
CD (Malalasekera et al. 2009). However, there was no comparison group with CD that did 
not to the GFD. The authors speculated that the lower mean albumin:creatinine ratio was 
attributable to consumption of less high-temperature processed foods in the GFD, as 
evidenced by lower plasma advanced glycation end-product ﬂuorescence in those with CD 
vs. without CD. Whilst we did not assess dietary intake, we speculate that patients who did 
not adhere to a GFD may have consumed more highly processed gluten-containing foods, 
along with higher salt and high-fat intake. We also did not measure inﬂammatory markers 
such as erythrocyte sedimentation rate (ESR) or c-reactive protein (CRP), however it is 
plausible that lack of adherence to the GFD may be associated with chronic low-grade 
inﬂammation, which may also play a role in early elevation of AER. Collectively, these data 
support further investigation of dietary factors, including advanced glycation end-products, 
on complications risk, particularly among individuals with coexisting T1D and CD.  
 
In summary, Chapter 5 demonstrated that GFD non-adherence is associated with early 
elevation of AER, which is a recognized risk factor for future development of 
microalbuminuria in T1D (Schultz et al. 2000, Stone et al. 2006, Dunger et al. 2007, 
102 
Donaghue et al. 2009). While the relationship between poor glycaemic control and 
microvascular complications is well-established (DCCT 1993), non-adherence to the GFD was 
associated with elevated AER, independent of HbA1c. Our findings support the need for 
education to support adherence to the GFD in people with CD and regular dietetic review to 
ensure adequate dietary education. This study also provides further rationale for CD 
screening in T1D as presented in Chapters 3 and 4.  
The GFD, which is pervasive and life long, coupled with the demands of managing T1D, may 
be expected to result in lower QoL in youth living with both conditions, as shown in adults 
(Bakker et al. 2013).  In Chapter 6 the results of a case-control study demonstrated that the 
additional diagnosis of CD did not impair QoL in youth and their parents, although 
differences emerged when stratifying youth by GFD adherence. This was the first study to 
demonstrate that youth who did not adhere to the GFD had lower well-being and diabetes 
speciﬁc QoL, accompanied by suboptimal glycaemic control. Youth who were symptomatic 
at the time of diagnosis of CD were more likely to adhere to the GFD and reported better 
QoL. There was no difference in diabetes-speciﬁc QoL in youth with CD treated with CSII vs 
MDI; however, the CD–speciﬁc scale suggested a greater burden of having to follow a 
lifelong diet in those treated with CSII. 
We have demonstrated a subgroup of youth with CD identiﬁed through screening who have 
difﬁculty implementing the GFD. This highlights the impact of screening for CD in T1D 
particularly given CD often presents asymptomatically (Pham-Short et al. 2014). However, 
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symptoms may be identiﬁed retrospectively; more than one-half of asymptomatic children 
diagnosed with CD indicated (on a Likert scale) feeling “much better” or “somewhat better” 
after starting the GFD compared with beforehand. The majority of patients (69%) in this 
study adhered to the GFD, with adherence inﬂuenced by parental support, CD awareness, 
and availability of GF products (Rosen et al. 2011). As screening is now recognized as a 
standard of care in T1D (American Diabetes Association 2018, Mahmud et al. 2018), 
strategies are needed to intervene in those who resist the GFD. In our study, those who 
adopted the GFD within the ﬁrst year of CD diagnosis were more likely to maintain GFD 
adherence. This identiﬁes a crucial time for follow-up of the GFD and to discuss barriers the 
family may face. 
Adherence to a GFD was higher in those displaying CD-related symptoms before being 
diagnosed with CD. Interestingly, however, parents of symptomatic youth reported a 
greater strain on their family relationships, and emotional and social well-being. This may be 
owing to parents actively supporting the GFD for their children by educating others and 
preplanning for meals eaten outside of the home. Although burdensome, this extra support 
has proven beneﬁcial for the well-being and GFD adherence of adolescents (Olsson et al. 
2008). Youth who adhere to the GFD and their parents were more likely to consider the diet 
beneﬁcial, a ﬁnding that mirrors studies of youth with CD only (van Doorn et al. 2008). 
Youth who were GFD adherent and their family were more likely to eat together, which is a 
recognized indicator of greater nutritional quality in the general population (Hammons et al. 
2011), as well as in T1D (Kornides et al. 2014). This greater level of parental involvement 
may also extend to T1D management, which is reﬂected in the better glycaemic control in 
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the patients who adhered to the GFD, as we and others have previously reported (Sanchez-
Albisua et al. 2005, Pham-Short et al. 2013). The lower general well-being reported by youth 
who did not adhere to the GFD and their parents may be owing to perceived greater 
difﬁculty with the GFD, because youth who did not adhere expressed extreme sadness at 
having to follow a diet for CD , which has also been reported in CD alone (Wagner et al. 
2008, Barratt et al. 2011). 
 
We have shown that living with T1D and CD is not associated with lower QoL. However, we 
identiﬁed that youth who do not adhere to the GFD have lower well-being and diabetes-
speciﬁc QoL, along with suboptimal glycaemic control than youth who adhere to the GFD. 
This places them at risk of vascular complications (Pitocco et al. 2011, Mollazadegan et al. 
2013, Pham-Short et al. 2013, Rohrer et al. 2015). Regular monitoring of adherence in youth 
with coexisting T1D and CD will enable identiﬁcation of the subgroup who do not adhere, 
who may beneﬁt from more intensive clinical and psychosocial support. 
 
9.3 THE IMPACT OF THE GFD ON GLYCAEMIC EXCURSIONS 
The GFD has a high GI and low-fibre content, which potentially influences glycaemic 
excursions in T1D and CD. Our case-control study (Chapter 7) of youth with coexisting T1D 
and CD, compared to T1D alone utilised CGMS worn uninterrupted for six days. This was the 
first study to examine the impact of the GFD in youth with coexisting CD and T1D on 
glycaemic variability and nutrient intake. The GFD was associated with greater glycaemic 
excursions, characterized by a faster time to peak BGL, higher peak and higher two-hour 
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post prandial BGLs, despite similar exogenous insulin requirements. The GFD and the gluten-
containing diet had similar macronutrient distributions that met national nutritional 
guidelines, however the intake of saturated fat and sodium were above national and 
international recommendations, while the intake of dietary fibre and calcium was 
inadequate. 
The test meal of GF cereal consumed by all study participants was associated with greater 
glycaemic excursions in youth with T1D and CD compared with their T1D alone peers. The 
observation of faster glucose absorption in those with CD expands on a physiological study 
in which solutions of increasing glucose concentrations were infused into the small intestine 
and glucose absorption measured by the production of electrical activity (Apparent Km) 
(Read et al. 1976). Interestingly, higher Apparent Km was correlated with longer duration of 
GFD consumption in patients with CD and was higher than in controls. Similarly, we found a 
positive relationship between longer CD duration and higher 2 hour postprandial BGL. This 
suggests that chronic exposure to the GFD, which has a higher GI, modifies glucose 
transport and results in more rapid glucose absorption. In support of this hypothesis, three 
molecules that transport glucose (SGLT1, PEPT1 and NHE3) were higher in patients with 
treated vs untreated CD (Laforenza et al. 2010), implying that carbohydrates specific to the 
GFD may alter intra-intestinal gene transcription. The consideration of insulin timing given 
10-15mins pre-prandially and lower GI choices, in addition to stronger insulin to
carbohydrate ratios may minimise glycaemic excursions reported in our study. 
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GF pasta consumed by healthy adults also results in elevated postprandial glucose 
excursions (Johnston et al. 2017). This American study reported 57% higher plasma glucose 
concentrations for GF rice and corn pasta, compared to wheat pasta. Glycaemic variability 
associated with the GF diet may have further health implications and disease risk that 
warrants investigation, particularly as the GFD gains popularity in the general population 
(Kim et al. 2016), and as CD prevalence increases (Liu et al. 2017).  
 
The dietary intake of youth with T1D alone and those with both conditions was at the lower 
end of both national and international guideline recommendations for carbohydrates, 
inadequate for fibre and calcium and high for saturated fats (Schofield 1985, NHMRC 2012, 
Smart et al. 2014). The latter finding is consistent with dietary data in youth with T1D from 
the US and Europe (Schober et al. 1999, Helgeson et al. 2006, Lodefalk et al. 2006, Overby et 
al. 2007), while the inadequate fibre intake is consistent with data in T1D or CD populations 
(Thompson et al. 2005, Hopman et al. 2006), but not coexisting T1D and CD. Although fibre 
intake was inadequate for those on the GFD, they consumed more fruit, which is a naturally 
GF carbohydrate food.  This may have offset the expected reduction in carbohydrate grain-
based products that is often seen in studies of individuals with CD alone (Thompson et al. 
2005), but was not observed in our study group. The detailed dietary histories obtained 
from all patients in this study, irrespective of coexisting CD, indicate there is scope for 
improvement in dietary quality and reinforces the importance of dietary education in their 
management. 
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Our free-living study enables a more accurate depiction of life in youth with T1D and those 
with coexisting CD.  Correction doses of insulin were administered pre-meal, thereby 
providing an unbiased assessment of post-meal glucose excursions. All but one of our 
patients adhered to the GFD and therefore our results may not be applicable to those who 
do not adhere to the GFD; this is a population that warrants further study given we and 
others have demonstrated they have suboptimal glycaemic control (Chapter 5), lower QoL 
(Chapter 6) and are at greater risk of microvascular complications (Chapter 5). To further 
develop the findings of Chapter 5, and investigate any additional clinical effects of the 
coexistence of T1D and CD, we also examined bone health in Chapter 8. 
9.4 ABNORMAL BONE STRUCTURE IN YOUTH WITH T1D AND CD 
Utilising both DXA and pQCT, we assessed bone structure in youth with coexisting T1D and 
CD compared to T1D alone in a case-control study (Chapter 8). This was the first study to 
examine the impact of biopsy proven CD on bone in youth with coexisting T1D and CD. We 
found abnormal bone structure in those with both conditions, characterized by lower radial 
BMC, and lower radial cortical BMC, despite similar sized bone to youth with T1D alone.  
Those with coexisting T1D and CD also had a lower BMC:LTM, with higher material density, 
suggesting an impairment of bone development compared to those with T1D alone. 
Moreover, lower BMC:LTM coupled with higher total vBMD indicates a state of lower bone 
turnover, resulting in older and stiffer bones.   
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BMC:LTM was signiﬁcantly lower in those with coexisting T1D and CD, even though neither 
LTM adjusted for height nor muscle size were signiﬁcantly different between the two 
groups. Low BMC:LTM in the setting of normal LTM for height suggests the skeleton is 
unable to adequately respond to the force applied to it through muscle pull and implies a 
primary bone abnormality (Hogler et al. 2003).  Alternatively, it may be that muscle force is 
reduced in those with T1Dand CD despite normal muscle size, since muscle power correlates 
with bone strength in healthy adolescents (Janz et al. 2015). Exercise, particularly resistance 
training, increases muscle strength (Faigenbaum et al. 1999) and BMD (Gutin et al. 1999) in 
children. However, we did not document activity levels in this population or undertake 
measures of muscle force, so it is unknown whether there are differences in these factors 
between the two groups.  
In conclusion, the final study in this body of work demonstrated that youth with T1D and CD 
have a low bone turnover state, resulting in high BMD with reduced response to muscle 
pull, compared to those with T1D alone. Youth with coexisting T1D and CD also 
demonstrated lower radial trabecular bone and BMC compared with those with T1D alone. 
These structural differences were independent of LTM, glycaemic control and dietary 
calcium intake, but insulin doses were higher in those with CD. The findings suggest that 
regular monitoring of bone health is needed in youth with both conditions to enable early 
interventions such as regular weight bearing exercise and support GFD adherence to 
optimize bone health. These recommendations are particularly important in those with 
longer T1D duration, which is associated with increased fracture risk (Botushanov et al. 
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2009), and because GFD adherence for five years was associated with full recovery of BMD 
in those with CD alone (Grace-Farfaglia 2015). 
9.5 IMPLICATIONS FOR CLINICAL PRACTICE AND FUTURE RESEARCH 
A summary of the main findings, clinical implications and recommendations from this body 
of work is shown in Figure 9.1. Clinical practice recommendations based on the studies that 
comprise this thesis include: 
• Screen for CD at the time of diabetes diagnosis and at two and five years thereafter.
This recommendation has been incorporated into clinical practice guidelines by ADA
(American Diabetes Association 2018) and ISPAD (Mahmud et al. 2018), with both
societies updating their 2018 screening recommendations, citing our systematic review
as level B evidence. Screen for CD beyond 10 years of T1D duration, especially for
those diagnosed with T1D < 5 years of age.
• Support adherence to the GFD by regular dietary review and serological testing, as
adherence is associated with lower AER, better glycaemic control and higher QoL.
• Address the greater glycaemic variability in youth with coexisting T1D and CD, through
adjustment of insulin regimens, including insulin to carbohydrate ratios.
• Educate and monitor for inadequate nutritional intake in youth with coexisting T1D
and CD.
• Regularly monitor bone health in youth with coexisting T1D and CD, due to the
additive risk for adverse measures of bone health.
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Future studies should include prospective cohorts with at least five years of diabetes 
duration, to enable reliable assessment of the impact of screening after T1D diagnosis. 
Studies incorporating both children and adults will enable further evaluation of the 
frequency of CD screening in T1D, as well as examination of the effect of age and gender at 
diabetes diagnosis on the development of CD. Large observational cohort studies, such as 
ADDN, DPV and T1DX, should consider examining glycaemic variability, QoL and bone health 
in the broader T1D population, particularly among those with longer disease duration.  CD 
specific studies, in those with or without coexisting T1D, should examine factors associated 
with GFD adherence and results should be stratified by GFD adherence. Studies of 
complications in people with T1D and CD should investigate the role of dietary factors 
including AGEs, and the impact of CSII vs MDI on complications risk, given CSII reduces 
complications in T1D (Zabeen et al. 2016).  Assessment of glycaemic variability should 
incorporate CGM over longer periods of time, and consider whether variability can be 
reduced by dietary changes such as increased fibre, or different insulin administration 
algorithms, rates or volumes as suggested. Finally, intervention studies will provide the 
highest level of evidence to address these research questions; for example use of MDI vs 
CSII/hybrid closed loop, or interventions to improve bone health in people with T1D and CD.  
9.6 CONCLUSIONS 
In conclusion, screening for CD within the first 10 years of T1D diagnosis will yield the 
highest prevalence of CD. The additional diagnosis of CD is not associated with lower QoL 
among youth with T1D, however non-adherence to the GFD is associated with lower QoL 
and early signs of nephropathy. The GFD is associated with greater glycaemic variability, 
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despite similar macronutrient profiles to the gluten-containing diet. Overall, the dietary 
quality of youth with T1D, with or without coexisting CD, is suboptimal, with inadequate 
calcium, folate and fibre intake, as well as excessive saturated fat and sodium. The 
coexistence of CD and T1D confers an additional burden on bone health, resulting in 
abnormal cortical and trabecular bone. Clinical management should address adherence to 
the GFD, glycaemic variability and dietary quality. Current evidence suggests there is no 
benefit of CSII vs MDI in youth with T1D and CD, however CSII negatively impacts on some 
aspects of QoL.  
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should be 
performed at 
diabetes diagnosis 
and for at least 10 
years in young 
children
Chapter 3 -
"Incidence" 
Longitudinal Study
▪ Coexisting T1D +
CD is common.
Incidence of 7.1 per
1,000 patient years.
▪ Highest risk of CD
in those < 5 years of 
age at time of T1D 
diagnosis
▪ CD screening
should be
considered at
diagnosis, 2 years 
and 5 years of T1D 
duration
▪ ADA and ISPAD 
2018 Standards of 
medical care and 
consensus practice 
guidelines  adapted 
to revise screening 
guidelines
Chapter 5 -
"Screening" 
Systematic Review
▪ Weighted pooled
prevalence of 5.1%
in 11,157 children
▪ 40% diagnosed
with CD within 1
year of T1D, 55%
within 2 years, 79%
witihin 5 years
▪ Living with T1D
and CD does not
seem to impact QoL 
negatively
▪ Regular monitroing 
of GFD adherence, 
to identify GFD non-
adherence, whereby 
more intenstive 
clinical and 
psychosocial support 
may be beneficial
Chapter 6 -
"Quality of Life" 
Case control study
▪ T1D and CD
patients report
similar QoL
▪ GFD non-adherent
youth report lower
diabetes specific
QoL and general well
being, along with
worse glycaemic
control
▪ Recommend 
regular monitoring 
of bone health in 
youth with T1D + 
CD. Future research
should examine 
early interventions 
to improve bone 
health 
Chapter 8 -
"Bone Health"    
Case control Study
▪ T1D + CD youth
have abnormal
trabecular and
cortical bone
▪ Lower bone
turnover state with
reduced response to
muscle pull
▪ CD screening
should be
considered at
diagnosis, 2 years 
and 5 years of T1D 
duration
▪ ADA and ISPAD
2018 Standards of
medical care and
consensus practice
guidelines  adapted
to revise screening
guidelines
Chapter 4 -
"Screening" 
Systematic Review
▪ Weighted pooled
prevalence of 5.1%
in 11,157 children
▪ 40% diagnosed
with CD within 1
year of T1D, 55%
within 2 years, 79%
witihin 5 years
▪ Support the need 
for GFD adherence, 
and regular dietary 
review. 
▪ Provides further
rationale for CD 
screening 
"Complications" 
Comparative Study
▪ T1D + CD group 
had better glycaemic 
control 
▪ GFD nonadherence 
associated with early 
signs of kidney 
disease
or
re i te siv  
▪ T1D and CD 
patients report 
similar QoL 
▪ GFD non-adherent 
youth report lower 
diabetes specific 
QoL and general well 
being, along with 
worse glycaemic 
control 
▪ Dietary advice for
youth with T1D + CD 
should emphasize 
increasing fibre, 
folate and calcium 
intake, and reducing 
saturated fat and 
sodium intake, with 
further attention to 
increase thiamin 
intake for those on 
GFD
Chapter 7 -
"Glycaemic variability 
and nutrient intake"  
Case control study 
▪ T1D + CD youth
have greater post
prandial excursions
despite similar pre-
meal BGLs
▪ Similar total energy
and macronutrient 
intake, inadequate 
calcium, folate, fibre 
intake, high 
saturated fat, high 
sodium
▪ Recommend
regular monitoring 
of bone health in 
youth with T1D + 
CD. 
Future research 
should examine 
early interventions 
to improve bone 
health 
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Young people with coeliac disease are not at increased risk of 
microvascular complications despite longer diabetes duration 
Anna Pham1,2,  Kim C. Donaghue1,2, Geoff R Ambler1,2, Albert K Chan1, Janine Cusumano1, Stephen Hing1, Maria E Craig1,2
1. The Institute of Endocrinology and Diabetes, The Children’s Hospital at Westmead, Sydney, Australia
2. Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, Australia
Aims 
1. To examine glycaemic control, anthropometry and microvascular
complications in those with T1DM and CD (T1DM+CD) vs T1DM
(T1DM).
2. To determine whether adherence with the gluten free diet (GFD)
impacts on glycaemic control, anthropometry or microvascular
complications.
Table 2. Characteristics of those with, or without coeliac disease 
T1DM  
(n = 2449) 
T1DM+CD 
 (n = 139) 
p-value
Age at visit 16.3 [14.7 – 17.8] 15.9 [14.3 – 17.7] 0.12 
Age at diabetes diagnosis 8.6 [5.4-11.3] 7.1 [3.1 – 10.0] < 0.0001 
HbA1c (%) 8.6 [7.1 – 9.6] 8.3 [7.7-9.3] 0.084 
Height SDS 0.23 [-0.45 – 0.89] 0.19 [-0.60 – 0.85] 0.36 
Weight SDS 0.77 [0.18-1.26] 0.68 [0.14-1.24] 0.56 
BMI SDS 0.71 [0.16-1.20] 0.76 [0.11 – 1.25] 0.77 
Cholesterol (mmol/L) 4.4 [3.9 – 5.0] 4.4 [3.9 – 5.1] 0.55 
Insulin dose/weight (unit/kg/day) 1.06 [0.88 – 1.28] 1.14 [0.92 – 1.35] 0.019 
Retinopathy 541/2296 (24%) 27/132 (20%) 0.41 
Microalbuminuria (AER) 46/1025 (4%) 1/56 (2%) 0.51 
Results 
• Trend to better glycaemic control in those with CD (p = 0.084)
• Compliance to GFD associated with better glycaemic control than
those GFD non-compliant, or without CD (p=0.0031)
• Non-compliance to GFD associated with worst glycaemic control
compared to those GFD compliant, or without CD
• Trend to lower BMI SDS in those GFD compliant compared to than
those GFD non-complaint (p = 0.056)
• Trend to lower insulin dose/weight in those GFD compliant compared
to those GFD non-compliant
• Presence of CD in T1DM does not increase risk of microvascular
complications
Introduction 
The coexistence of type 1 diabetes mellitus (T1DM) and coeliac disease 
(CD) is well documented, with prevalence rates varying from 1-10%
worldwide.
Non-adherence  with treatment causes different problems in T1DM and 
CD. The burden of two chronic diseases may make complications more
likely.
Established risk factors for complications of T1DM include longer 
disease duration, older age and puberty, with improved glycaemic control 
conferring significant risk reduction for microvascular complications.  
Left untreated, patients with CD are at increased risk of iron deficiency, 
anaemia, fertility problems, gastrointestinal malignancy and mortality.  
Furthermore individuals with T1DM and CD may be at increased risk of 
microvascular complications due to chronic inflammation . To date, there 
are no published studies examining whether CD increases rates of 
microvascular complications in T1DM.  
Conclusions 
• Young people with T1DM and CD who adhere to the GFD
have better glycaemic control, lower weight SDS and lower
BMI SDS and less retinopathy.
• We speculate that young people who struggle with CD also
struggle with diabetes management and may benefit from
further support and education.
• CD does not appear to negatively influence anthropometry
or microvascular complications risk
Contact: Anna Pham   annap3@chw.edu.au 
Results - Table 1. Comparison of those without coeliac disease, and by GFD accordance
T1DM 
(n=2449) 
GFDComp 
 (n=71) 
GFDNon 
(n=56) 
p-value*
Age at visit 16.4 [14.7 – 17.8] 16.4 [14.7 – 17.9] 15.3 [13.9 – 17.3] 0.030 
Age at diabetes diagnosis 8.6 [5.4 – 11.3] 6.5 [2.8 – 9.7] 7.5 [3.1 – 10.9] <0.0001 
HbA1c (%) 8.6 [7.7-9.6] 8.2 [7.5 – 9.0] 8.8 [7.9 – 9.9] 0.0031 
Height SDS 0.23 [-0.45 - 0.89] 0.02 [-0.63 - 0.72] 0.27 [-0.58 - 0.81] 0.21 
Weight SDS 0.77 [0.18 - 1.26] 0.48 [-0.11 - 1.13] 0.98 [0.23 - 1.44] 0.051 
BMI SDS 0.71 [0.16 - 1.20] 0.61 [0.06 - 1.12] 1.07 [0.25 - 1.33] 0.13 
Cholesterol (mmol/L) 4.4 [3.9 - 5.0] 4.2 [3.9 - 5.0] 4.4 [3.9 - 5.3] 0.76 
Insulin dose/weight (unit/kg/day) 1.06 [0.88 - 1.28] 1.11 [0.9 - 1.29] 1.17 [1.00 - 1.48] 0.028 
Retinopathy 541/2296 (24%) 9/68 (13%) 15/53 (28%) 0.097 
Microalbuminuria (AER) 46/1025 (4%) 0/28 (0%) 1/24 (4%) 0.52 
*p-value from analysis of variance, comparing the three groups
Patient Group 
Comparative study of T1DM (n=2551) and T1DM+CD (n=145) 
individuals aged 9 to <20 years attending complications assessment 
between 1990–2011 at their most recent visit.  
For comparison, those with biopsy confirmed CD were further stratified 
by gluten free diet (GFD) accordance. TTG antibody titres within the 
normal range at time of visit were defined as GFD compliance 
(GFDComp) or otherwise defined as GFD Non-compliance (GFDNon). 
Methods 
Investigations included: 
• Albumin excretion rate (AER) by times overnight urine collections
• Early retinopathy was detected using 7-field fundal photography 4
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Increased risk of microalbuminuria in young people with diabetes and 
coeliac disease with poor gluten free diet adherence 
Anna Pham-Short1,2,  Kim C. Donaghue1,2, Geoff R Ambler1,2, Albert K Chan1, Janine Cusumano1, Stephen Hing1, Maria E Craig1,2
1. The Institute of Endocrinology and Diabetes, The Children’s Hospital at Westmead, Sydney, Australia
2. Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, Australia
Aims 
1. To examine glycaemic control, anthropometry and microvascular
complications in those with T1DM and CD (T1DM+CD) vs T1DM
(T1DM).
2. To determine whether adherence with the gluten free diet (GFD)
impacts on glycaemic control, anthropometry or microvascular
complications.
Table 2. Characteristics of those with, or without coeliac disease 
T1DM  
(n = 2511) 
T1DM+CD 
 (n = 145) 
p-value
Age at visit (yrs) 16.5 [14.8 – 17.8] 16.1 [14.3 – 17.8] 0.13 
Age at diabetes diagnosis (yrs) 8.3 [5.3-11.3] 6.7 [3.0 – 10.0] < 0.0001 
Diabetes duration (yrs) 7.2 [4.9 -10.3] 9.6 [6.3 -12.2] <0.0001 
HbA1c (%) 8.6 [7.7 – 9.6] 8.3 [7.6-9.3] 0.08 
Height SDS 0.23 [-0.45 - 0.89] 0.24 [-0.60 - 0.87] 0.54 
Weight SDS 0.77 [0.15-1.20] 0.67 [0.08-1.21] 0.51 
BMI SDS 0.70 [0.16-1.20] 0.76 [0.11 – 1.25] 0.89 
Cholesterol (mmol/L) 4.3 [3.8 – 5.0] 4.4 [3.8 – 5.0] 0.97 
Insulin dose/weight (unit/kg/day) 1.05 [0.87 – 1.28] 1.14 [0.92 – 1.35] 0.02 
Retinopathy 556/2382 (23%) 31/140 (22%) 0.74 
Mean AER > 7.5μg/min 601/2119 (28%) 39/130 (30%) 0.69 
Mean ACR  0.76 [0.55 – 1.23]  0.79 [0.61 – 1.26] 0.43 
Peripheral nerve abnormality 627/2426 (26%) 40/144 (28%) 0.61 
Results 
• Trend to better glycaemic control in those with CD (p = 0.08)
• Non-compliance with GFD is associated with a higher risk of early
elevation of AER (p = 0.043)
• Compliance to the GFD is not associated with height, weight, nor BMI
SDS
• Presence of CD in T1DM does not increase risk of neuropathy or
retinopathy  development despite longer diabetes duration
• Young people with CD and T1DM are diagnosed with T1DM at an
earlier age (p < 0.0001)
Introduction 
The coexistence of type 1 diabetes mellitus (T1DM) and coeliac disease 
(CD) is well documented, with prevalence rates varying from 1-10%
worldwide.
As individual conditions, T1DM and CD have their own sets of 
complications. The impact of two chronic diseases may increase the risk 
of complications.  
Established risk factors for complications of T1DM include longer 
disease duration, older age and puberty, with improved glycaemic control 
conferring significant risk reduction for microvascular complications.  
Left untreated, patients with CD are at increased risk of iron deficiency, 
anaemia, fertility problems, gastrointestinal malignancy and mortality.  
Furthermore individuals with T1DM and CD may be at increased risk of 
microvascular complications due to chronic inflammation . To date, there 
are no published studies examining whether CD increases rates of 
microvascular complications in T1DM.  
Conclusions 
• Increased risk of microalbuminuria in young people with diabetes and CD with poor gluten free diet adherence
• CD does not appear to negatively influence anthropometry, glycaemic control, neuropathy or nephropathy complication risk despite longer diabetes
duration.
• We speculate that the development of microvascular complications is influenced by more than glycaemic control and diabetes duration
Contact: Anna Pham   anna.pham@health.nsw.gov.au 
Patient Group 
Comparative study of T1DM (n=2511) and T1DM+CD (n=145) 
individuals aged 9 to <20 years attending complications assessment 
between 1990–2011 at their most recent visit.  
For comparison, those with biopsy confirmed CD were further stratified 
by gluten free diet (GFD) accordance. TTG antibody titres within the 
normal range at time of visit were defined as GFD compliance 
(GFDComp) or otherwise defined as GFD Non-compliance (GFDNon). 
Methods 
Investigations included: 
• Glycaemic control measured by HbA1c
• Albumin excretion rate (AER) by timed overnight urine collections
• Early retinopathy was detected using 7-field fundal photography
Table 3. Characteristics stratified by GFD accordance 
GFDComp 
(n=76) 
GFDNon 
(n=51)  
p-value
Age at visit 15.6 [14.1 – 17.3] 16.6 [15.0 – 18.1] 0.12 
Age at diabetes diagnosis 6.4 [2.6 – 9.5] 8.1 [3.1 – 11.1] 0.20 
Diabetes duration (yrs) 9.4 [6.6 – 12.2] 9.3 [6.3 – 12.3] 0.71 
HbA1c (%) 8.3 [7.7 – 9.0] 8.5 [7.6 – 9.4] 0.40 
Height SDS 0.20 [–0.60 to 0.72] 0.29 [–0.58 to 1.00] 0.67 
Weight SDS 0.63 [0.15 – 1.14] 0.97 [0.22 – 1.33] 0.14 
BMI SDS 0.62 [0.04 – 1.21] 1.05 [0.38 – 1.30] 0.14 
Cholesterol (mmol/L) 4.4 [3.7 – 5.0] 4.4 [4.0 – 5.0] 0.44 
Insulin dose/weight (unit/kg/day) 1.08 [0.90 – 1.34] 1.16 [0.91 – 1.34] 0.42 
Retinopathy 13/74 (18%) 14/49 (29%) 0.15 
Mean AER > 7.5μg/min 17/70 (24%) 19/45(42%) 0.04 
Mean ACR 0.79 [0.64 – 1.26] 0.96 [0.47 – 1.30] 0.86 
Peripheral nerve abnormality 19/75 (25%) 17/51 (33%) 0.33 
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Methods 
• Comparative study of 2510 young people with T1D (CD-), and 129 biopsy
proven CD+ aged <20 years at their most recent to the Diabetes complications
screening visit from 1990 – 2010
• GFD adherence defined as EMA or TTG titres within the normal range (GFD+),
or elevated (GFD-) at time of visit.
Complications Screening: 
• Retinopathy by 7-field stereoscopic fundal photography
• Timed overnight urine collections for AER. Early elevation defined as  AER >
7.5µg /min
• Peripheral neuropathy – by thermal threshold and vibration perception at the
foot and pupillometry for autonomic neuropathy
Statistical Analysis - Analyses performed using SPSS, version 20. 
• Continuous variables compared between groups using analysis of variance and
categorical variables using χ2- tests.
• Binary logistic regression used to examine association between complication
outcomes (presence or absence) and explanatory variables including GFD+ vs
GFD-, age, HbA1c, gender, BMI SDS, insulin/kg/day and use of continuous
subcutaneous insulin infusion therapy (CSII).
• Interaction terms such as HbA1c x GFD- were examined in multivariate models.
Table 2. Characteristics and complications rates stratified by GFD adherence 
GFD + (n=69) GFD - (n=60) p-value
Age at diabetes diagnosis (years) 6.7 [2.9 – 9.6] 7.3 [2.8 – 1.0] 0.48 
Current age 15.8 [14.4 – 17.8] 16.4 [14.3 – 17.9] 0.43 
Diabetes duration (years) 9.2 [6.60 – 12.22] 9.4 [ 6.3 – 12.3] 0.81 
Coeliac disease duration (years) 6.2 [3.1 – 9.6] 6.7 [2.8 – 11.5] 0.54 
Male gender (%) 26/69 (38%) 29/60 (48%) 0.22 
HbA1c (%) 8.2 [7.6 – 9.0] 8.7 [7.8-10.0] 0.003 
Mean HbA1c last 12 months (%) 8.2 [7.8 – 8.8] 8.8 [7.8 – 10.0] 0.009 
HbA1c > 9.0% 10/69 (14%) 23/58 (40%) 0.002 
Insulin Pump therapy 15/68 (22%) 10/58 (17%) 0.50 
Height SDS 0.75 [-0.60 – 0.72] 0.29 [-0.58 – 1.00] 0.51 
Weight SDS 0.59 [0.13 – 1.13] 0.95 [0.22 – 1.33] 0.39 
BMI SDS 0.61 [0.06 – 1.10] 1.00 [0.28 – 1.30] 0.61 
Cholesterol (mmol/l) 4.20 [3.70 – 5.00] 4.45 [3.93 – 5.1] 0.08 
Insulin dose (unit/kg/day) 1.03 [0.88 – 1.27] 1.15 [0.99 – 1.46] 0.002 
AER > 7.5 µg/min 15/65 (23%) 21/52 (40%) 0.04 
Peripheral nerve abnormality 17/68 (25%) 19/60 (32%) 0.40 
Retinopathy 12/67 (18%) 15/58 (26%) 0.38 
Pupillary abnormality 32/55 (58%) 31/50 (62%) 0.69 
Results Summary 
Background 
There are conflicting data on the risk of microvascular complications among 
individuals with type 1 diabetes (T1D) and coeliac disease (CD).  
Some studies show that coexisting CD (CD+) is associated with increased risk of 
retinopathy and vascular disease, whilst others show reduced risk of nephropathy 
and retinopathy.  
Risk factors are likely to be multifactorial, although the role of glycemic control 
has not been consistently associated with complications risk in CD+. 
Furthermore, the role of long-term gluten free diet adherence (GFD+) on 
complications risk has not been examined.  
Table 1. Characteristics and complications rates in those with diabetes with, or 
without coexisting coeliac disease 
CD- (n=2510) CD + (n = 129) p-value
Age at diabetes diagnosis (years) 8.6 [5.3 – 11.4] 7.1 [2.9 – 10.0] < 0.001 
Current age 16.5 [14.8 – 17.9] 16.1 [14.3 – 17.8] 0.13 
Diabetes duration (years) 7.2 [4.9 – 10.4] 9.3 [6.3 –12.2] <0.001 
Coeliac disease duration (years) - 6.6 [3.0 – 10.3] 
Male gender (%) 1206/2510 (48%) 55/129 (43%) 0.24 
HbA1c (%) 8.6 [7.7 – 9.6] 8.3 [7.6 – 9.3] 0.04 
Mean HbA1c last 12 months (%) 8.6 [7.8 – 9.6] 8.3 [7.8 – 9.4] 0.08 
HbA1c > 9.0% 927 / 2447 (38%) 33/127 (26%) 0.03 
Insulin Pump therapy 322/2468 (13%) 25/126 (20%) 0.04 
Height SDS 0.23 [-0.45 – 0.90] 0.20 [-0.58 – 0.85] 0.28 
Weight SDS 0.78 [0.17 – 1.26] 0.75 [0.15 – 1.22] 0.86 
BMI SDS 0.70 [0.15 – 1.20] 0.81 [0.16 -1.26] 0.59 
Cholesterol (mmol/l) 4.3 [3.8 – 5.0] 4.4 [3.8 – 5.0] 0.54 
Insulin dose (unit/kg/day) 1.05 [0.87 – 1.28] 1.08 [0.91 – 1.34] 0.08 
AER > 7.5 µg/min 600/2118 (28%) 36/117 (31%) 0.60 
Peripheral nerve abnormality 627/2425 (26%) 36/128 (28%) 0.61 
Retinopathy 556/2381 (23%) 27/125 (22%) 0.75 
Pupillary abnormality 1020/1771 (58%) 63/105 (60%) 0.69 
Discussion 
• To our knowledge, this is the first study  to compare complication rates in
young people with co-existing T1D and CD, stratified by GFD adherence
• GFD- is associated with early evidence of renal disease, independent of
glycemic control
• The GFD, which contains less high temperature processed foods and
hence less advanced glycation end-product (AGEs), may play a role in
reduced complications risk – this warrants further investigation
• A potential limitation of our study include the use of cross-sectional
analysis, however median diabetes duration was > 9 years and data were
analysed to the last study visit to enable longest diabetes and CD duration
Clinical Indications 
• Our findings support the need for adherence to the GFD in people with
CD and regular dietetic review to ensure adequate dietary education.
• Our findings also support guidelines for CD screening in type 1 diabetes.
Hypothesis 
We hypothesized that for young people with T1D, CD+ and poor GFD adherence 
(GFD-) would have higher complications rates, independent of glycemic control 
CD – vs CD+ GFD + vs GFD - 
• CD+ cases were significantly
younger at diabetes diagnosis, and
therefore had longer diabetes
duration
• HbA1c was significantly lower in
CD+ (8.3% vs 8.6%)
• CSII use was higher in CD+ (20% vs
13%)
• There were no differences in
anthropometry, cholesterol or
complications rates in CD- vs CD+
• There were no differences in current age,
gender, diabetes duration or CD duration
• GFD+ had significantly better glycemic control
than GFD- at most recent visit (8.2% vs 8.7%)
• The frequency of early elevation of AER was
significantly higher in GFD- vs GFD+ (40% vs
23%).
• In multivariate logistic regression, elevated
AER was associated with GFD- (odds ratio
2.37, 95% CI P=0.039) and diabetes duration
(OR 1.13, 95% CI P=0.026).
• HbA1c was not significant in univariate
analysis (OR 1.24, p=0.1) or in the multivariate
model.
• The interaction between HbA1c and GFD- was
also not significant (p=0.13).
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Introduction 
The coexistence of type 1 diabetes mellitus (T1D) and coeliac disease 
(CD) is well documented, but data on the effects on bone health are 
limited. In CD, there is increased fracture risk in both children and 
adults, whilst in T1D, there is increased fracture risk in adults. As 
childhood and adolescence are important times for attaining peak bone 
mass during growth, assessing bone health in children is important. 
 
Various factors in adolescents with T1D may contribute to overall poor 
bone health and lower peak bone mass. These include non-adherence 
with diabetes management such as insulin omission, insufficient dietary 
calcium intake and increased calcium excretion. 
 
Dual energy X-ray absorptiometry (DXA) is the gold standard in assessing 
bone mineral density (BMD) and bone mineral content (BMC). Peripheral 
quantitative computed tomography (pQCT) is another tool that allows for 
determination of trabecular and cortical vBMD and provides data on 
bone size and shape which allow for determination of bone strength.    
Table 2. DXA (n=32), pQCT (radial and tibial , n=25)  
 
   
 
Conclusions 
•  Patient group has overall normal bone, ie. > -2.0 SD 
•  Statistically significant reduction in trabecular bone mass in all areas 
measured  
•  pQCT data suggest discrepency between cortical bone development in 
radius and tibia which requires further investigation 
Future Research 
•  Prospective studies (DEXA and pQCT scans every 1-2 years) in youth with T1D 
and CD, and T1D (control data) are needed to understand the natural history of 
bone density in to adulthood. In addition, the relationship between optimal 
management of T1D and CD, and bone outcomes, should be examined. 
Table 1. Patient characteristics 
Mean + SD 
Median age at visit (years) 13.9 + 3.5 
Age at T1D diagnosis (years) 6.3 + 4.0 
Age at CD diagnosis (years) 9.3 + 4.1 
Duration of T1D (years) 7.6 + 3.9 
Duration of CD (years) 4.6 + 3.4 
HbA1c at visit (%) 8.3 + 1.2 
Height z-score 0.04 + 1.3 
Z-score (95% CI) p-value 
D
XA
 re
su
lts
 Total BMD (DXA) -0.21 (-0.60 to 0.18) 0.29 
Total BMC (DXA) 0.10 (-0.36 to 0.55) 0.66 
L1 – 4 vBMD (DXA) -0.57 (-1.00 to -0.14) 0.01 
LTM for height 0.09 (-0.34 to 0.53) 0.67 
BMC/LTM -0.15 (-0.55 to 0.25) 0.44 
R
ad
ia
l p
Q
C
T 
re
su
lts
 
4% BMC total -0.90 (-1.46 to -0.35) <0.01 
4% vBMD trabecular  -1.24 (-1.84 to -0.64) < 0.001 
4% CSA total bone -0.33 (-0.74 to 0.08) 0.03 
66% BMC cortical -1.62 (-2.17 to -1.07) <0.001 
66% Cortical thickness  0.03 (-0.28 to 0.34) 0.83 
66% vBMD cortical  0.31 (-0.70 to 1.32) 0.54 
66% CSA total bone -0.41 (-1.07 to 0.24) 0.21 
66% CSA cortical -0.22 (-0.74 to 0.30) 0.40 
CSA muscle -0.89 (-1.53 to -0.25) <0.01 
Cortical BMC/muscle CSA -0.82 (-1.32 to -0.33) <0.01 
Ti
bi
al
 p
Q
C
T 
re
su
lts
 4% vBMD trabecular -0.59 (-0.88 to -0.30) < 0.001 
66% BMC cortical -0.22 (-0.68 to 0.23) 0.32 
66% Cortical thickness -0.66 (-0.89 to -0.43) < 0.001 
66% vBMD cortical 0.44 (0.17 – 0.70) 0.02 
66% CSA total bone 0.65 (0.02 – 1.28) 0.04 
66% CSA cortical -0.38 (-0.80 o 0.04) 0.07 
CSA muscle -0.20 (-0.71 to 0.31 0.43 
Cortical BMC/muscle CSA -0.10 (-0.52 to 0.32) 0.63 
Image 3. 4% of 
tibial length 
Variable 
BMC total 
CSA total bone 
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Aim  
To examine bone and muscle parameters in children and adolescents 
with T1D and CD from a tertiary pediatric centre using DXA and pQCT. 
 
Methods 
Observational study of 32 children and adolescents with T1DM and 
biopsy proven CD. 
 
DXA provided measurements of total BMD, bone mineral content (BMC), 
lumbar spine volumetric BMD (vBMD), lean tissue mass (LTM) and 
reported as z-scores for age. 
 
pQCT of the radius and tibia was also performed in 25; reported as z-
score for age in metaphyseal and diaphyseal bone (4% and 66% of bone 
length, respectively) . pQCT measurements included volumetric BMD 
(vBMD), cortical BMC, cross sectional area (CSA) of total bone, CSA 
cortical bone, CSA relative cortical bone, CSA muscle, cortical BMC/
muscle CSA.  
Results 
•  Reduced trabecular bone density is evident – with reduced lumbar 
spine vBMD, and reduced trabecular vBMD in both the radius and tibia.  
•  Radial cortical bone essentially normal, as was total body BMD. 
•  Tibial bone results indicate increased size, with thin and dense cortices.  
•  Muscle mass and muscle bone health in relation for total body and tibia 
are normal, with reduced muscle CSA in the radius. 
Interpretation 
Results 
Aim  
Children and adolescents with T1D and CD will have lower BMD and 
abnormal bone development compared to age and sex matched controls 
 
Hypothesis  
Images of radial pQCT results from a 17 year old boy with T1DM + CD 
Image 1. 4% of radial length 
Image 2. 66% of radial 
length 
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Objectives 
To systematically review the incidence and prevalence of coeliac disease (CD) 
in type 1 diabetes (T1D) and determine the optimal screening frequency for 
CD.  
Conclusions  
CD is relatively common in young persons under 21 years of age with T1D; greatest 
risk is within 1 year of diabetes onset but 21% are diagnosed after more than 5 
years diabetes duration.  
We recommend screening at diabetes diagnosis, annually for the first 2 years, and 
again at least once before 5 years of diabetes duration.  
Whilst CD can be diagnosed beyond 10 years after diabetes diagnosis, more 
research is required to establish the optimal screening frequency beyond 5 years of 
diabetes duration as well as the optimal screening frequency in adults with T1D.  
 
Background 
The co-existence of type 1 diabetes (T1D) and coeliac disease (CD) has been 
recognised since the 1960s but data on the optimal screening frequency for 
CD in T1D are limited. Prevalence rates from cross sectional and longitudinal 
studies range from 1.6% to 16.4% worldwide. 
 
Recognized side effects of untreated CD include iron deficiency, anaemia, and 
growth retardation. In T1D, non-adherence to the gluten free diet has been 
associated with early elevation of albumin excretion rate, whilst CD duration 
beyond 10 years irrespective of GFD adherence, has been associated with 
diabetic retinopathy. The rationale for CD screening in T1D is to prevent these 
complications and to maximise growth.  
 
Seroconversion from negative to positive CD autoantibodies can occur beyond 
10 years of T1D duration, further supporting the importance of repeated 
screening for CD.  
 
Despite the well-recognised increased risk of CD in T1D and the potential for 
increased morbidity, there are no systematic reviews examining incidence of 
CD nor the optimal screening frequency for CD in T1D. The recommended 
screening frequency is variable and not evidence based. Thus, we 
systematically reviewed incidence and prevalence of CD in people with T1D in 
order to inform screening guidelines.  
1. Systematically review the epidemiology of biopsy proven CD in people with 
T1D, with subgroup analysis by age, gender and duration of diabetes.  
 
2. Review the risk of CD in people at the time of T1D diagnosis, and specific 
time points after diagnosis to determine optimal screening frequency. 
Methods 
Inclusion Criteria:  
• Longitudinal studies 
• Screened for CD using either endomysial antibodies (EMA), or tissue transglutaminase 
autoantibodies (TTG) at least twice 
• Children, adolescents of adults with T1D 
• Human studies  
• Reported in English 
• CD confirmed by small bowel biopsy 
 
Databases used: EMBASE, Medline, Cochrane to 30th June 2014 
Study quality assessed by Newcastle-Ottawa quality assessment scale 
 
Outcomes examined: prevalence, incidence, cumulative incidence 
Pooled prevalence calculated as the total number of CD cases divided by the total number of 
patients screened (n=11,156) 
Incidence density: calculated as total number of diagnosed cases divided by the number of 
patients screened up to point of interest (n = 4839, 8789, and 20,299 at 1,2 and 5 years 
respectively).  
Results 
Results 
• 9 studies – 7 from Europe, 2 from Australia 
• Total population: 11,156 young people diagnosed with T1D < 21 years  
• Median follow up time 10 years (range 5 – 18 years) 
• 587 cases of biopsy proven CD – 41 CD cases diagnosed prior to T1D] 
• Pooled prevalence – 5.3%  
• Seroconversion ranged from 2 – 10.2 years 
• No relationship between age at diabetes diagnosis,  nor gender  
• Five studies reported CD symptomology in those with T1D and CD (n=308), 85% 
of cases asymptomatic  and identified via screening  
• Screening recommendations from studies variable – ranging from at DM 
diagnosis, to annually for ‘several’ years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes 
duration 
Incidence / 
1,000 patient 
years  
1 year 43.3 
2 years 32.7 
5 years 20.0 
Study Aims  
Within 1 
year  
40% 
1-2 years  
14% 
2 to <5 
years 
25% 
5 - 10 
years  
16% 
> 10 years 
5% 
Figure 2. Time between CD and T1D diagnosis (n=536) 
Figure 1. Flow chart of number of citations retrieved by individual searches and number of studies included in review 
Table 1. Pooled incidence 
density calculated from 
available data in publications 
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Quality of Life in Type 1 Diabetes and Celiac Disease: 
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Evidence of long-term negative outcomes for individuals living with type 1 diabetes 
(T1D) and celiac disease (CD) are emerging; these include an increased risk of 
retinopathy, nephropathy, and subclinical atherosclerosis, at times independent of 
glycemic control. This suggests that those who struggle with the coexistence of both 
chronic conditions are at higher risk of complications; however, there is a paucity of 
data on the impact of living with both conditions on quality of life (QoL) and general well-
being.
T1D negatively impacts QoL, particularly among girls and prepubertal children. 
Mealtime behaviour problems in T1D are commonly reported, compounded by the 
demands of carbohydrate counting and eating to manage blood glucose levels 
independent of hunger. CD is managed by a GFD, which requires the substitution of 
commonly available carbohydrate foods such as wheat-based breads, cereal, and pasta. 
Continuous subcutaneous insulin infusion (CSII) allows for flexibility with meal times 
and food choices, and thus can alleviate the restrictive nature of the GFD. However, the 
impact of CSII on QoL in those with T1D+CD has not been studied. 
QoL studies in those with T1D + CD are scarce and conflicting. The only pediatric study 
found no difference in generic or diabetes-specific QoL in those with T1D + CD 
compared to T1D alone. In contrast, adults with T1D + CD reported lower generic and 
diabetes specific QoL. Given these conflicting findings, we examined the effect of the 
‘double diagnosis’ on QoL, well-being and eating behaviours in youth and their parents. 
Background
To evaluate quality of life (QoL) and glycemic control in youth with T1D + CD vs T1D only. 
We hypothesize that QoL scores would be lower in youth with T1D + CD and those non-
adherent to the gluten free diet (GFD) compared with their peers with T1D only. 
Objectives
Methods
Patient population
• Cross-sectional case control study of youth with T1D + CD (n=35) and T1D alone
(n=35) attending routine diabetes outpatient clinic appointments.
• Inclusion criteria:    ● 8-18 years ● T1D > 1 year ● CD > 6 months
• Cases matched by age (+ 1 year), diabetes duration ( + 1 year), most recent HbA1c
(+ 0.5%) and mode of diabetes management (MDI or CSII). Controls had at least one
negative CD screen in previous 12 months
Questionnaires
• Youth and their parents/guardians completed age-specific questionnaires and proxy
questionnaires at the study visit
• Generic QoL measured by:   PedsQL Generic Core Scale (version 4.0), General Well-
Being Scale (GWBS, Standard Version)
• Diabetes specific QoL measured by:  PedsQL Diabetes Module (version 3.2)
• Eating behaviours measured by: Locally modified Eating Behaviours questionnaire
• Parents/guardians also completed the PedsQL Family Impact Scale
• Celiac disease specific QoL measured by: Celiac disease DUX (CDDUX)
Respondents asked to rate how frequently each item was problematic over the past 1 
month Each questionnaire assigned a total and subdomain score ranging from 0 to 
100, with higher scores reflecting higher QoL/general wellbeing or healthier eating 
behaviours.
GFD Adherence 
• Assessed both clinically and serologically
Results
• Generic, diabetes-specific, general well being, family impact, and eating behaviour QoL
scores did not differ between those with T1D + CD vs T1D only
• GFD- youth reported lower general well-being (P=0.2), and diabetes-specific QoL
(P=0.003) than youth GFD+
• GFD- youth and their parents were less likely to find the diet beneficial than their
GFD+ peers (P = 0.04 and P=0.03)
• CSII and MDI patients with T1D + CD reported similar overall QoL scores for all
questionnaires. CSII youth indicated on the CDDUX they were unhappier about having
to follow a life-long diet (P=0.01), with their parents reporting greater diabetes
treatment barriers (P=0.35) on the diabetes-specific QoL questionnaire.
• Duration of CD or T1D (either as continuous or categorical variable) was not
associated with any QoL measures.
Table 1. Clinical characteristics of patient groups stratified by presence or 
absence of celiac disease and GFD adherence in those with celiac disease
T1D only 
(n=35)
T1D + CD 
(n=35)
P GFD+ 
(n=24)
GFD-
(n=11)
P
Female n (%) 19 (54) 20 (57) 0.81 12 (50%) 8 (73) 0.21
Age at study visit (y) 13.6 ± 3 13.7 ±
3.1
0.93 13.5 ± 3.1 14.2 ±
3.1
0.52
Age at diabetes diagnosis (y) 6.1 ± 3.8 6.1 ± 3.9 0.9 6.3 ± 4.1 5.7 ± 3.6 0.68
Diabetes duration (y) 7.5 ± 3.9 7.6 ± 3.3 0.57 7.2 ± 3.4 8.5 ± 3.0 0.26
HbA1c at visit (%) 8.4 ± 1.6 8.5 ± 1.6 0.99 8.0 ± 1.2 9.6 ± 1.9 0.02
Lifetime HbA1c (%) 7.8 ± 0.8 8.0 ± 0.7 0.21 7.8 ± 0.7 8.5 ± 0.6 0.007
CSII, n (%) 26 (74) 23 (66) 0.43 16 (67) 7 (64) 0.86
Insulin, U/kg/d 0.9 ± 0.3 0.9 ± 0.2 0.50 0.9 ± 0.2 0.9 ± 0.3 0.9
Age at CD diagnosis (y) - 9.1 ± 3.5 9.1 ± 3.6 9.1 ± 3.6 0.98
Duration of CD (y) 4.6 ± 2.7 4.4 ± 2.7 5.2 ± 2.7 0.42
Symptomatic before CD 
diagnosis
21 (60%) 18 (75%) 3 (27%) 0.007
GFD adopted within first year 25 (71%) 24 (100%) 1 (9%) <0.001
Data are n (%) or mean + SD. Bold signifies results of significance, P < 0.05
Conclusions
• The additional diagnosis of CD does not impair QoL in youth nor their parents
• Youth non-adherent to the GFD have lower general well-being, and lower diabetes
specific QoL, accompanied by worse glycemic control.
• Youth who displayed CD symptoms prior to diagnosis, or noted in retrospect were
more likely to adhere to GFD and reported better QoL
• CSII and MDI patients reported similar diabetes specific QoL scores, however the CD
specific questionnaire identifed CSII youth report greater burden with having to follow
a lifelong diet
• GFD+ influenced by family support, CD awareness, and availablity of GF foods.
• As screening is now recognised as a standard of care in T1D, strategies are needed
to intervene in those who resist the GFD. Regular monitoring of adherence in youth
with coexisting T1D and CD will enable idenfication of the GFD- subgroup, who may
benefit from more intensive clinical and pyschosocial support.
Table 2. Total QoL questionnaire scores for youth with T1D vs youth T1D + CD, and GFD adherent vs GFD non-adherent T1D + CD youth
T1D T1D + CD P GFD+ GFD- P
Item
s
Mean ± SD α Mean ± SD α Mean ± SD α Mean ± SD α
GWBS – Child report 7 64 ± 26 0.90 70 ± 24 0.90 0.44 76 ± 23 0.91 57 ± 20 0.86 0.02
GWBS – Parent proxy report 7 72 ± 25 0.84 65 ± 22 0.84 0.29 73 ± 22 0.83 50 ± 12 0.89 0.001
PedsQL Generic – Child 23 83 ± 12 0.87 81 ± 12 0.88 0.34 84 ± 10 0.86 75 ± 14 0.88 0.11
PedsQL Generic – Parent proxy 23 76 ± 12 0.94 76 ± 13 0.89 0.98 77 ± 10 0.88 73 ± 17 0.9 0.39
PedsQL Diabetes Module - Child 33 73 ± 14 0.84 70 ± 16 0.95 0.36 75 ± 13 0.95 58 ± 16 0.87 0.003
PedsQL Diabetes Module – Parent proxy 33 70 ± 17 0.94 66 ± 15 0.91 0.29 68 ± 13 0.9 61 ± 17 0.92 0.25
Eating behaviour specific – Child 24 64 ± 9 0.6 62 ± 13 0.82 0.34 64 ± 14 0.85 57 ± 9 0.66 0.08
Eating behaviour specific – Parent 24 68 ± 10 0.73 62 ± 13 0.78 0.045 64 ± 13 0.84 57 ± 11 0.79 0.11
Family Impact Scale – Parent report 36 70 ± 17 0.97 68 ± 18 0.96 0.93 69 ± 17 0.96 65 ± 21 0.97 0.67
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APPENDIX B. QUALITY OF LIFE QUESTIONNAIRES USED IN CHAPTER 6 
i. 8-12 year old Child QoL questionnaires
ii. 8-12 year old Parent QoL questionnaires
iii. 13-18 year old Child QoL questionnaires
iv. 13-18 year old Parent QoL questionnaires
v. CDDUX – Coeliac Disease questionnaire
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Questionnaires 
 
This survey aims to find out how different aspects of life effect of you and your 
family.  The information we gather from this will help us understand how type 1 
diabetes affects you and your family’s life, shopping habits and your family’s eating 
patterns. 
 
On the following pages is a list of things that might be a problem for you. Please tell 
us how much of a problem each one has been for you during the past ONE MONTH 
by circling:  
0 if it is never a problem 
1 if it is almost never a problem  
2 if it is sometimes a problem  
3 if it is often a problem 
4 if it almost always a problem 
 
There are no right or wrong answers. If you do not understand a question, please ask for help.  
 
Please take time to answer all the questions. 
It will take about 20-30 minutes. 
Thanks for your help in completing this survey. 
If you have any questions, please contact Anna Pham-Short (02) 9845 3073 
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PedsQL – Pediatric Quality of Life Inventory Version 4.0 Child Report (ages 8 - 12) 
In the past ONE month, how much of a problem has this been for you..  
ABOUT MY HEALTH AND ACTIVITIES (problems with…) 
Never Almost 
never 
Some 
times 
Often Almost 
always 
1. It is hard for me to walk more than one block 0 1 2 3 4 
2. It is hard for me to run 0 1 2 3 4 
3. It is hard for me to do sports activity or exercise 0 1 2 3 4 
4. It is hard for me to lift something heavy 0 1 2 3 4 
5. It is hard for me to take a bath or shower by myself 0 1 2 3 4 
6. It is hard for me to do chores around the house 0 1 2 3 4 
7. I hurt or ache 0 1 2 3 4 
8. I have low energy 0 1 2 3 4 
ABOUT MY FEELINGS (problems with…) 
Never Almost 
never 
Some 
times 
Often Almost 
always 
1. I feel afraid or scared 0 1 2 3 4 
2. I feel sad or blue 0 1 2 3 4 
3. I feel angry 0 1 2 3 4 
4. I have trouble sleeping 0 1 2 3 4 
5. I worry about what will happen to me 0 1 2 3 4 
ABOUT SCHOOL (problems with…) 
Never Almost 
never 
Some 
times 
Often Almost 
always 
1. It is hard to pay attention in class 0 1 2 3 4 
2. I forget things 0 1 2 3 4 
3. I have trouble keeping up with my schoolwork 0 1 2 3 4 
4. I miss school because of not feeling well 0 1 2 3 4 
5. I miss school to go to the doctor or hospital 0 1 2 3 4 
Directions 
Children with diabetes sometimes have special problems. Please tell us how much of 
a problem each one has been for you during the past ONE month by circling. 
In the past ONE month, how much of a problem has this been for you… 
ABOUT MY DIABETES (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. I feel hungry 0 1 2 3 4 
2. I feel thirsty 0 1 2 3 4 
3. I have to go to the bathroom too often 0 1 2 3 4 
4. I have tummy aches 0 1 2 3 4 
5. I have headaches 0 1 2 3 4 
6. I feel like I need to throw up 0 1 2 3 4 
7. I go “low” 0 1 2 3 4 
8. I go “high” 0 1 2 3 4 
9. I feel tired 0 1 2 3 4 
10. I get shaky 0 1 2 3 4 
11. I get sweaty 0 1 2 3 4 
12. I feel dizzy 0 1 2 3 4 
13. I feel weak 0 1 2 3 4 
14. I have trouble sleeping 0 1 2 3 4 
15. I get cranky or grumpy 0 1 2 3 4 
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TREATMENT – I (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. It hurts to get my finger pricked 0 1 2 3 4 
2. It hurts to get insulin shots 0 1 2 3 4 
3. I am embarrassed by my diabetes treatment 0 1 2 3 4 
4. My parents and I argue about my diabetes care 0 1 2 3 4 
5. It is hard for me to do everything I need to do to care for my
diabetes
0 1 2 3 4 
6. It hurts to get my finger pricked 0 1 2 3 4 
Whether you do these things on your own or with the help of your parents, please answer how hard these 
things were to do in the past ONE month 
Treatment – II (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. It is hard for me to take blood glucose levels 0 1 2 3 4 
2. It is hard for me to take insulin shots 0 1 2 3 4 
3. It is hard for me to exercise or do sports 0 1 2 3 4 
4. It is hard for me to keep track of carbohydrates 0 1 2 3 4 
5. It is hard for me to carry a fast-acting carbohydrate 0 1 2 3 4 
6. It is hard for me to snack when I go “low” 0 1 2 3 4 
In the past ONE month, how much of a problem has this been for you… 
Worry (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. I worry about going “low” 0 1 2 3 4 
2. I worry about going “high” 0 1 2 3 4 
In the past ONE month, how much of a problem has this been for you… 
Worry (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. It is hard for me to tell the doctors and nurses how I feel 0 1 2 3 4 
2. It is hard for me to ask the doctors and nurses questions 0 1 2 3 4 
3. It is hard for me to explain my illness to other people 0 1 2 3 4 
4. I am embarrassed about having diabetes 0 1 2 3 4 
Directions 
These questions are about meals and eating for you and your family. Please tell us 
which statement applies to you and your family by circling the numbers. 
I FIND… 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. I like eating meals 0 1 2 3 4 
2. I eat the same meals as the rest of the family 0 1 2 3 4 
3. I get to choose what I want to eat 0 1 2 3 4 
4. Eating what the hospital has told me to is easy to follow 0 1 2 3 4 
5. I think my parents don’t give me enough food 0 1 2 3 4 
6. I think my parents give me too much food 0 1 2 3 4 
7. I like trying new foods 0 1 2 3 4 
8. My parents tell me when and how much to eat 0 1 2 3 4 
9. I decide how much and when to eat 0 1 2 3 4 
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FAMILY AND FRIENDS 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
10. I help prepare meals 0 1 2 3 4 
11. Our family likes eating the same foods together 0 1 2 3 4 
12. Our family eats dinner together 0 1 2 3 4 
13. I help shop for food 0 1 2 3 4 
14. Friends are interested in what I eat 0 1 2 3 4 
15. Friends tease me about what I eat 0 1 2 3 4 
16. Choosing foods is easy when going out with family/friends 0 1 2 3 4 
17. The TV is on during meals 0 1 2 3 4 
18. I find it hard to eat at school 0 1 2 3 4 
19. My family argues about what I should eat 0 1 2 3 4 
20. I think what I eat is important 0 1 2 3 4 
21. Outside of home, we ask how people make food 0 1 2 3 4 
CARBOHYDRATE COUNTING 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
22. My parents count carbohydrates for me 0 1 2 3 4 
23. I count carbohydrates 0 1 2 3 4 
24. Before I eat, my parents use things to figure out how much I
can eat 
0 1 2 3 4 
We use: Measuring cups/Kitchen scales/Traffic Light Guide To Food 
Carbohydrate Counter/Calorie King / Other: ______ 
0 1 2 3 4 
Tell us what you think… 
25. What do you like most about meals and eating?
__________________________________________________________________
__________________________________________________________________
26. What do you like least about meals and eating?
________________________________________________________________________
________________________________________________________________________
27. How many times a week does your family eat dinner together?
________________________________________________________________________
Please tick:  
I have  Type 1 diabetes for _____ years  Coeliac Disease for _______ years
THANK YOU FOR YOUR TIME 
*************************************************************************** 
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Questionnaires 
This survey aims to find out different aspects of life effect of your child and family. 
The information we gather from this will help us understand how type 1 diabetes 
affects you and your family’s life, shopping habits and your family’s eating patterns. 
On the following pages is a list of things that might be a problem for your child. 
Please tell us how much of a problem each one has been for your child during the 
past ONE MONTH by circling: 
0 if it is never a problem 
1 if it is almost never a problem 
2 if it is sometimes a problem  
3 if it is often a problem 
4 if it almost always a problem 
There are no right or wrong answers. If you do not understand a question, please ask for help. 
Please take time to answer all the questions. 
It will take about 20-30 minutes.
Thanks for your help in completing this survey. 
If you have any questions, please contact Anna Pham-Short (02) 9845 3073
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In the past ONE month, how much of a problem has your child had with… 
DIABETES (problems with…) 
Never Almost 
Never 
Some 
times 
Often Almost 
always 
1. Feeling hungry 0 1 2 3 4 
2. Feeling thirsty 0 1 2 3 4 
3. Having to go to the bathroom too often 0 1 2 3 4 
4. Having tummy aches 0 1 2 3 4 
5. Having headaches 0 1 2 3 4 
6. Feeling  like he/she needs to throw up 0 1 2 3 4 
7. Going “low” 0 1 2 3 4 
8. Going “high” 0 1 2 3 4 
9. Feeling tired 0 1 2 3 4 
10. Getting shaky 0 1 2 3 4 
11. Getting sweaty 0 1 2 3 4 
12. Feeling dizzy 0 1 2 3 4 
13. Feeling weak 0 1 2 3 4 
14. Having trouble sleeping 0 1 2 3 4 
15. Getting cranky or grumpy 0 1 2 3 4 
In the past ONE month, how much of a problem has your child had with… 
TREATMENT – I (problems with…) 
Never Almost 
Never 
Some 
times 
Often Almost 
always 
1. Finger pricks causing him/her pain 0 1 2 3 4 
2. Insulin shots causing him/her pain 0 1 2 3 4 
3. Getting embarrassed about his/her diabetes treatment 0 1 2 3 4 
4. Arguing with me or my spouse about diabetes care 0 1 2 3 4 
5. It is hard for my child to do everything he/she needs to do to
care for his/her diabetes
0 1 2 3 4 
Whether your child does these things independently or with your help, please answer how difficult these 
things were to do in the past ONE month. (Note: This section is not asking about your child’s independence 
in these areas, just how hard they were to do).  
TREATMENT – II (problems with…) 
Never Almost 
Never 
Some 
times 
Often Almost 
always 
1. It is hard for my child to take blood glucose levels 0 1 2 3 4 
2. It is hard for my child to take insulin shots 0 1 2 3 4 
3. It is hard for my child to exercise or do sports 0 1 2 3 4 
4. It is hard for my child to track carbohydrates 0 1 2 3 4 
5. It is hard for my child to carry a fast-acting carbohydrate 0 1 2 3 4 
6. It is hard for my child to snack when he/she  goes “low” 0 1 2 3 4 
In the past ONE month, how much of a problem has your child had with… 
WORRY (problems with…) 
Never Almost 
Never 
Some 
times 
Often Almost 
always 
1. Worrying about going “low” 0 1 2 3 4 
2. Worrying about going “high” 0 1 2 3 4 
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In the past ONE month, how much of a problem has your child had with… 
COMMUNICATION (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Telling the doctors and nurses how he/she feels 0 1 2 3 4 
2. Asking the doctors and nurses questions 0 1 2 3 4 
3. Explaining his/her illness to other people 0 1 2 3 4 
4. Getting embarrassed about having diabetes 0 1 2 3 4 
In the past ONE month, how much of a problem has your child had with… 
PHYSICAL FUNCTIONING (problems with…) 
Never Almost 
never 
Some 
times 
Often Almost 
always 
1. Walking more than one block 0 1 2 3 4 
2. Running 0 1 2 3 4 
3. Participating in sports activity or exercise 0 1 2 3 4 
4. Lifting something heavy 0 1 2 3 4 
5. Taking a bath or shower by him or herself 0 1 2 3 4 
6. Doing chores around the house 0 1 2 3 4 
7. Having hurts or aches 0 1 2 3 4 
8. Low energy level 0 1 2 3 4 
EMOTIONAL FUNCTIONING (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Feeling afraid or sad 0 1 2 3 4 
2. Feeling sad or blue 0 1 2 3 4 
3. Feeling angry 0 1 2 3 4 
4. Trouble sleeping 0 1 2 3 4 
5. Worrying about what will happen to him or her 0 1 2 3 4 
SOCIAL FUNCTIONING (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Getting along with other children 0 1 2 3 4 
2. Other kids not wanting to be his or her friend 0 1 2 3 4 
3. Getting teased by other children 0 1 2 3 4 
4. Not able to do things that other children his or her age can do 0 1 2 3 4 
5. Keeping up when playing with other children 0 1 2 3 4 
SCHOOL FUNCTIONING (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Paying attention in class 0 1 2 3 4 
2. Forgetting  things 0 1 2 3 4 
3. Keeping up with schoolwork 0 1 2 3 4 
4. Missing school because of not feeling well 0 1 2 3 4 
5. Missing school to go to the doctor or hospital 0 1 2 3 4 
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Directions 
Families of children sometimes have special concerns or difficulties because of the 
child’s health. Below is a list of things that might be a problem for you. Please tell us 
how much of a problem each one has been for you during the past ONE month.   
In the past ONE month, as a result of your child’s health, how much of a problem have you had with… 
Physical Functioning (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I feel tired during the day 0 1 2 3 4 
2. I feel tired when I wake up in the morning 0 1 2 3 4 
3. I feel too tired to do the things I like to do 0 1 2 3 4 
4. I get headaches 0 1 2 3 4 
5. I feel physically weak 0 1 2 3 4 
6. I feel sick to my stomach 0 1 2 3 4 
Emotional Functioning (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I feel anxious 0 1 2 3 4 
2. I feel sad 0 1 2 3 4 
3. I feel angry 0 1 2 3 4 
4. I get frustrated 0 1 2 3 4 
5. I feel helpless or hopeless 0 1 2 3 4 
Social functioning (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I feel isolated from others 0 1 2 3 4 
2. I have trouble getting support from others 0 1 2 3 4 
3. It is hard to find time for social activities 0 1 2 3 4 
4. I do not have enough energy for social activities 0 1 2 3 4 
Cognitive functioning (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. It is hard for me to keep my attention on things 0 1 2 3 4 
2. It is hard for me to remember what people tell me 0 1 2 3 4 
3. It is hard for me to remember what I just heard 0 1 2 3 4 
4. It is hard for me to think quickly 0 1 2 3 4 
5. I have trouble remembering what I was just thinking 0 1 2 3 4 
Communication (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I feel that others do not understand my family’s situation 0 1 2 3 4 
2. It is hard for me to talk about my child’s health with others 0 1 2 3 4 
3. It is hard for me to tell doctors and nurses how I feel 0 1 2 3 4 
Worry (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I worry about whether or not my child’s medical treatments are
working
0 1 2 3 4 
2. I worry about the side effects of my child’s medications/medical
treatments
0 1 2 3 4 
3. I worry about how others will react to my child’s condition 0 1 2 3 4 
4. I worry about how my child’s illness is affecting other family
members
0 1 2 3 4 
5. I worry about my child’s future 0 1 2 3 4 
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Directions 
Below is a list of things that might be a problem for your family. Please tell us how 
much of a problem each one has been for your family during the past ONE month. 
In the past ONE month, as a result of your child’s health, how much of a problem has your family had with… 
Daily activities (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. Family activities taking more time and effort 0 1 2 3 4 
2. Difficulty finding time to finish household tasks 0 1 2 3 4 
3. Feeling too tired to finish household tasks 0 1 2 3 4 
Family relationships (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. Lack of communication between family members 0 1 2 3 4 
2. Conflicts between family members 0 1 2 3 4 
3. Difficulty making decisions together as a family 0 1 2 3 4 
4. Difficulty solving family problems together 0 1 2 3 4 
5. Stress or tension between family members 0 1 2 3 4 
In the past ONE month, how often has your child had difficulty with… 
Gastrointestinal Symptoms  (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. Pain in his/her abdomen or stomach 0 1 2 3 4 
2. Diarrhoea 0 1 2 3 4 
3. Constipation 0 1 2 3 4 
4. Nausea 0 1 2 3 4 
5. Vomiting 0 1 2 3 4 
6. Discomfort in his/her abdomen or stomach 0 1 2 3 4 
7. Passing gas 0 1 2 3 4 
8. Not feeling hungry 0 1 2 3 4 
9. Bloating 0 1 2 3 4 
Directions 
These questions are about meals and eating for your child and family. Please tell us 
which statement applies to you and your family by circling the numbers. 
FOR YOUR CHILD’S EATING PATTERNS, YOU FIND… 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Meal times are enjoyable. 0 1 2 3 4 
2. They eat the same meals as the rest of the family 0 1 2 3 4 
3. They feel in control of their eating habits 0 1 2 3 4 
4. The recommended meal plan is easy to follow 0 1 2 3 4 
5. I give my child less food than they say they want 0 1 2 3 4 
6. They like trying new foods 0 1 2 3 4 
7. I decide how much and when my child eats 0 1 2 3 4 
They decide how much and when to eat 0 1 2 3 4 
8. Meal times are enjoyable. 0 1 2 3 4 
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FAMILY AND FRIENDS 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
9. Preparation of family meals is difficult 0 1 2 3 4 
10. Meals are accepted by family members. 0 1 2 3 4 
11. Shopping for food is difficult 0 1 2 3 4 
12. Shopping for food is expensive 0 1 2 3 4 
13. Friends are interested in my child’s eating pattern 0 1 2 3 4 
14. Friends are not supportive of my child’s eating pattern 0 1 2 3 4 
15. Choosing foods is easy when going out with family/friends 0 1 2 3 4 
16. It is difficult to find foods my child likes to eat 0 1 2 3 4 
17. Meal times are difficult at school 0 1 2 3 4 
18. Family members argue about what to feed my child 0 1 2 3 4 
19. The diet is beneficial to my child. 0 1 2 3 4 
20. Outside of home, we ask what ingredients are in meals 0 1 2 3 4 
CARBOHYDRATE COUNTING 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
21. I count carbohydrates for my child 0 1 2 3 4 
22. My child counts carbohydrates 0 1 2 3 4 
23. We use tools to help count carbohydrates 0 1 2 3 4 
We use: Measuring cups/Kitchen scales/Traffic Light Guide To Food 
Carbohydrate Counter/Calorie King / Other: ______ 
0 1 2 3 4 
Comment about your child’s usual eating patterns 
24. What does your child like most about meals and eating?
__________________________________________________________________
__________________________________________________________________
25. What does your child like least about meals and eating?
________________________________________________________________________
________________________________________________________________________
26. How many times a week does your family eat dinner together?
________________________________________________________________________
My child has :   Type 1 diabetes for _____ years      Coeliac Disease for ______ years 
THANK YOU FOR YOUR TIME 
********************************************************************* 
Teen 13-18years 
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Questionnaires 
This survey aims to find out how different aspects of life effect of you and your family.  
The information we gather from this will help us understand how type 1 diabetes 
affects you and your family’s life, shopping habits and your family’s eating patterns. 
On the following pages is a list of things that might be a problem for you. Please tell 
us how much of a problem each one has been for you during the past ONE MONTH 
by circling: 
0 if it is never a problem 
1 if it is almost never a problem 
2 if it is sometimes a problem  
3 if it is often a problem 
4 if it almost always a problem 
There are no right or wrong answers. If you do not understand a question, please ask for help. 
Please take time to answer all the questions. 
It will take about 20-30 minutes.
Thanks for your help in completing this survey. 
If you have any questions, please contact Anna Pham-Short (02) 9845 3073
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In the past ONE month, how much of a problem has this been for you… 
About my diabetes (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. I feel hungry 0 1 2 3 4 
2. I feel thirsty 0 1 2 3 4 
3. I have to go to the bathroom too often 0 1 2 3 4 
4. I have stomachaches 0 1 2 3 4 
5. I have headaches 0 1 2 3 4 
6. I feel like I need to throw up 0 1 2 3 4 
7. I go “low” 0 1 2 3 4 
8. I go “high” 0 1 2 3 4 
9. I feel tired 0 1 2 3 4 
10. I get shaky 0 1 2 3 4 
11. I get sweaty 0 1 2 3 4 
12. I feel dizzy 0 1 2 3 4 
13. I feel weak 0 1 2 3 4 
14. I have trouble sleeping 0 1 2 3 4 
15. I get cranky or grumpy 0 1 2 3 4 
In the past ONE month, how much of a problem has this been for you… 
Treatment – I (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. It hurts to get my finger pricked 0 1 2 3 4 
2. It hurts to get insulin shots 0 1 2 3 4 
3. I am embarrassed by my diabetes treatment 0 1 2 3 4 
4. My parents and I argue about my diabetes care 0 1 2 3 4 
5. It is hard for me to do everything I need to do to care for my
diabetes
0 1 2 3 4 
Whether you do these things on your own or with the help of your parents, please answer how hard these 
things were to do in the past ONE month 
Treatment – II (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. It is hard for me to take blood glucose levels 0 1 2 3 4 
2. It is hard for me to take insulin shots 0 1 2 3 4 
3. It is hard for me to exercise or do sports 0 1 2 3 4 
4. It is hard for me to keep track of carbohydrates 0 1 2 3 4 
5. It is hard for me to carry a fast-acting carbohydrate 0 1 2 3 4 
6. It is hard for me to snack when I go “low” 0 1 2 3 4 
In the past ONE month, how much of a problem has this been for you… 
Worry (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. I worry about going “low” 0 1 2 3 4 
2. I worry about going “high” 0 1 2 3 4 
3. I worry about long-term complications from diabetes 0 1 2 3 4 
In the past ONE month, how much of a problem has this been for you… 
Communication (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. It is hard for me to tell the doctors and nurses how I feel 0 1 2 3 4 
2. It is hard for me to ask the doctors and nurses questions 0 1 2 3 4 
3. It is hard for me to explain my illness to other people 0 1 2 3 4 
4. I am embarrassed about having diabetes 0 1 2 3 4 
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In the past ONE month, how much of a problem has this been for you.. 
About my health and activities (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. It is hard for me to walk more than one block 0 1 2 3 4 
2. It is hard for me to run 0 1 2 3 4 
3. It is hard for me to do sports activity or exercise 0 1 2 3 4 
4. It is hard for me to lift something heavy 0 1 2 3 4 
5. It is hard for me to take a bath or shower by myself 0 1 2 3 4 
6. It is hard for me to do chores around the house 0 1 2 3 4 
7. I hurt or ache 0 1 2 3 4 
8. I have low energy 0 1 2 3 4 
About my feelings (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. I feel afraid or scared 0 1 2 3 4 
2. I feel sad or blue 0 1 2 3 4 
3. I feel angry 0 1 2 3 4 
4. I have trouble sleeping 0 1 2 3 4 
5. I worry about what will happen to me 0 1 2 3 4 
How I get along with others (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. I have trouble getting along with other teens 0 1 2 3 4 
2. Other teens do not want to be my friend 0 1 2 3 4 
3. Other teens tease me 0 1 2 3 4 
4. I cannot do things that other teens my age can do 0 1 2 3 4 
5. It is hard to keep up with my peers 0 1 2 3 4 
About school (problems with…) Never Very 
seldom 
Some 
times 
Often All the 
time 
1. I find it hard to pay attention in class 0 1 2 3 4 
2. I forget things 0 1 2 3 4 
3. I have trouble keeping up with my schoolwork 0 1 2 3 4 
4. I miss school because of not feeling well 0 1 2 3 4 
5. I miss school to go to the doctor or hospital 0 1 2 3 4 
In the past ONE month, how much does this sound like you… 
About Me Never Very 
seldom 
Some 
times 
Often All the 
time 
1. I feel happy 0 1 2 3 4 
2. I feel good about myself 0 1 2 3 4 
3. I feel good about my health 0 1 2 3 4 
4. I get support from my family or friends 0 1 2 3 4 
5. I think good things with happen to me 0 1 2 3 4 
6. I think my health will be good in the future 0 1 2 3 4 
In the past ONE month… 
In General Bad Fair Good Very 
Good 
Excellent 
1. In general, how is your health? 0 1 2 3 4 
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Directions 
These questions are about meals and eating for you and your family. Please tell us 
which statement applies to you and your family by circling the numbers. 
I FIND… 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. I like eating meals 0 1 2 3 4 
2. I eat the same meals as the rest of the family 0 1 2 3 4 
3. I get to choose what I want to eat 0 1 2 3 4 
4. Eating what the hospital has told me to is easy to follow 0 1 2 3 4 
5. I think my parents don’t give me enough food 0 1 2 3 4 
6. I think my parents give me too much food 0 1 2 3 4 
7. I like trying new foods 0 1 2 3 4 
8. My parents tell me when and how much to eat 0 1 2 3 4 
9. I decide how much and when to eat 0 1 2 3 4 
FAMILY AND FRIENDS 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
10. I help prepare meals 0 1 2 3 4 
11. Our family likes eating the same foods together 0 1 2 3 4 
12. Our family eats dinner together 0 1 2 3 4 
13. I help shop for food 0 1 2 3 4 
14. Friends are interested in what I eat 0 1 2 3 4 
15. Friends tease me about what I eat 0 1 2 3 4 
16. Choosing foods is easy when going out with family/friends 0 1 2 3 4 
17. The TV is on during meals 0 1 2 3 4 
18. I find it hard to eat at school 0 1 2 3 4 
19. My family argues about what I should eat 0 1 2 3 4 
20. I think what I eat is important 0 1 2 3 4 
21. Outside of home, we ask how people make food 0 1 2 3 4 
CARBOHYDRATE COUNTING 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
22. My parents count carbohydrates for me 0 1 2 3 4 
23. I count carbohydrates 0 1 2 3 4 
24. Before I eat, my parents use things to figure out how much I
can eat 
0 1 2 3 4 
We use: Measuring cups/Kitchen scales/Traffic Light Guide To Food 
Carbohydrate Counter/Calorie King / Other: ______ 
0 1 2 3 4 
Tell us what you think… 
25. What do you like most about meals and eating?  ________________________________
26. What do you like least about meals and eating? _________________________________
27. How many times a week does your family eat dinner together? ____________________
Please tick:  I have  Type 1 diabetes for _____ years  Coeliac Disease for _______ years
THANK YOU FOR YOUR TIME 
*************************************************************************** 
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Questionnaires 
This survey aims to find out how different aspects of life effect of your child and family. 
The information we gather from this will help us understand how type 1 diabetes 
affects you and your family’s life, shopping habits and your family’s eating patterns. 
On the following pages is a list of things that might be a problem for your teen. 
Please tell us how much of a problem each one has been for your teen during the 
past ONE MONTH by circling: 
0 if it is never a problem 
1 if it is almost never a problem 
2 if it is sometimes a problem  
3 if it is often a problem 
4 if it almost always a problem 
There are no right or wrong answers. If you do not understand a question, please ask for help. 
Please take time to answer all the questions. 
It will take about 20-30 minutes.
Thanks for your help in completing this survey. 
If you have any questions, please contact Anna Pham-Short (02) 9845 3073
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In the past ONE month, how much of a problem has your teen had with… 
DIABETES (problems with…) 
Never Almost 
Never 
Some 
times 
Often Almost 
always 
1. Feeling hungry 0 1 2 3 4 
2. Feeling thirsty 0 1 2 3 4 
3. Having to go to the bathroom too often 0 1 2 3 4 
4. Having tummy aches 0 1 2 3 4 
5. Having headaches 0 1 2 3 4 
6. Feeling  like he/she needs to throw up 0 1 2 3 4 
7. Going “low” 0 1 2 3 4 
8. Going “high” 0 1 2 3 4 
9. Feeling tired 0 1 2 3 4 
10. Getting shaky 0 1 2 3 4 
11. Getting sweaty 0 1 2 3 4 
12. Feeling dizzy 0 1 2 3 4 
13. Feeling weak 0 1 2 3 4 
14. Having trouble sleeping 0 1 2 3 4 
15. Getting cranky or grumpy 0 1 2 3 4 
In the past ONE month, how much of a problem has your teen had with… 
TREATMENT – I (problems with…) 
Never Almost 
Never 
Some 
times 
Often Almost 
always 
1. Finger pricks causing him/her pain 0 1 2 3 4 
2. Insulin shots causing him/her pain 0 1 2 3 4 
3. Getting embarrassed about his/her diabetes treatment 0 1 2 3 4 
4. Arguing with me or my spouse about diabetes care 0 1 2 3 4 
5. It is hard for my teen to do everything he/she needs to do to
care for his/her diabetes
0 1 2 3 4 
Whether your teen does these things independently or with your help, please answer how difficult these 
things were to do in the past ONE month. (Note: This section is not asking about your teen’s independence 
in these areas, just how hard they were to do).  
TREATMENT – II (problems with…) 
Never Almost 
Never 
Some 
times 
Often Almost 
always 
1. It is hard for my teen to take blood glucose levels 0 1 2 3 4 
2. It is hard for my teen to take insulin shots 0 1 2 3 4 
3. It is hard for my teen to exercise or do sports 0 1 2 3 4 
4. It is hard for my teen to track carbohydrates 0 1 2 3 4 
5. It is hard for my teen to carry a fast-acting carbohydrate 0 1 2 3 4 
6. It is hard for my teen to snack when he/she  goes “low” 0 1 2 3 4 
In the past ONE month, how much of a problem has your teen had with… 
WORRY (problems with…) 
Never Almost 
Never 
Some 
times 
Often Almost 
always 
1. Worrying about going “low” 0 1 2 3 4 
2. Worrying about going “high” 0 1 2 3 4 
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In the past ONE month, how much of a problem has your teen had with… 
COMMUNICATION (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Telling the doctors and nurses how he/she feels 0 1 2 3 4 
2. Asking the doctors and nurses questions 0 1 2 3 4 
3. Explaining his/her illness to other people 0 1 2 3 4 
4. Getting embarrassed about having diabetes 0 1 2 3 4 
In the past ONE month, how much of a problem has your teen had with… 
PHYSICAL FUNCTIONING (problems with…) 
Never Almost 
never 
Some 
times 
Often Almost 
always 
1. Walking more than one block 0 1 2 3 4 
2. Running 0 1 2 3 4 
3. Participating in sports activity or exercise 0 1 2 3 4 
4. Lifting something heavy 0 1 2 3 4 
5. Taking a bath or shower by him or herself 0 1 2 3 4 
6. Doing chores around the house 0 1 2 3 4 
7. Having hurts or aches 0 1 2 3 4 
8. Low energy level 0 1 2 3 4 
EMOTIONAL FUNCTIONING (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Feeling afraid or sad 0 1 2 3 4 
2. Feeling sad or blue 0 1 2 3 4 
3. Feeling angry 0 1 2 3 4 
4. Trouble sleeping 0 1 2 3 4 
5. Worrying about what will happen to him or her 0 1 2 3 4 
SOCIAL FUNCTIONING (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Getting along with other teens 0 1 2 3 4 
2. Other teens not wanting to be his or her friend 0 1 2 3 4 
3. Getting teased by other teens 0 1 2 3 4 
4. Not able to do things that other teens his or her age can do 0 1 2 3 4 
5. Keeping up when playing with other teens 0 1 2 3 4 
SCHOOL FUNCTIONING (problems with…) 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Paying attention in class 0 1 2 3 4 
2. Forgetting  things 0 1 2 3 4 
3. Keeping up with schoolwork 0 1 2 3 4 
4. Missing school because of not feeling well 0 1 2 3 4 
5. Missing school to go to the doctor or hospital 0 1 2 3 4 
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Directions 
Families of children sometimes have special concerns or difficulties because of the 
child’s health. Below is a list of things that might be a problem for you. Please tell us 
how much of a problem each one has been for you during the past ONE month.   
In the past ONE month, as a result of your child’s health, how much of a problem have you had with… 
Physical Functioning (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I feel tired during the day 0 1 2 3 4 
2. I feel tired when I wake up in the morning 0 1 2 3 4 
3. I feel too tired to do the things I like to do 0 1 2 3 4 
4. I get headaches 0 1 2 3 4 
5. I feel physically weak 0 1 2 3 4 
6. I feel sick to my stomach 0 1 2 3 4 
Emotional Functioning (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I feel anxious 0 1 2 3 4 
2. I feel sad 0 1 2 3 4 
3. I feel angry 0 1 2 3 4 
4. I get frustrated 0 1 2 3 4 
5. I feel helpless or hopeless 0 1 2 3 4 
Social functioning (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I feel isolated from others 0 1 2 3 4 
2. I have trouble getting support from others 0 1 2 3 4 
3. It is hard to find time for social activities 0 1 2 3 4 
4. I do not have enough energy for social activities 0 1 2 3 4 
Cognitive functioning (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. It is hard for me to keep my attention on things 0 1 2 3 4 
2. It is hard for me to remember what people tell me 0 1 2 3 4 
3. It is hard for me to remember what I just heard 0 1 2 3 4 
4. It is hard for me to think quickly 0 1 2 3 4 
5. I have trouble remembering what I was just thinking 0 1 2 3 4 
Communication (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I feel that others do not understand my family’s situation 0 1 2 3 4 
2. It is hard for me to talk about my child’s health with others 0 1 2 3 4 
3. It is hard for me to tell doctors and nurses how I feel 0 1 2 3 4 
Worry (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. I worry about whether or not my child’s medical treatments are
working
0 1 2 3 4 
2. I worry about the side effects of my child’s medications/medical
treatments
0 1 2 3 4 
3. I worry about how others will react to my child’s condition 0 1 2 3 4 
4. I worry about how my child’s illness is affecting other family
members
0 1 2 3 4 
5. I worry about my child’s future 0 1 2 3 4 
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Directions 
Below is a list of things that might be a problem for your family. Please tell us how 
much of a problem each one has been for your family during the past ONE month. 
In the past ONE month, as a result of your child’s health, how much of a problem has your family had with… 
Daily activities (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. Family activities taking more time and effort 0 1 2 3 4 
2. Difficulty finding time to finish household tasks 0 1 2 3 4 
3. Feeling too tired to finish household tasks 0 1 2 3 4 
Family relationships (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. Lack of communication between family members 0 1 2 3 4 
2. Conflicts between family members 0 1 2 3 4 
3. Difficulty making decisions together as a family 0 1 2 3 4 
4. Difficulty solving family problems together 0 1 2 3 4 
5. Stress or tension between family members 0 1 2 3 4 
In the past ONE month, how often has your child had difficulty with… 
Gastrointestinal Symptoms  (problems with…) Never Almost 
Never 
Some 
times 
Often Almost 
Always 
1. Pain in his/her abdomen or stomach 0 1 2 3 4 
2. Diarrhoea 0 1 2 3 4 
3. Constipation 0 1 2 3 4 
4. Nausea 0 1 2 3 4 
5. Vomiting 0 1 2 3 4 
6. Discomfort in his/her abdomen or stomach 0 1 2 3 4 
7. Passing gas 0 1 2 3 4 
8. Not feeling hungry 0 1 2 3 4 
9. Bloating 0 1 2 3 4 
Directions 
These questions are about meals and eating for your child and family. Please tell us 
which statement applies to you and your family by circling the numbers. 
FOR YOUR CHILD’S EATING PATTERNS, YOU FIND… 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. Meal times are enjoyable. 0 1 2 3 4 
2. They eat the same meals as the rest of the family 0 1 2 3 4 
3. They feel in control of their eating habits 0 1 2 3 4 
4. The recommended meal plan is easy to follow 0 1 2 3 4 
5. I give my child less food than they say they want 0 1 2 3 4 
6. They like trying new foods 0 1 2 3 4 
7. I decide how much and when my child eats 0 1 2 3 4 
They decide how much and when to eat 0 1 2 3 4 
8. Meal times are enjoyable. 0 1 2 3 4 
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FAMILY AND FRIENDS 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
9. Preparation of family meals is difficult 0 1 2 3 4 
10. Meals are accepted by family members. 0 1 2 3 4 
11. Shopping for food is difficult 0 1 2 3 4 
12. Shopping for food is expensive 0 1 2 3 4 
13. Friends are interested in my child’s eating pattern 0 1 2 3 4 
14. Friends are not supportive of my child’s eating pattern 0 1 2 3 4 
15. Choosing foods is easy when going out with family/friends 0 1 2 3 4 
16. It is difficult to find foods my child likes to eat 0 1 2 3 4 
17. Meal times are difficult at school 0 1 2 3 4 
18. Family members argue about what to feed my child 0 1 2 3 4 
19. The diet is beneficial to my child. 0 1 2 3 4 
20. Outside of home, we ask what ingredients are in meals 0 1 2 3 4 
CARBOHYDRATE COUNTING 
Never Almost 
Never 
Some-
times 
Often Almost 
Always 
21. I count carbohydrates for my child 0 1 2 3 4 
22. My child counts carbohydrates 0 1 2 3 4 
23. We use tools to help count carbohydrates 0 1 2 3 4 
We use: Measuring cups/Kitchen scales/Traffic Light Guide To Food 
Carbohydrate Counter/Calorie King / Other: ______ 
0 1 2 3 4 
Comment about your child’s usual eating patterns 
24. What does your child like most about meals and eating?
__________________________________________________________________
__________________________________________________________________
25. What does your child like least about meals and eating?
________________________________________________________________________
________________________________________________________________________
26. How many times a week does your family eat dinner together?
________________________________________________________________________
My child has :   Type 1 diabetes for _____ years      Coeliac Disease for ______ years 
THANK YOU FOR YOUR TIME 
********************************************************************* 
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Coeliac Disease Questionnaire 
This survey aims to find out how you feel about living with coeliac disease. 
For each of the sentences, circle the face that best explains how you feel. 
There are no right or wrong answers. If you do not understand a question, please ask for help. 
Please take time to answer all the questions. 
It will take about 5-10 minutes.
Thanks for your help in completing this survey. 
If you have any questions, please contact Anna Pham-Short (02) 9845 3073 
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Communication  
1. Talking about coeliac disease, I find… 
 
 
2. When I have to explain to others what coeliac disease is, I 
feel… 
 
 
Talking about my coeliac disease with others my age, I find… 
 
 
 
Having Coeliac Disease  
4. When at school if I am given food containing gluten, I find 
it… 
 
5. When someone offers me food that I can’t have, I feel… 
 
 
6. When I think of food containing gluten, I feel… 
 
 
 
Diet  
7. Not being able to eat anything I want, I find… 
 
 
8. Having to follow a lifelong diet, I find… 
 
 
9. Having to pay attention to what I eat, I find… 
 
 
10. Having coeliac disease is… 
 
 
11. Not being able to eat all the things other people eat, I 
find… 
 
12. Following a diet for my coeliac disease is… 
 
 
 
 
 
 
 
 
 
 
 
